Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.[ADDRESS_440546] Lenses in Senofilcon A with a Blue -Blocking Chromophore 
Protocol CR -6521  
Version: 3.0  
 
Date: 01 June 2023  
 
 
Investigational Products: The test product will be rotationally stabilized astigmatic soft contact [CONTACT_169750] A with a chromophore to block High -Energy Visible Light (HEVL). The control lens will be the 
ACUVUE® OASYS 1 Day for Astigmatism (AO1DfA ) contact [CONTACT_13276].  
 
Keywords: Astigmatism, toric contact [CONTACT_13276],  senofilcon  A, chromophore, High -Energy Visible  Light,  
dispensing, daily wear, daily disposable, ocular physiology, lens fit, rotational performance, logMAR visual 
acuity, CLUE Vision, CLUE C omfort, CLUE Handling, situational visual performance, ACUVUE® OASYS 1 - 
Day for Astigmatism,  Single  use Eye-Cept® Rewetting  Drops,  LacriPure  Saline  Solution,  ScleralFil  Preservative 
Free Saline  Solution.  
 
Statement of Compliance to protocol, GCP and applic able regulatory guidelines:  
 
This clinical trial will be conducted in compliance with ISO [ZIP_CODE]:2020 Clinical investigation of medical 
devices for human subjects – Good clinical practice,1 and the Declaration of Helsinki.2 
 
Confidentiality Statement:  
This document contains confidential information, which should not be copi[INVESTIGATOR_530], referred to, released or published 
without written approval from [COMPANY_012] Vision Care, Inc. The information may not be disclosed to 
others except to the extent necessary to obtain Institutional Review Board/Independent Ethics Committee 
approval  and informed  consent,  or as required  by [CONTACT_19543],  Federal  and State  Laws,  as applicable.  Persons  to 
whom  this information  is disclosed  must  be informed  that this information  is privileged  and confidential  and that 
it should not be further disclosed without the written permission of [COMPANY_012] Vision Care, Inc. Any 
supplemental information that may be added to this document is also confidential and proprietary to Johnson &  
Johnson Vision Care, Inc. and must be kept in confidence in the same manner as the contents of this  document.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 2 of 163   
  
TABLE OF CONTENTS  
PROTOCOL TITLE, NUMBER, VERSION  AND  DATE  ................................ ......................  6 
SPONSOR NAME  [CONTACT_253462]  ................................ ................................ .......................  6 
MEDICAL  MONITOR  ................................ ................................ ................................ .............  6 
AUTHORIZED  SIGNATURES  ................................ ................................ ...............................  7 
CHANGE  HISTORY  ................................ ................................ ................................ ................  8 
SYNOPSIS  ................................ ................................ ................................ ................................  9 
COMMONLY USED ABBREVIATIONS, ACRONYMS AND DEFINITIONS OF  TERMS  
………………………………………………………………………………………………..[ADDRESS_440547] s ................................ ................  15 
1.2. Intended Use of  Investigational  Products  ................................ ................................ . 15 
1.3. Summary of Findings from  Nonclinical  Studies  ................................ ......................  15 
1.4. Summary of Known Risks and Benefits to  Human  Subjects  ................................ ... 15 
1.5. Relevant  Literature  References  and Prior  Clinical  Data  Relevant  to Proposed  Clinical 
Study…  ................................ ................................ ................................ ...............................  [ADDRESS_440548] Articles  ................................ ................................ ............................  21 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 3 of 163   
 6.2. Ancillary  Supplies/Products  ................................ ................................ .....................  [ADDRESS_440549] Articles  ................................ ................................ ................  23 
7. STUDY  EVALUATIONS  ................................ ................................ ..............................  23 
7.1. Time and  Event Schedule  ................................ ................................ .........................  23 
7.2. Detailed  Study Procedures  ................................ ................................ .......................  24 
VISIT  1 ................................ ................................ ................................ ...........................  24 
VISIT  2 ................................ ................................ ................................ ...........................  30 
VISIT  3 ................................ ................................ ................................ ...........................  32 
VISIT  4 ................................ ................................ ................................ ...........................  32 
FINAL  EVALUATION  ................................ ................................ ................................ .. 33 
7.3. Unscheduled  Visits  ................................ ................................ ................................ ... 33 
7.4. Laboratory  Procedures  ................................ ................................ .............................  34 
8. SUBJECTS  COMPLETION/WITHDRAWAL ................................ ..............................  34 
8.1. Completion  Criteria  ................................ ................................ ................................ .. 34 
8.2. Withdrawal/Discontinuation from  the Study  ................................ ...........................  34 
9. PRE-STUDY AND  CONCOMITANT  INTERVENTION/MEDICATI ON .................  [ADDRESS_440550]  QUALITY  COMPLAINTS  .................  38 
13. ADVERSE  EVENTS  ................................ ................................ ................................ ...... 39 
13.1. Definitions  and Classifications ................................ ................................ .................  39 
13.2. Assessing  Adverse  Events  ................................ ................................ ........................  40 
13.2.1.  Causality  Assessment  ................................ ................................ ....................  40 
13.2.2.  Severity  Assessment  ................................ ................................ ......................  41 
13.3. Documentation and Follow -Up of Adverse  Events  ................................ .................  41 
13.4. Reporting  Adverse  Events  ................................ ................................ ........................  42 
13.4.1.  Reporting Adverse Events  to Sponsor  ................................ ..........................  42 
13.4.2.  Reporting  Adverse  Events  to the Responsible  IEC/IRB  and Health  Authorities  
……………………………………………………………… ………………43  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.[ADDRESS_440551]  KEEPI[INVESTIGATOR_1645]/ARCHIVING  ................................ ... 51 
15.1. Electronic Case Report  Form/Data  Collection  ................................ .........................  [ADDRESS_440552]  ................................ ................................ ................................ .........  52 
15.3. Trial Registration  on ClinicalTrials.gov ................................ ................................ ... 52 
16. DATA  MANAGEMENT  ................................ ................................ ................................  52 
16.1. Access to  Source  Data/Document  ................................ ................................ ............  52 
16.2. Confidentiality  of Information  ................................ ................................ .................  52 
16.3. Data  Quality Assurance  ................................ ................................ ............................  52 
16.4. Data Monitoring  Committee  (DMC)  ................................ ................................ ........  [ADDRESS_440553]  (IEC/IRB)  ..............  [ADDRESS_440554]  RETENTION  ................................ ................................ ...................  56 
20. FINANCIAL  CONSIDERATIONS  ................................ ................................ ...............  56 
21. PUBLICATION  ................................ ................................ ................................ ..............  56 
22. REFERENCES  ................................ ................................ ................................ ...............  56 
APPENDIX A: PATIENT REPORTED OUTCOMES  (STUDY  QUESTIONNAIRES)  ..... 58 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 5 of 163   
 APPENDIX B: PATIENT  INSTRUCTION  GUIDE  ................................ .............................  74 
APPENDIX C: PACKAGE INSERT  (APPROVED  PRODUCT)  ................................ .........  75 
APPENDIX  D: ................................ ................................ ................................ ......................  [ADDRESS_440555] REPORTED  OCULAR  SYMPTOMS/PROBLEMS  ........................  111 
DETERMINATION OF DISTANCE SPHEROCYLINDRICAL REFRACTIVE 
ERROR  ................................ ................................ ................................ ................................ . 113 
BIOMICROSCOPY  SCALE  ................................ ................................ ..............  119 
DISTANCE AND NEAR SNELLEN VISUAL  ACUITY  EVALUATION  ...... 125 
TORIC  FIT EVALUATION  ................................ ................................ ...............  130 
PATIENT  REPORTED  OUTCOMES  ................................ ................................  135 
LENS INSERTION  AND  REMOVAL  ................................ ..............................  137 
VISUAL ACUITY CHART LUMINANCE AND ROOM ILLUMINATION 
TESTING  ................................ ................................ ................................ ..............................  140 
APPENDIX E: IRIS  COLOR  SCALE  ................................ ................................ ..................  149 
APPENDIX  F: GUIDELINES FOR COVID -19 RISK  MITIGATION  .............  151 
PROTOCOL COMPLIANCE INVESTIGATOR(S)  SIGNATURE  [CONTACT_1783]  ........................  [ADDRESS_440556] OF TABLES  
Table 1:  Test Articles  ................................ ................................ ................................ ..............  21 
Table 2:  Ancillary  Supplies ................................ ................................ ................................ ..... 22 
Table 3: Time  and Events  ................................ ................................ ................................ ....... 23 
Table 4: Disallowed  systemic  medications  ................................ ................................ .............  36 
Table 5: Disallowed  systemic  antihistamines  ................................ ................................ .........  36 
Table 6: Examples of major and minor  protocol deviations  ................................ ...................  37 
Table 7: Historical Studies Utilized for Sample  Size Calculations  ................................ ........  44 
Table 8: Historical Data by [CONTACT_27759] – Test Lens  ................................ ................................ .. 44 
Table  9: Sample  Size Estimates  for Co-Primary  Safety,  Efficacy  and Secondar y Endpoints  
............................................................................................................................. ....................  [ADDRESS_440557] OF FIGURES  
Figure 1:  Study Flowchart  ................................ ................................ ................................ ...... 13  
 
 
 
 
 
 
Clinical Study Protocol  
John son & Johnson  Vision  Care,  Ine. 
- CR-6521, v 3.0 JJVC CONFIDE NTIAL 
Page 6 of 16 3  
  
PROTOCOL TITLE , NUMBER, VERSION AND DATE  
Title : Design Validat ion of To ric Con tact Lenses in Senofilcon A with a Blue -Blocking Ch romophore 
Protocol Number: CR -6521 
Version: 3.0 
Date: 01 June 202 3 
 
 
 
SPONSOR NAME [CONTACT_353940] & John son Vision Care, Ine. (JJVC ) 
[ADDRESS_440558] 
Jacksonville, FL [ZIP_CODE]  
 
 
 
MEDICAL MONITOR  
The Medica!  Moni tor must be notified by [CONTACT_93822]/site by e-mail or telephone  within 24 how-s of 
leaming  of a Seriou s Adverse Event. The Medica! Monitor  may be conta cted dw-ing business how-s for adverse 
event questions. General study related que stions should be directed towards yow- ass igned clinical research 
associate . 
 
The Medica!Monitoring Plan i s maintained a s a separate document and included in the Trial Master F ile. 

Clinical Study Protocol  
John son & Johnson  Vision  Care,  Ine. 
- CR-6521, v 3.0 JJVC CONFIDE NTIAL 
Page 7 of 16 3  
  
AUTHORIZED SIGNATURES  
The signatures below cons titutes the approva l of this p rotocol and the attachments and provide the necessa1y 
assmances that this tria l will be conduc ted according to all stipu lation s of the protocol , including a ll statements 
regarding confidentiality , and according to loca l legal and regulato1y requir ements and applicab le U.S. federa! 
regula tions,3 ISO [ZIP_CODE]:2020 ,1 and the Declaration of Helsinki .2 
 
Author & Study 
Responsib le Clinician  
 
 
Clinical Opera tions 
Manager  
 
 
 
Biostatistician  
 
 
 
Biostatistician Review  
 
 
 
Data Management   
See Electronic Signature  [CONTACT_353941] c Signa t._u_re_R_epo_,_·t  _    
DATE  
 
 
 
DATE  
 
 
See Electroni c -Sign_a_t_.u_re_R_ep_o,_·t  _    
DATE  
 
 
 
Medica ! Safet y Officer  See Electroni c Sign_a_t_w_·e_Rep_o_,·_t  _    
DATE  
 
 
Approver   
See Electronic  Signature  [CONTACT_353942]   _    
DATE  

Clinical Study Protocol  
John son & Johnson  Vision  Care,  Ine. 
- CR-6521, v 3.0 JJVC CONFIDE NTIAL 
Page 8 of 16 3  
  
CHANGE IDSTORY  
 
 
Version  Origina tor Description of Change(s) and 
Section Numbe s Affec ted Justification for Change  Date 
1.0   Original Protocol.  N/A [ADDRESS_440559] lenses are  being  remade  
under  new Protocol  
Managemen t build protocol. 
Addi tional  over-labelling  20 January , 
2023  
  Protocol Managemen t 
protocol   was   created   for a  
  subset of the con trol lenses .  
3.0   Section 7 .1 Time and E vents 
Table : Remo ved the 'x' from 
Distance HLHC visual acuity 
using  ETDRS  charts  at Visit 3 as 
this is not applicable . 
 
Upda ted biostatistician reviewer  Accmacy  
 
 
 
 
 
Accmacy  01 Jun, 2023  
 

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.[ADDRESS_440560], Jacksonville, FL [ZIP_CODE]  
Clinical Phase  Clinical trial phase: Design validation  
Design control phase: Confirmatory phase, phase [ADDRESS_440561] Article(s)  Investigational Products: The test product will be rotationally stabilized 
astigmatic  soft contact  [CONTACT_169753]  A with a chromophore  to block 
High -Energy Visible Light (HEVL).  
Approved Products: The control product will be ACUVUE® OASYS 1 -
Day for Astigmatism (AO1DfA) contact [CONTACT_13276].  
Wear and Replacement 
Schedules  Wear Schedule: Daily wear 
Replacement Schedule: Daily  disposable  
Objectives  The primary objectives of this study are to demonstrate that the 
investigational toric contact [CONTACT_169753] A with a blue -blocking 
chromophore meet the design validation requirements related to visual 
acuity, eye health, fit acceptance, and subject ive vision.  
 
The secondary objectives of this study are to demonstrate that the 
investigational toric contact [CONTACT_169753] A with a blue -blocking 
chromophore meet the market preference requirements related to 
subjective handling and comfort.  
 
An ex ploratory objective of this study is to evaluate the subjective 
response to specific situational visual performance questions regarding  
vision while driving and during digital device use for the test lenses 
compared to the control lenses.  
Study Endpoints  Primary endpoints:  
• Grade 3 or higher biomicroscopy findings related to study lens 
wear (Yes/No)  
• Acceptable lens fit  (Yes/No)  
• Monocular, High -Luminance, High -Contrast (HLHC) distance 
Visual Acuity (VA)  (logMAR)  
• Absolute lens orientation ≤ 10 ° (Yes/No)  
• Lens rotational stability with blinks ≤ 5°  (Yes/No)  
• CLUE Vision  score  
 
Secondary endpoints:  
• CLUE Handling  score  
• CLUE Comfort score  
 
Exploratory endpoints:  
• Ability  to see comfortably  while  driving  during  the day 
 
• My vision  was clear  enough  to allow  me to drive  at night  
 
• Reduction in the feeling of tired eyes from using a computer or 
other digital device  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.[ADDRESS_440562] will be randomized into one of two unique sequences to wear two 
different study lenses one at a time o ver two wear periods (test followed 
by [CONTACT_353872]).  During  each wear  period  the lenses 
will be worn bilaterally for approximately one week (7 2 days) in a daily 
disposable modality. Subjective comfort, vision and handling will be 
assessed using the CLUE questionnaire at fitting and follow -up visits for 
each wear period. HLHC monocular VA will be assessed at the follow -up 
evaluation using ETDRS charts. There will be a washout period of 
approximately one week (7 2 days) between wear  periods.  
 
See the flow chart at the end of the synopsis table for the schematic of the 
study visits and procedures of main observations (  
Figure 1).  
Sample Size  This study will have an enrollment target of approximately [ADDRESS_440563] 165 to complete (assuming a dropout rate of 10%).  
Study Duration  Total study duration including the enrollment period is anticipated to be 
approximately [ADDRESS_440564] lens wearers with bilateral 
astigmatism who are between 18 and 39 years of age (inclusive).  
Eligibility Criteria - Inclusion  Potential subjects must satisfy of all the following criteria to be enrolled in 
the study.  
 
Inclusion Criteria following Screening 
The subject must:  
1. Read, understand, and sign the STATEMENT OF INFORMED 
CONSENT and receive a fully executed copy of the  form.  
2. Appear able and willing to adhere to the instructions set forth in this 
clinical  protocol.  
3. Be between  18 and 39 years  of age (inclusive)  at the time of screening.  
4. Habitually wear soft contact [CONTACT_35482] a daily or daily 
disposable  wear  modality  (i.e., not extended  wear  modality).  Habitual 
wearer  is defined  as a minimum  of [ADDRESS_440565]:  
6. In both eyes,  have  refractive  error  suitable  for correction  with the toric 
contact [CONTACT_353873]:  
a. Sphere powers (DS) -1.50 through -4.00 in 0.25  steps  
b. Cylinder powers (DC) -0.75 and  -1.25 
c. Axes () 170, 180, 10, 80, 90,  [ADDRESS_440566] corrected  monocular  distance  visual  acuity  of 20/30  or better 
in each  eye. 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 11 of 163   
  
 
Eligibility Criteria – Exclusion  Potential subjects who meet any of the following criteria will be excluded 
from participating in the study:  
 
Exclusion Criteria following Screening 
The subject must not:  
1. Be currently pregnant or  lactating.  
2. Be diabetic.  
3. Be currently  using  any ocular  medicat ions or have  an ocular  infection 
of any type.  
4. By [CONTACT_6270] -report, have any ocular or systemic disease, allergies, 
infection, or use of medication that might contraindicate or interfere 
with contact [CONTACT_13279], or otherwise compromise study endpoints, 
including infectious disease (e.g., hepatitis, tuberculo sis), contagious 
immunosuppressive disease (e.g., Human Immunodeficiency Virus 
[HIV]), autoimmune disease (e.g. rheumatoid arthritis, Sjögren’s 
syndrome),  or history  of serious  mental  illness  or seizures.  See section  
9.[ADDRESS_440567] habitually worn rigid gas permeable (RGP) lenses, 
orthokeratology lenses, or hybrid lenses (e.g. SynergEyes, SoftPerm) 
within the past [ADDRESS_440568] a history of strabismus or  amblyopia.  
9. Be an employee (e.g., Investigator, Coordinator, Technician) or 
immediate family member of an employee (including partner, child, 
parent, grandparent, grandchild or sibli ng of the employee or their 
spouse) of the clinical  site. 
10. Have participated in a contact [CONTACT_169756] [ADDRESS_440569] not:  
11. Have clinically significant (grade 3 or higher on the FDA grading 
scale ) slit lamp findings (e.g., corneal edema, neovascularization or 
staining, tarsal abnormalities or bulbar injection) or other corneal or 
ocular disease or abnormalities that contraindicate contact [CONTACT_353874] (incl uding entropi[INVESTIGATOR_2394], 
ectropi[INVESTIGATOR_2394], chalazia, recurrent styes, glaucoma, history of recurrent 
corneal erosions, aphakia, moderate or above corneal distortion, 
herpetic  keratitis).  
12. Have fluctuations in vision due to clinically significant dry eye or 
other ocular  conditions.  
13. Have  had or have  planned  (within  the study  period)  any ocular  or 
intraocular surgery (e.g., radial keratotomy, PRK, LASIK, iridotomy, 
retinal laser photocoagulation, etc.).  
Disallowed 
Medications/Interventions  Subjects will not be eligible to enroll if they are taking any ocular 
medications, or any systemic medications that would normally 
contraindicate contact [CONTACT_129811]. See section 9.1 for details regarding disallowe d systemic 
medications.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 12 of 163   
  
 
Measurements and Procedures  Key procedures associated with the endpoints for this study will include:  
- Measurement of HLHC VA using ETDRS  charts  
- Examination of the anterior segment using a slit lamp biomicroscope 
and grading findings using the FDA grading  scale  
- Assessment of general lens fitting characteristics (centration, 
movement, push -up test) 
- Assessment  of lens orientation  and rotational  stabi lity using  a slit lamp 
biomicroscope  
- Overseeing completion of subjective  questionnaires  
Microbiology or Other 
Laboratory Testing  Not applicable for this study.  
Study Termination  The occurrence of an Unanticipated Adverse Device Effect (UADE) or 
Serious Adverse Event (SAE) for which a causal relationship to a test 
article cannot be ruled out, will result in stoppi[INVESTIGATOR_93783]. In the event of a UADE  or SAE, the Sponsor 
Medical  Monitor  may unmask  the treatment  regimen  of subject(s)  and may 
discuss this with the Principal Investigator [INVESTIGATOR_353849].  
Ancillary Supplies/ Study - 
Specific Materials  Lens cases, fluorescein strips and preservative -free rewetting drops / 
artificial tears will be supplied for use as needed . 
Principal Investigator(s) and 
Study Institution(s)/Site(s)  A full list of Principal Investigators, clinical sites, and institutions is kept 
separately from the Study Protocol and is included in the study Trial 
Master File.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 13 of 163   
 Washout Period  
A washout period of 7 2 days duration will  
be observed between wear periods  Visit 1: Screening 
Statement of Informed Consent 
Demographics  
Medical History & Concomitant Medications 
Habitual Contact [CONTACT_353875] (habitual lenses)  
 
Lens Fitting (#1 through #2)  
Lens assignment and insertion  
Timed rotation assessments, lens settling 
Toric and general fit assessment  
Spherical over -refraction, modification if required 
CLUE post -fit questionnaire  
Lenses dispensed for 7 [ADDRESS_440570] reported ocular symptoms 
Entrance VA and biomicroscopy 
Confirm continuing eligibility   
Figure 1: Study Flowchart  
 
 
 
 
 
 
 
Follow -up (#1 through #2) 
CLUE follow -up questionnaire 
ETDRS HLHC visual  acuity  
Record lens orientation 
Lens removal 
Biomi croscopy 
Schedule next visit   
 
 
After follow -up #1  
 
 After follow -up #2  
 
 Final Evaluation 
Spherocylindrical refraction 
Completion status  
Biomicroscopy (if discontinued early)  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.[ADDRESS_440571]  
ADHD  Attention Deficit Hyperactivity  Disorder  
AE Adverse Event/Adverse  Experience  
AO1DfA   ACUVUE  OASYS®  1-DAY  with HydraLuxe ™ TECHNOLOGY  for 
ASTIGMATISM  
BSCVA  Best Spectacle Corrected Visual  Acuity  
CFR  Code of Federal Regulations  
CLUE  Contact [CONTACT_353876] -[ADDRESS_440572] 
HIV Human Immunodeficiency  Virus  
IB Investigator’s  Brochure  
ICH The International Council for  Harmonization  
IDE Investigational Device  Exemption  
IEC Independent Ethics  Committee  
IRB Institutional Review  Board  
ISO International Organization for  Standardization  
ITT Intent -to-Treat  
JJVC  [COMPANY_012] Vision Care,  Inc. 
LASIK  Laser -Assisted in Situ  Keratomileusis  
LogMAR  Logarithm of Minimal Angle of  Resolution  
OD Right Eye  
OS Left Eye 
OU Both Eyes  
PIG Patient Instruction Guide  
PQC  Product Quality Complaint  
PRK  Photorefractive  Keratectomy  
PRO  Patient Reported Outcome  
QA Quality Assurance  
SAE  Serious Adverse Event/Serious Adverse  Experience  
SAP Statistical Analysis  Plan 
SAS Statistical Analysis  System  
SD Standard Deviation  
UADE  Unanticipated Adverse Device  Effect  
[LOCATION_003]DE  Unanticipated Serious Adverse Device  Effect  
VA Visual  Acuity  
 
 
1. INTRODUCTION AND  BACKGROUND  
High Energy Visible Light (HEVL) may be generally defined as the visible region of the electromagnetic 
spectrum with wavelengths shorter than 500 nm. Due to Rayleigh scattering, light within this range of  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.[ADDRESS_440573] when looking at distant objects. At approximately 435 nm, visible light has 
enough energy to damage the retinal pi[INVESTIGATOR_353850]. 
Additionally, the retinal receptors responsible for photoentrainment (entrainment of the circadian rhythm in 
response to patterns of light and dark) are maximally sensitive to light at approximately 480 nm.  
 
Ophthalmic lenses that block High Energy Visible Light (HEVL) may offer improved vision through enhanced 
chromatic  contrast  sensitivity.  Such  lenses  may also provide  greater  retinal  protection  than regular  lenses  without 
spectral filtering. This study will  evaluate the clinical performance of a daily disposable, toric lens design 
incorporating a HEVL -blocking  chromophore  
 
1.1. Name [CONTACT_353943] a toric contact [CONTACT_169759] A contai ning a HEVL -blocking 
chromophore  ACUVUE® OASYS 1 -Day for Astigmatism (AO1DfA) contact [CONTACT_353877] a control  lens. 
 
Further details about the test and control articles are given in section [ADDRESS_440574] 8 hours per day and 5 days per week over 
a wear period of 7±2 days. Two wear periods will be completed in total, with a washout period of 7±[ADDRESS_440575] 
version of the Investigator's Brochure.[ADDRESS_440576] lens worn in the same modality (i.e., daily disposable wear). No 
additional risks associated with participation in this investigation are antic ipated.  
 
Comprehensive risk and benefit information regarding the test design and the AO1DfA control lens are included 
in the latest  versions  of the Investigator's  Brochure4 and the AO1DfA  package  insert  (Appendix  C), respectively.  
 
1.5. Relevant Literature References and Prior Clinical Data Relevant to Proposed Clinical  Study  
Prototype toric lens designs  featuring  the chromophore have previously been evaluated in several JJVC - 
sponsored clinical trials. Safety data from these trials suggest the investigational lenses have a safety profile 
equivalent to currently marketed soft contact [CONTACT_353878]; a review of literatur e references and prior clinical 
data related to the test designs is given in the Investigator’s  Brochure.4 
 
For further details regarding the AO1DfA control lens, refer to the AO1DfA package insert (Appendix C).  
 
 
2. STUDY OBJECTIVES, ENDPOINTS AND  HYPOTHESES  
 
2.1. Objectives  
Primary Objective:  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 16 of 163   
  
The objective  of this study  is to demonstrate  that the investigational  lens meets  the validation  requirements  related 
to objective and subjective vision, eye health, fit acceptance, toric rotation, and rotational  stability.  
 
Secondary Objective:  
The secondary objective of this study is to demonstrate that the investigational lens meets the user needs with 
respect to subjective lens handling and comfort.  
 
Exploratory Objective  
An exploratory objective of this study is to evaluate the subjective response to specific situational visual 
performance questions regarding vision while driving and during digital device use for the test lenses compared 
to the control lenses.  
 
2.2. Endpoints  
Primary Safety Endpoints:  
 
Slit Lamp Findings (SLF)  
SLFs (Grade 3 or higher) related to study lens wear will be assessed for each eye at all study visits (scheduled 
and unscheduled). SLFs will be evaluated and graded using the FDA Grading scale from 0 to 4 , where Grade 0 
represents the absence of findings and 1 to 4 representing successively worse findings. The percentage of eyes 
with Grade 3 or higher SLF will be analyzed and will include  corneal infiltrates.  See in Appendix D 
for more details on the coll ection of  SLFs.  
 
Acceptable Lens Fit  
Acceptable lens fit will be assessed at all study visits (scheduled and unscheduled) for each subject eye. 
Acceptable  fit is a binary  response  where  Y=1 if lens fit is acceptable  and Y=0 otherwise.  Lens  fit will be deemed 
unacceptable if any one of the fol lowing criteria are  met: 
• limbal exposure at primary gaze or with extreme eye  movement;  
• edge  lift; 
• excessive movement in primary up  gaze;  
• insufficient movement in all three of the following conditions: primary gaze, up gaze, and push up test. 
Eyes  with multiple  unacceptable  fitting  events  will be counted  only once.  See in Appendix H for 
additional details regarding lens fit  assessments.  
 
Primary Efficacy Endpoints:  
 
Visual Acuity (logMAR)  
Visual  acuity  (VA)  will be assessed  monocularly  at the 1-week  follow -up evaluation  under  high-luminance  high- 
contrast  (HLHC)  conditions  at a test distance  of 4 meters  using  ETDRS  Charts.  See in Appendix D  for 
details regarding the collection of visual  acuity.  
 
Toric Lens Orientation  
Toric  lens orientation  (scribe  mark  position  relative  to 6 o’clock)  will be assessed  for each eye at 1, [ADDRESS_440577] 15 minutes  after lens insertion  at the fitting  visit is the primary  endpoint.  Lens  orientation  is a binary  response 
where  Y=1 if the absolute  lens orientation  is ≤ 10° and Y=[ADDRESS_440578] 15 minutes after lens insertion at the 
fitting visit is the  primary endpoint. Rotational stability is a binary response where Y=1 if the lens stability with 
blinks  is ≤ 5° and Y=0 otherwise.  See in Appendix  D for details  regarding  the collection  of lens stability 
with blinks.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.[ADDRESS_440579] Lens User Experience (CLUE ™) questionnaire after 
approximately 1 week of lens wear. CLUE ™ is a validated, patient -reported outcomes questionnaire to assess 
patient -experience attributes of soft, disposable co ntact lenses (comfort, vision, handling, and packaging) in a 
contact -lens wearing population in the US, ages 18 -65. Derived CLUE ™ scores using Item Response Theory 
(IRT)  follow  a normal  distribution  with a population  average  score  of 60 (SD 20), where  higher scores  indicate  a 
more  favorable/positive  response  with a range  of 0-120. A 5-point  increase  in an average  CLUE ™ score  translates 
into 10% shift in the distribution of scores for population of soft contact  [CONTACT_13293].5 
 
Secondary Endpoints  
• CLUE Handling score at  follow -up 
• CLUE Comfort score at follow -up 
 
Exploratory Endpoints  
• Ability to see comfortably while driving during the  day 
• My vision was clear enough to allow me to drive at  night  
• Reduction  in the feeling  of tired eyes from  using  a computer  or other  digital  device  
 
2.3. Hypotheses  
 
Co-Primary Safety Hypotheses:  
 
1. The percentage of eyes with one or more clinically significant, study -lens related, slit -lamp findings 
(Grade 3 or 4) following wear of the test lenses will be less than  5%. 
 
2. At least 80% of lens fits will be acceptable at th e dispensing  visit. 
 
Both co -primary safety hypotheses must be met in order to test any co -primary efficacy hypotheses. 
Co-Primary Efficacy Hypotheses:  
1. After  approximately  1-week  of wear,  the mean  monocular,  high-luminance,  high-contrast  distance  visual 
acuity for the test lens will be lower than 0.00 logMAR (equivalent to 20/20 Snellen visual  acuity).  
 
2. Following lens settling (at least 15 minutes) at the dispensing visit, at least 80% of lens fits will have 
absolute rotation less than or equal to 10 degrees.  
 
3. Following lens settling (at least 15 minutes) at the dispensing visit, at least 80% of lens fits will have 
lens rotational stability with blink less than or equal to 5  degrees.  
 
4. After approximately 1 week of wear, the mean overall CLUE ™ Vision  score for the test lens will be 
statistically greater than [ADDRESS_440580] 
any secondary hypotheses.  
 
Secondary Hypotheses:  
1. After approximately 1  week of wear, the mean overall CLUE ™ Handling score for the test lens will be 
greater than 61 points with 95% statistical  confidence.  
 
2. After approximately 1 week of wear, the mean overall CLUE ™ Comfort score for the test lens will be 
greater than 58 points with 95% statistical  confidence.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 18 of 163   
  
Exploratory  Hypotheses:  
 
1. After approximately [ADDRESS_440581] one of the following subjective questionnaire items asked at the follow -up visit:  
a. Ability to see comfortably while driving during the  day 
b. My vision was clear enough to allow me to drive at night  
c. Reduct ion in the feeling of tired eyes from using a computer or other digital device 
A non -inferiority margin of 10% will be  used.  
 
 
3. TARGETED STUDY  POPULATION  
 
3.1. General  Characteristics  
The target  population  for this study  will be healthy  adult  soft contact  [CONTACT_353879]  [ADDRESS_440582] satisfy all of the following criteria to be enrolled in the study:  
 
Inclusion Criteria following Screening 
The subject must:  
1. Read,  understand,  and sign the STATEMENT  OF INFORMED  CONSENT  and receive  a fully  executed 
copy of the  form.  
2. Appear able and willing to adhere to the instructions set forth in this clinical  protocol.  
3. Be between 18 and 39 years of age (inclusive) at the time of  screening.  
4. Habitually wear soft contact [CONTACT_35482] a daily or daily disposable wear modality  (i.e., not 
extended wear modality). Habitual wearer is defined as a minimum of [ADDRESS_440583] lens powers available in 
this study:  
a. Sphere powers (DS) -1.50 through -4.00 in 0.25  steps  
b. Cylinder powers (DC) -0.75 and  -1.25 
c. Axes () 170, 180, 10, 80, 90,  [ADDRESS_440584] corrected monocular distance visual acuity of 20/30 or better in each  eye. 
 
3.3. Exclusion  Criteria  
Potential subjects who meet any of the following criteria will be excluded from participating in the study:  
 
Exclusion Criteria following Screening 
The subject must not:  
1. Be currently pregnant or  lactating.  
2. Be diabetic.  
3. Be currently using any ocular medications or have an ocular infection of any  type.  
4. By [CONTACT_6270] -report, have any ocular or systemic disease, allergies, infection, or use of medication that might 
contraindicate or interfere with contact [CONTACT_13279], or otherwise c ompromise study endpoints, including 
infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive disease (e.g., Human 
Immunodeficiency Virus [HIV]), autoimmune disease (e.g. rheumatoid arthritis, Sjögren’s syndrome), 
or history of seri ous mental illness or seizures. See section 9.[ADDRESS_440585] habitually worn rigid gas permeable (RGP) lenses, orthokeratology lenses, or hybrid lenses (e.g. 
SynergEyes, SoftPerm) within the past 6 mo nths.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.[ADDRESS_440586] a history of strabismus or  amblyopia.  
9. Be an employee (e.g., Investigator, Coordinator, Technician) or immediate family member of an 
employee (including partner, child, parent, grandparent, grandchild or sibling of the employee or their 
spouse) of the clinical  site. 
10. Have participated in a conta ct lens or lens care product clinical trial within [ADDRESS_440587] not:  
11. Have  clinically  significant  (grade  3 or higher  on the FDA  grading  scale)  slit lamp  findings  (e.g.,  corneal 
edema,  neovascularization  or staining,  tarsal  abnormalities  or bulbar  injection)  or other  corneal  or ocular 
disease or abnormalities that contraindicate contact [CONTACT_129811] (including entropi[INVESTIGATOR_2394], ectropi[INVESTIGATOR_2394], chalazia, recurrent styes, glaucoma, history of recurrent 
corneal erosions, aphakia, moderate or above corneal distortion, herpetic  keratitis).  
12. Have fluctuations in vision due to clinically significant dry eye or other ocular  conditions.  
13. Have had or have p lanned (within the study period) any ocular or intraocular surgery (e.g., radial 
keratotomy, PRK, LASIK, iridotomy, retinal laser photocoagulation,  etc.).  
 
3.4. Enrollment Strategy  
Study subjects will be recruited from the Institution/clinical site’s subject database and/or utilizing Independent 
Ethics Committee (IEC) or Institutional Review Board (IRB) approved materials.  
 
 
4. STUDY DESIGN AND  RATIONALE  
 
4.1. Description of Study Design  
This will be a 4-visit,  randomized,  controlled,  single -masked,  bilateral  wear,  dispensing,  2-treatment,  2-sequence, 
2-period crossover  study.  
 
At the initial visit (Visit 1), eligible subjects will be randomized into one of two unique sequences to wear two 
different study lenses one at a time over two wear periods (test/control or control/test). Subjects will wear each 
study lens type in a daily wear, daily disposable modality for approximately [ADDRESS_440588] 5 days during each wear period. Subjective 
comfort, vision and handling will be assessed using the CLU E questionnaire at both fitting and follow -up visits 
for each wear period. Monocular HLHC VA will be assessed at the follow -up evaluation using ETDRS charts. 
There will be a washout period of 7 [ADDRESS_440589] predefined 
targets specified in the Customer Requirements Document, based on historical performance of the ACUVUE® 
OASYS  1-Day for Astigmatism  contact  [CONTACT_13276].[ADDRESS_440590] is to the 
monitor the clinical performance, as the lenses for this study will be manufactured from the Flexible 
Manufacturing Platform (FMP), which is not the dis tributional line utilized for the Control lens (AO1Dfa). 
Moreover, this is only the second study where lenses from the FMP line are being  evaluated.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.[ADDRESS_440591] on subjects’ visual acuity, toric lens orientation, rotational stability, lens fit or SLFs since these 
endpoints are objective in nature, there will be a 1 -week washout period between study lenses, and different 
EDTRS charts will be utilized for each eye (left vs. right) to help reduce potential for optotype memorization 
during collection of visual acuity.  
 
However, there is a potential risk of carryover effect in all data collected from this study design, however , this is 
a greater risk for subjective responses than objective ones, i.e., CLUE vision scores. If a sequence effect is 
observed in the statistical model, then the primary hypothesis will be tested on data from the first period only.  
 
 
4.3. Enrollment Target a nd Study  Duration  
This study  will have  an enrollment  target  of approximately  [ADDRESS_440592]; total study duration including the enrollment period is expected to be approximately [ADDRESS_440593] Article Allocation  
The study lenses will be worn bilaterally in a randomized fashion using a 2x2 crossover design with 2 lens types 
and 2 periods. At Visit 1, eligible subjects will be randomized to one of two unique lens wear sequences using a 
computer -generated randomizati on scheme provided by [CONTACT_15282]. Permuted block randomization 
will be used to avoid bias in the assignment of subjects to treatment, and to enhance the validity of statistical 
comparisons across treatment groups. Each block will contain two  different lens trial sequences. The 
randomization scheme will be generated using the PROC PLAN procedure from Statistical Analysis System 
(SAS) Software Version 9.4 or higher (SAS Institute, Cary,  NC).[ADDRESS_440594] occurred prior to randomization:  
 
• Informed consent mus t have been  obtained.  
• The subject must have met all eligibility  criteria.  
• The subject’s screening and baseline information must have been  collected.  
 
When dispensing test articles, the following steps should be followed to maintain randomization codes:  
1. Investigator or designee (documented on the Delegation Log) will consult the lens fitting schedule to 
obtain the test article assignment for that subject  prior to  dispensing.  
2. Investigator or designee will record the subject’s number on the appropriate line of the randomization 
(lens fitting)  schedule.  
3. Investigator  or designee  will pull the appropriate  test articles  from  the study  supply.  All test articles  that 
are opened, whether dispensed (placed/fit on eye or dispensed outside the clinical site) or not, must be 
recorded on the Test Article Accountability Log in the “Dispensed”  section.  
 
5.2. Masking  
To reduce  the potential  for bias, this will be a single -masked  trial;  subjects  will not be aware  of the identity  of the 
assigned  lenses,  however,  due to the difference  in appearance  of the test lenses  containing  the 
Clinical Study Protocol 
John son & Johnson Vision Care, Ine. 
- CR-6521, v 3.[ADDRESS_440595] and contro l designs. 
The id entity (i.e., brand and type) ofthe studylense s will bemas ked by [CONTACT_353880] , lot number , sphere power , cylinder power , axis, expi[INVESTIGATOR_353851]. 
Investigato rs, site staff and sponsor personnel (including the medica l monito r) will be aware of the identity of the 
test and contro l lenses. 
 
5.3. Procedure s for Maintaining and Breaking the Masking  
The test aiticles  mask shall  not be brok en unless information  conc eming  the lens type is necessary for 
the urgen t medica l treatmen t of a subjec t. The Spon sor must be notified  before  the mask  is broken . 
 
 
6. STUDY  INTERVENTION  
 
6.1. Identi ty of Te st Articles  
The follo wing contact [CONTACT_35498]:  
 
Table 1: Test Article s 
 
 Test Contrnl  
Test Atticle Fonu  Sofi con tact lens 
 
Design/ Description  TRAlOO  and TRA200  serie s toric 
contact [CONTACT_353881] -blocking 
chromo hore  AOlD fA 
Desi<>   Name  [CONTACT_353944]2XX  AOlD fA 
Manufacturer  Johnson & John son Vision Ca re, Ine.  
 
-1.50 to -4.00 in 0.25 ste s 
-0.75, -1.25  
10, 80, 90, 100, 170, 180 
Nominal Wat er Content 
% 38  
Nominal Base Curve 
mm 8.5  
Lens Diameter (mm) 14.3  
Fiducial ma rks 6 and 12 o 'clock fiducial lines  
Dk (Fatt method , 
boundary co ITected , 
edge COITected , x10-11 
[cm2 /sec] [ml O i/ ml x 
mm H0       at 35°C  
 
[ADDRESS_440596] and control lenses will be available in 132 unique  lens powers (11 sphere  powers x 2 cylinder 
powers x 6 axes). 

Clinical Study Protocol 
John son & Johnson Vision Care, Ine. 
- CR-6521, v 3.0 JJV C CONFIDE NTIAL  
Page 22 of 163   
  
For each  study  lens design (test and control ), the total numb er of test lenses to be used in this study  (not including 
lenses that are r eplaced due to droppage , loss or damage) is expected to be approxima tely 2520 lenses (target 
enrollment  of [ADDRESS_440597]  x 7 days per wear period) . 
 
6.2. Ancillar y Supplie s/Product s 
The follo wing solutions will be u sed in this study : 
 
Table 2: Ancillary Supp lies 
 Non-Preserv ed Rewetting Droos 
Solution Name/De scription  Single u se Ey e-Cept ® 
Rewett .ing Drops LacriPure Saline  
Solu tion ScleralFil Prese rvative 
Free Saline So lution  
Manufacturer  Optics Labora tory Menicon  Bausch & Lomb  
Preservati ve None  None  None  
 
Lens cases and fluore scein strips (either 0.6 mg or 1.0 mg ) will be supplied for u se as need ed. 
 
6.3. Admini stration of Test  Article s 
Test aiticles will be di spensed to subject s meeting all eligibility re quirement s, including any di spensing 
requir ements set fo1ih in thi s clinical p rotocol. Subjec ts will be di spensed an adequa te supply of test a1ticle s to 
compl ete the study. Lost or datnaged test article s may be replaced at the discr etion of the in vestigator and/or the 
sponsor. 
 
6.4. Packaging and Labeling  
The test articles will be packaged in bli sters as the primaiy packaging . The test aiticle will be over-labeled to 
mask the subjec t to the id entity of the lens. The sample study label is shown below: 
 
Prima1y  Packa  ggi.'-'--- Secondaiy  Packaging  
Sponsored By/Parrairre  par: 
 
Johnson & Johnsoo V'ision care, Ine. 
[ADDRESS_440598]  
Jacksonvile ,FL [ZIP_CODE] , [LOCATION_003] 
Conten1s/Contenu:  
 
Contact [CONTACT_353882] u esolulion 
 
 
 
 
 
6.5. . Storage  Condition s 
Test a1ticles  will be maintained  at ambient  temperature s at the clinical  site. Test a1ticles  must be kept under  secure 
condition s. 
 
6.6. Collection and Storage of  Sample s 
No sample s will be collected a s pati of thestudy procedures.  CAUTOI N: INVESllGAllONALDEVICE 
UMITEDBY U.S. LAW 
TOINVESTIGAllONA L USE 
EXCLUS VIELY FOR 
CUNICALINVESTIGATIONS  
I Cnm:Onecontact  [CONTACT_353883]1sokitim.  
ISTE   R I  L  E I I [EJ 
LOT ABC123 
SPH -1.00 
CYL-0.75 AXIS  180 
EXP 2025 /12/31  
CR-6521  RC A 
Clinical Study Protocol 
[COMPANY_012] Vision Care,  Ine. 
- CR-6521, v 3.[ADDRESS_440599] aiticle a ssociatedwith an Adverse Event and/or a Produc t Quality Complaint mu st 
be retained and stored in a gla ss vial with moderate solution pending directions from the sponsor for potential 
retum to JN C . 
 
6.7. Acco untability of Test A11 icles 
JNC will provide the Investigator with sufficient quantitie s of study article s and supplie s to complete the 
investigation. The In vestigator is a sked to retain all lens shipmen t documentation for the te st article accountability 
record s. 
 
Test ait icles must be kept in a locked storage cabinet , acces sible onl y to those a ssigned b y the In vestigator for 
dispensing. The In vestigator may delegate thi s activity to authorized study site personnel li sted on the Site 
Delegation Log. All te st article s must be accounted. This include s: 
1. What  was dispensed  for the subject for trial fitting , to wear out of the office , or issued for the subject  to 
replace appropriately between visits. 
2. What was retumed to the In vestigator unu sed, including expi[INVESTIGATOR_353852]. 
3. The number and reason for unplanned replacement s. 
 
The In vestigator will collect all unused test article s from the subjec ts at the end of the subjec t's pa1ticip ation. 
Subject retumed unused test article s must be separa ted from the clinical study invent01y of un-dispensed test 
article s and must be l abeled with the subject number and date of retum. Follo wing final reconcilia tion of test 
article s by [CONTACT_2037] , the In vestigator or monitor will retum all unused test a1ticles to JN C . 
 
If there i s a discrepanc y between the shipment documents and the con tents, contact [CONTACT_353884]. 
 
 
7. STUDY  EVA LUATIONS 
 
7.1. Time and Event Schedule 
Table 3: Time and E vents 
 
 
Visit Infonnation  Visit 1 
Screening , 
Baseline , 
Lens  Fitting 
#1 Visit 2  
Follow -up #1  Visit 3 
Continuance , 
Lens Fitting 
#2 Visit 4  
Follow-up #2, 
Final Evaluation  
 
Time Point   
Day0  7 ±2 days  
following 
Visit 1 7 ±2 days  
following 
Visit 2 7 ± 2 days  
following Visit  
3 
Minimum  lens wear  time  
immediate ly prior  to visit  Mustwear  
habitual lenses  1 hour (study  
lenses)  No 
reauirement  1 hour (study  
lenses)  
Estimated Visit Duration  2.5 hours  1.5 hours  1.5 hours  1.5 hours  
Statement of info1med con sent X    
Demographic s X    
Medica! hi sto1y/concomi tant 
medica tions  
X  
X  
X  
X 
Habitual contact [CONTACT_353885]1mation  X    
Habitual lens wear time  X    
Eligibilitv at Screening  X    
Subiect reoorted ocular svmotolllS  X X X X 
Baseline PRO oue stionn aire X    
Entrance visual acuitv  X X X X 

Clinical Study Protocol 
[COMPANY_012] Vision Care,  Ine. 
- CR-6521, v 3.0 JJVC CONFIDEN TIAL 
Page 24 of 163  
  
 
 
Visit Infon nation  Visit 1 
Screening , 
Baseline, 
Lens F itting  
#1 Visit 2 
Follow-up #1 Visit 3 
Continuance , 
Lens Fitting 
#2 Visit 4 
Follow-up #2, 
Final Evaluation  
 
Time Point   
Day 0 7 ±2 days 
following  
Visit 1 7 ±2 days 
following  
Visit 2 7 ± 2 days 
following Visit  
3 
Minim um l ens wear time 
inunediate lv orior to visit  Mustwear 
habitual lenses  1 hour (study  
lenses)  No 
reauirement  1 hour (study  
lenses)  
Estimated Visit Dura tion 2.5 hours  1.5 ho urs 1.5 hours 1.5 hours  
Remo ve habitual lenses X  X  
Subjective Sphero -Cylindrical  
Refraction   
X    
X 
Slit Lamp Biomicro scoov  X X X X 
Eligibility at Baseline  X    
Iris color  X    
Lens Selection  X  X  
Lens inser tion and timed rotation 
assessments   
X   
X  
Lens settling  X  X  
Toric fi t assessment  X  X  
General fi t assessment  X  X  
Soherical over-refrac tion X  X  
Lens modification (if nece ssarv) X  X  
Post-fit PRO aue stionnaire  X  X  
Additional samples of toric len s 
orienta tion foerformed tv. •ice)  
X  
X  
X  
X 
Exit visua l acuitv  X  X  
Disoensiniz criteria  X  X  
Disoensiniz instructions  X  X  
Schedule next visit X X X  
Wear time and comoliance   X X X 
Collect unwom lenses  X X X 
Follow -uo PRO auestionnaire   X X X 
Distance HLHC visua l acuity using 
ETDRS cha1 t s   
X   
X 
Toric len s orientation   X X X 
Lens remo val  X X X 
Continuance    X  
Subiect comoletion status     X 
 
7.2. DetailedStudy Procedu res 
 
VISIT l 
Subjects must wear their habitual contac t lenses to this visit. 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Ine. 
Page 25 of 163  
  
Visit 1: Screenimz 
Step  Procedure  Details   
1.[ADDRESS_440600] read, understand, and sign the  
Statement  of Info1med  Consent  before  being  enrolled 
into the study. The Principa l Investigator or his/her 
designee conduc ting the info1med consent discussion 
must  also sign the consent fonn . 
 
Note: The subjec t must be provided a signed  copy  of 
this document.   
1.[ADDRESS_440601] ' s year of birth , age, gender, race, 
and ethnicitv.   
1.[ADDRESS_440602] ' s medical histo1yand concomitant 
medica tions.  
1.[ADDRESS_440603] ' s habitual lens type, parameters , 
lens care solution, wear modality , and approximate  
orescriotion date.   
1.[ADDRESS_440604] 's habitual contac t lenses.  
1.[ADDRESS_440605]  be answered  ''y es" and ali responses to Exclusion 
Criteria must be answered " no" for the subject to be 
considered  eligible . 
 
If subject is deemed to be ineligible after screening , 
proceed to Final Evaluation and complete Subject 
Disposition. Refraction and Biomicro scopy fo1ms  do 
not need  to be comole ted as oait of Final  Evaluation .  
 
 
Visit 1: Base line  
 Step  Procedure  Details  
1.[ADDRESS_440606] any subjec t reported oculai·symptoms reported 
with re ard to their habitua l contact [CONTACT_13276]. 
1.[ADDRESS_440607] the monocu lai·distance Snellen visual acuity 
for each e ye (OD, OS) to the neare st letter with the 
subject 's habitual contac t lens cot1'ection . Subject s 
must continue until at least 50% of the letter s on a line 
are read incot1'ectl .  
1.[ADDRESS_440608] ' s habitual  contac t lenses will be remo ved 
and stored  in a lens case, if required .  
 
 
 
 
 
 
 
 
 

Clinical Study Protocol 
[COMPANY_012] Vision Care, Ine. 
Page 26 of 163  
 CR-6521, v 3.0 -  
 
 
JJVC C ONFIDE NTIAL 
Clinical Study Proto col 
John son & John son Vision Care, Ine. 
- CR-6521, v 3.0 JJVC C ONFIDE NTIAL  
Page 27 of 163   
 
 
 
Visit 1: Base line  
 Step  Procedure  Details  
1.11  Subjective sphero ­ 
cylindrical refraction  Conduct a full spherocylindrical bare eye subjective 
refrac tion wi th binocular balance and record the 
resultant monocular visua l acuity fo r each eye to the 
nearest letter . 
Note: The duo -chrome te st should be used for refining  
the monocular  and binocular  spherical  endpoint s. This 
test will be considered to ha ve reached the endpoin t 
when  the targets on red and green  backgrounds  appear 
to be equall y sharp. How ever, ifthe subje ct's resp onse 
chan gse immedi ately from  "red" to "gre.en" with a 
0.25DS  change  in power , the endpoint  will be the most 
plus power  (with "red" targe t clearer ) before  this 
reversal.  
 
 
 
 
 
 
 
 
 
 
 
 1.12 Slit lamp biomicroscopy  The FDA Slit Lamp  Classification  Scale  will be used 
to grade  finding s. If any slit lamp  finding  is graded  as 
3 or worse,  the visit will be discontinued ; howe ver, the 
subject may repeat the baseline e valuation (one time) 
at a later date once  the condi tion lessens. 
Should  the clearance  of the fluorescein  need  to be 
expedi ted, preservative-free rewetting  drop s or 
artificial tears ma be instilled.  
1.[ADDRESS_440609] be 
answered  " yes" and all respon ses to Exclu sion Criteria 
questions must be answered "no" for the subjec t to be 
considered  eligible . 
If subject is deemed to be ineligible after baseline , 
roceed to Final E valuation .  
1.[ADDRESS_440610] ' s iris color 
usin<>  the sca le  ro vi ded  A endix  E. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 AppendixE  

Clinical Study Proto col 
John son & John son Vision Care, Ine. 
- CR-6521, v 3.0 JJVC C ONFIDE NTIAL  
Page 28 of 163   
  
 
 
 
 
 
 
Visit 1: Lens Fittin #[ADDRESS_440611] the fitting lens power s based on ve1t ex­ 
con-ecte d subjecti ve refraction for each eye, with 
consideration of the following guidelines:  
1. Label cylinde r axis should be determined by 
[CONTACT_353886] s to the  
nearest 1O deg rees. Axis  ending  in the digit  '5' 
should be rounded toward s [ADDRESS_440612] -the-rule astigmatism (e.g., 
175 should be rounded to 180, 105 should be 
roun ded to 100). 
2. Cylinder power should be cho sen based on  the 
following table:   

Clinical Study Proto col 
John son & John son Vision Care, Ine. 
- CR-6521, v 3.0 JJVC C ONFIDE NTIAL  
Page 29 of 163   
 
 
 
Visit 1: Lens Fittin #1  
Step  Procedure  Details  
   
 
 
 
 
 
 
 
3. The fitting lens spherical  equivalent  (SE) 
power (label sphere power + 1/2 of the label  
cylinder power ) should be as close as possible  
to the SE of the vertex -con ec ted refrac tion. If 
the  SE  of  the  vertex -con ected  refra ction is 
exac tly halfv.•ay betv. •een two label  SE powers , 
the least minu s label  ower should be fi t first.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1.[ADDRESS_440613]  for datnage  and 
remo ve. reinsert or re lace as necessa  . 
1.17 Time d rotation 
assessments during 
settling period  Start a stopwatch (or suitable smartphoneor tablet 
tirnin g app) as soon as the right lens is inse1et d. Reco rd 
lens rotation (direction and magnitude) to the nearest 
degree at one (1) and three (3) minu tes following 
inser tion. 
Note: All lenses in this study ha ve scribe mark s at the 
6 o'clock  position  and rotation measuremen ts are made 
relative to a ve1tical  reference  line.  
 
 
 
 
 
 
 
 1.[ADDRESS_440614] for datnage and  
remo ve, reinsert, or re lace as necessa . 
1.19  Time d rotation 
assessments during 
settling period  Start a stopwatch (or suitable smartphoneo r tablet 
tirnin g app) as soon as the left lens is inse1et d. Record 
lens rotation  (direction  and magnitude)  to the nearest 
degree at one (1) and three (3) minu tes following 
inse1tion . 
Note: All lenses in this study ha ve scribe mark s at the 
6 o'clock  position  and rotation measuremen ts are made 
relative to a ve1tical  reference  line.  
1.[ADDRESS_440615]  
15 minutes followin<> left lens inser tion.  
Ve1tex conected 
cylinde r powe r (X) 
within the range : (DC)   
Label cylin der power to 
be fit (DC ) 
-0.625  X < -1.125  -0.75 
-1.125  X < -1.625  -1.25  
 
Clinical Study Proto col 
John son & John son Vision Care, Ine. 
- CR-6521, v 3.0 JJVC C ONFIDE NTIAL  
Page 30 of 163   
  
 
Visit 1: Lens Fittin #[ADDRESS_440616] for each eye:  
1. The rotational position to the nearest degree  
2. Lens stabi lity with blinks  
3. Toric  fit accepta bility. The toric  lens fit will 
be designated as ' unacceptable ' if either : 
a. The lens ABSOLUTE ROTATION is 
greater than [ADDRESS_440617] will be discontinued (proceed to final  
evaluation .  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1.22 General lens fit 
assessmen t The fitting  characteristics  of the lens in both eyes will 
be assesse d using a s lit lamp. Lens position 
(centration , limbal  exposure , edge  lift) and movement 
(prima ry and up gaze as well as push -up) will be 
assesse d. Fit accep tability is defined as any lens that 
does not display the following general fit 
characteristics : 
• Limb al exposure (presence o f clear comea ) in 
any direction of gaze . 
• Edge lift. 
• Insufficient movement in ali three movement  
assessments (primary gaze , up-gaze and push­  
up test). 
• Exce ssive movement in prima1y  gaze.  
If the ge neral fit is unaccepta ble for either eye, the 
subjec t will be discon tinued (proceed to exi t 
evaluation . 
1.23 Spherica l over-refrac tion Perfonn monocular spherical over -refraction using 
duo-chrome  to refme  the endpoin t as described in step 
1.11 (the final  spherical  endpoint  may be detennined  
binocularly) . 
The spherical over-refraction must be plano in both 
eyes to continue . 
If a non-plano over-refractionis found in either eye, 
the lens(es) must be refit with the indica ted change  in 
sphere power. If the indica ted lens power is not 
available for either eye (e.g., outside the available 
SKU  range) , the subject will be discontinued  (procee d 
to fmal evaluation . 

Clinical Study Proto col 
John son & John son Vision Care, Ine. 
- CR-6521, v 3.0 JJVC C ONFIDE NTIAL  
Page 31 of 163   
 Visit 1: Lens Fittin #1  
Step  Procedure  Details  
1.24 Lens modification (if 
nece ssa1y) If modification is necessary in one or both eyes, select 
the re ason for refitting len ses: 
• The settled lens rotation is such that a 
different cylinder axis would be more  
appropriate (use the LARS  rule to determine  
the replacemen t lens cylinder  axis)  
• The spherical  over -refraction  is not plano  
• Other (specify  reason ) 
Repe at steps  1.[ADDRESS_440618]-fit PRO 
questionnaire  Subjects will comp lete a PRO  questionnaire  regarding 
the initial comfo1t , vision and handling  of the study 
lense s. 
1.26 Additi onal sample of 
toric lens orien tation ( I) Instruct the subjec t to leave the consulting room and 
walk  around for at least [ADDRESS_440619] weari ng the study 
lense s. 
1.29 Dispensing criteria  Lenses may be dispen sed if both following  conditions 
are met: 
1. The monocular distance visual acuity wi th the 
study  lenses is equal  to or better  than 20/[ADDRESS_440620] indica tes that the comfo1t  and vision 
with the study len ses is acceptable . 
If either of these conditions is not met, the subjec t will 
be discontinued  roceed to exi t evaluation .  
1.30 Dispensing instruc tions If the study lenses are su itable for di spensing: 
• Instruct  the subjec t to wear  the study  lenses for at 
least 8 hour s per day (in a daily wear / daily 
dispo sable modality ) on at least [ADDRESS_440621] not wear their habitual 
lenses at any time dmi ng the dispensing period. 
• Provide the subjec t with a copy  of the Patient 
Instruction  Guide . 
• Preser vativ e-fre.e rewetting drop s are pe1mitted , if 
needed . 
• Dispense enough lense s  for the subjec t to 
comple te the wear period (i.e., up to and including  
their schedu led follow -up visit). At the 
investigator 's discretion , in instances where there 
is a high likelihood of the subject need ing 
replacement lense s (e.g., due to subjec t activ ities, 
unavaila bili of su·b ect or site durin the wear   

Clinical Study Proto col 
John son & John son Vision Care, Ine. 
- CR-6521, v 3.0 JJVC C ONFIDE NTIAL  
Page 32 of 163   
 
Visit 1: Lens Fittin #1  
Step  Procedure  Details  
  period, high likelihood ofl ens tears, etc.), one 
additional spare pair may be dispensed. 
1n the event that a subject require s additional 
lenses due to loss or damage , they may retum to the 
clinica l site for lens rep lacement. As much as 
reasonab ly possible, damaged lenses and packaging 
should be retumed to the clinica l site (in solution , if 
possib le) for shipp ing to the Sponsor.  If lens datnage  is 
present , complete the Product Quality Complai nt 
Fonu, store the lens ina labeled vial with sahne and 
retum it to the Sponsor . 
• Ensure the subject is aware of the con-ect len s 
power  for each  eye (label  the lenses with R and L 
as appropriate) . 
• Instruct the subjec t to bring their habitual  
spectacles or contact [CONTACT_353887] (to 
wear  follow ing remo val of the study lenses). 
• Instruct  the subjec t to also bring any unwom study 
lense s to the next visit.  
1.31  Schedule next visit Schedule the follow -up visit to occ ur in 7±2 days  
(coun ting the day of this visit as day O, the su bject may 
retum on day 5 through 9). Ensure the subject is 
instructed to wear the study lenses for at least [ADDRESS_440622] lenses to this visit to wear followi ng study lens 
remo val. 
 
Visit 2: Follow-U #[ADDRESS_440623]' s medical history 
(including adverse events) or concomitan t medica tions.  
 
 
 2.[ADDRESS_440624] repo1ted oc ular symptoms in 
response to a verbal open -ended symptoms 
uestio nnaire. 

Clinical Study Protocol 
[COMPANY_012] Vision Care,  Ine. 
- CR-6521, v 3.0 JJVC C ONFID ENTIAL  
Page 33 of 163  
 
 
 
Visit 2: Follow -U #1  
 Step  Procedure  Details  
2.5 Follow -up PRO 
questionnaire  Subjec ts will complete a PRO questionnaire to assess 
their experience with the study lenses.  
Note : at the end oj the second wear pel'iod (Visit 4: 
Follo w-Up #2 ) the PRO questionnaire ,vi/1 a/so 
ine/ude questions regarding lens preference  
bet, veen the lenses worn in thefirst and second  
wear eriods .  
2.[ADDRESS_440625] (HLHC ) visual acuity using ETDRS charts at 4 
meters. 
Measure each eye using the cha1 t s shown in the table 
below·  
 
 
 
 
 
 
 
 
 
Recorded letter -b -letter results into EDC.   
2.[ADDRESS_440626]  de0   -·ee. 
2.9 Addi tional sample of 
toric lens orientation (1) Instrnct the subject to lea ve the consulting room and 
walk around fo r at least [ADDRESS_440627]  de0   -·ee in each e  e. 
2.[ADDRESS_440628] will be 
moni tored as per the guidelines  given  in section  13. 
Shou ld the clearance of the fluorescein need to be 
expedited , preservative -free rewetting drops or a1tificial 
tears may be instilled.  
Study lenses may be discarded if there is no reason to  
store them followin<> biomicrosco  
2.[ADDRESS_440629]  wearing  their  habitual  
co!1'ec tion . 
Condition  HLHC  
Room illumination  > 400 lux 
Cha1t luminance  120 - 200 c d/m2 
Eye OD os 
Cha1ts  HC-1 
HC-2 HC-3 
HC-4 
 
Clinical Study Protocol 
[COMPANY_012] Vision Care,  Ine. 
- CR-6521, v 3.[ADDRESS_440630] be discon tinued , an 
adverse event will be recorded, and the subjec t will be 
moni tored as per the guideline s given in section 13. 
Should the clearance  of the fluorescein  need  to be 
exped ited, preservati ve free rewetting  drops  or 
a1tificia l tears ma be in stilled. Biomicroscopy  3.5 3.4 3.3 3.2 Ste 
3.1  
 
Visit 2: Follow-U #1  
Step  Procedure  Detai ls 
2.14  Schedu le next visit Schedule the next visit (Visit 3) to occur following a 
washout period of 7±2 days (coun ting the day of this 
visit as day O, the su bjec t may retum  on day 5 through 
9). Subjec ts may wear their habitua l lenses durin g the 
washout eriod .  
 
VISIT [ADDRESS_440631] reported ocu lar 
symptoms  
 
Entran ce visual acuity  
 
 
Remo ve habitua l lenses (if 
wom)  Visit 3: Continuance 
Detai ls 
Record any changes to the subjec t's medical hi story 
or concomitan t medication s. 
 
Record  any subjec t repo1ted  ocular symptoms  in 
response to a verbal open -ended  symp toms 
uestio nnaire.  
Record the entrance distance Snellen visual acuity for 
OD and OS with the subject wearing their habitua l 
con-ection . 
If wom, the subjec t's habitual contact [CONTACT_353888]. Lenses may be stored in a lens ca se, if 
re uired.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 V i s it 3: Lens Fittin g #2  
The steps followed  will be the same as those listed under Visit 1: Lens Fittin g #1. 
VISIT [ADDRESS_440632] 1 hour prior to the visit. 
Subjects should brin g their own habitua l spectacle s or contac t lenses to this visit to wear following study lens 
removal. 
 
  Visit 4: Follow-Up #2  
 
The steps followed  will be the same  as those listed  unde r Visit 2: Follo w-Up #1, up to and includ ing step 2.12 
'Biomicro scopy' (' Exit visual acuity' and 'Schedu le next visit' will not be completed here). Addi tionally , a 
Preferen ce Questionnairewil l be comple ted as pati ofthe  Follow -UpPRO  questionnaire  (step 2.5). 
Clinical Study Protocol 
[COMPANY_012] Vision Care,  Ine. 
- CR-6521, v 3.[ADDRESS_440633]-coITected 
distance visual acuity (OD and OS) to the nearest  letter . 
 
Note: This step is notneces saiy if the subjec t was exited 
due to scre.en failure.  
F.3 Exit Slit Latnp 
Biomicro scopy (for 
subject s that are 
discontinued eai·ly)  FDA Slit Lamp Classifica tion Scale will be used to 
grade the findings.  
 
If the cleai·ance  of the fluore  sc ein needs  to be expedited , 
preser vativ e-free re wetting drop s or saline may be 
instilled. This step is not necessaiy if the subject was 
exited due to screen  failure . 
 
Note: This step is notneces sa1y if the subjec t was exited 
due to screen failure, or if biomicroscopy was 
perfo1med  as patiof the final  follo w-up visit procedure s 
i.e„ immediatel rior to the final evaluati on .  
 
 
 
7.3. Unschedul ed Visits 
If , during  the investigation , a subjec t requires  an unscheduled  visit to the clinical  site, the follo wing information 
will be collected , as appropriate:  
• Chief complaint prompting the visit. If the reason is an adverse event, the applicable eCRF for the 
adverse event must be comple ted and subject record completed as appropria te. 
• Date  and time of the visit and all procedures  completed  at the unscheduled  visit. 
• Review of adverse event and concomitant  medication s. 
• Documentation of any test a1ticle dispensed or collec ted from the subjec t, if applicable . 
• Slit lainp  finding s (using the Slit Lamp  Classification  Scale) . 
 
If the Investigator  withdraws  a subjec t from  the study, the final  study  visit case repo1t  fonn s must  be completed 
indica ting the reason(s) why the subject  was withdrawn.  The subjec t record  must  be completed  documenting  the 
date and primary  reason for withdrawal and the study  CRA  notified.  
 
Any ocular and non -ocular Adverse Events that are ongoing at the time of the study visit will be follo wed by [CONTACT_3786] , within licen sure, until they ha ve resol ved, retumed to pre-treatment status , stabilized , or been 
satisfactorily explained . If futther treatment i.e., beyond licen sure is required , the subjec t will be refeITed to the 
appropriate health cai·e pro vider . 
 
The follo wing info1mation will be collec ted during an unschedu led visit. 

Clinical Study Protocol 
[COMPANY_012] Vision Care,  Ine. 
- CR-6521, v 3.[ADDRESS_440634] articles.  If the reason is 
other than resupply of previously dispensed  lense s, 
s  ec the reason for the visit.   
U.2 Chief Comp laints (if 
a licable  Record the subject' s chief complaint s for reason s for 
the unschedu led visit.  
U.3 Adverse E vents and 
Concomi tant 
Medications Review (if 
a licable  Review any changes  to the subject ' s medica l history or 
concomi tant medications from the previous study visit. 
Record any changes , and any adverse events.  
U.4 Entrance VA (if 
a licable  Record the entrance distance visual acuity (OD, OS) to 
the nearest letter. 
 U.5 Subjec tive Sphero­  
cylindrical Refraction (if 
applicable ) Perfo1m bare -eye sub jective spherocylindrica l 
refraction with a phorop ter (adopt the maximum plu s 
to maximum visual acuity (MPMVA) approach and 
use the duo-chrome test for binocu lar balancing ) and 
record the best cot1'ected distance  visua l acuity to the 
neare st letter OD, OS . 
U.6 SlitLamp 
Biomicro scopy (if 
applicabl e) FDA Slit Lamp Classification Sca le will be used to 
grade the findings. If the clearance of the fluore scein 
needs to be expedited , preservati ve-free re wetting  
dro s ma be in stilled.  
U.7 Dispensing (if 
applicable ) If the subjec t require s additional lenses to comple te the 
wear  period  and is eligible  to do so, provide additiona l 
lenses per the dispensing instmctions  given  in the 
detailed stud rocedures.   
 
 
 
 u.s Exit Visual Acuity (if 
a licable  Record the subject' s exit di stance visua l acuity (OD, 
OS to the nearest letter.  
 
NOTE : If the onl y rea son fo1· the unschedul ed visit is that the subje ct requir es additional te st article s, only 
the dispensing information n eeds to be record ed. 
 
7.4. Laborator y Procedure s 
Not applic able. 
 
 
8. SUBJECTS COMPLETI ON/WITHDR AWAL 
 
8.1. Completion  Criteria  
Subjects are con sidered to have comp leted the study if they:  
• provided infonned  consent.  
• they are eligible . 
• have  not withdra wn/discontinued  from  the study for any reason described  in section  8.2. 
• comple ted ali visits through  the final  visit (visit 4). 
• If ali visits were completed but an additiona l visit is considered nece ssary for subject care, follow the 
requirements  for unscheduled  visits in section  .7.3. 
 
8.2. Withdra wal/Di scontinuation  from  the Study 
A subject will be withdrawn from the study for any of the follo wing rea sons: 
• Subject withdra wal of consent. 
• Subject not compliant to protocol.  

Clinical Study Protocol  
Page 37 of 163   
 [COMPANY_012] Vision Care, Inc.  
 
• Subject lost to follow -up. 
• Subject no longer meets eligibility criteria (e.g. the subject becomes  pregnant).  
• Subject  develops  significant  or serious  adverse  events  necessitating  discontinuation  of study  lens wear.  
• Subjects who have experienced a Corneal Infiltrative Event  (CIE).  
• Investigator’s  clinical  judgment  regarding  the subject  safety  reasons  (that it is in the best interest  of the 
subject to stop  treatment).  
• Subject missed any study visits  
• Subject not compliant with study lens wear schedule.  
• Subject not successfully dispensed due to lack of efficacy and safety including poor vision, poor 
comfort, or unacceptable  fit. 
 
For discontinued subjects, the Investigator will:  
• Complete the current vis it (scheduled or  unscheduled).  
• Complete the Final Evaluation, indicating the reason that the subject was discontinued from the  study.  
• Record the spherocylindrical refraction with best corrected distance visual  acuity.  
• Collect used test article(s) (worn or brought to the visit) from the subject and discard them, unless 
otherwise stated in section  7.2. 
• Collect all unused test article(s) from the  subject.  
• Make arrangements for subject care, if needed, due to their study participation 
Additional subjects may be  enrolled if a subject discontinues from the study  prematurely.  
In cases where a subject is lost to follow -up, every possible effort must be made to contact [CONTACT_169764]/withdrawal. The measures taken to follow up must be documented 
including two written attempts and a certif ied letter (or equivalent) as the final attempt.  
 
 
9. PRE -STUDY AND CONCOMITANT  INTERVENTION/MEDICATION  
Concomitant medications will be documented during screening and updated during the study. Disallowed 
concomitant  interventions  for this study  include  ocular  medications  of any kind,  or any systemic  medications  that 
would normally contraindicate contact [CONTACT_350482] s wear or may otherwise compromise study  endpoints.  
 
9.1. Systemic  Medications  
Certain systemic medications are known to have a higher likelihood to interfere with contact [CONTACT_13279], chiefly 
by [CONTACT_35509].  
 
A summary of disallowed systemic medicat ions is shown in Table 4 . Subjects with a history of taking these 
medications will be allowed to enroll only if:  
• The medications have been taken on a continual, routine basis for at least 6 months,  and 
• The subject has demonstrated successful contact [CONTACT_13293] w ear during this  time.  
Or:  
• The subject  was taking  the medication  on a temporary  basis  and ceased  taking  that medication  at least 2 
weeks  prior  to signing  the informed  consent  (this is considered  sufficient  time for the medication  to have 
left the body prior to  enrollment).  
 
Subjects  with a history  of taking  medications  listed  in Table  4 on a long-term,  routine  basis  for less than 6 months 
will not be allowed to participate in the  study.  
 
 
 
 
 
 
 
 
 
 
CR-6521,  v 3.0 JJVC CONFIDENTIAL  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Ine. 
- CR-6521, v 3.0 JJVC CONFIDEN TIAL 
Page 38 of 163  
  
Table 4 : Disallowed systemic medic ations 
 
Class of Drug  Common Indication(s)  Common Examples  
Estrogens (not 
including 
contraceptive 
medication)  Menopause, os teoporo sis, vaginitis Vagifem , Estrace, Climara , Vivelle-Dot, 
Premarin , Minivelle , etc. 
Anticholinergics  In-itable bowel syndrome , Parkin son ' s 
disease, peptic ulcer , cystitis, nasal 
congestio n, cold symptoms, overacti ve 
bladder , COPD  Bentyl , Spi[INVESTIGATOR_35444] , Atro vent, Hyosyne , 
Levsin, Symax Fastab , Symax SL , 
Homax SL , Coge ntin, Tran sdenn Scop, 
etc. 
Beta -blocker s Hype 1tension,     angina,      heart      attack, 
migraine , atrial fibrillatio n, andrenal 
cancer, essential tumor , glaucoma  Toprol XL , Lopre ssor, Tenonnin, 
Propranolol , Timoptic , Trandate , Inderal 
LA, etc. 
Psychotropic s Antip sychotic (schizophrenia, mania) , 
antidepre ssion, antiobse ssive, antianx iety, 
mood stabi lizer, stimulant s (ADHD ) Zoloft , Celexa, Prozac ,  Lexapro , 
Effexor , Cymbalta , Ativan, Xanax , 
Desyrel, Wellb utrin, etc. 
Vitamin A analog s Cystic acne  Isotreti noin  
Analgesics  Urinruy tract infection  Phenazopyr idine HCL  
 
Example s of disallowed  system ic antihis tamines are given in Table  S. Subjec  ts wi th a hist01y  oftaking  systemic 
antihistam ines will be allowed to enroll only  if: 
• They have taken  antih istamines  continuous ly for at least 2 weeks,  and 
• They have demonstrated successfu l wear while taking the medication  
Or: 
• They stopped taking the medication for at least 2 weeks prior to enrollmen t. 
 
 
Table 5: Disallowed systemic antihistamines  
 
Class of Drug  Common Indica tion(s) Com mon Examples  
Antihi stamines  Allergic rhinitis , sedation , hives, allergic 
conjuncti vitis, skin allergy, itchin g, motion  
sickne ss Hydroxyz ine, Promethagan , Phenadoz , 
Vistaril, Claritin, Zyitec , Astepro, 
Astelin, Optivar, Allegra , Benadryl , etc. 
 
 
 
10. DEVIA TIONSF ROM THE PROT OCO L 
Investigator will notify study sponsor upon identific ation of a protocol de viation. Protocol de viations must be 
repo1ted to the sponsor within 24 hours after discov e1y of the protocol de viation. The In vestigator will report 
deviations per IRB/IEC requiremen ts. All deviations will be t racked, and con -ective actions implemen ted as 
appropr iate. 
 
If it become s necessa1y for the Investigator to implement a de viation in order to eliminate an immedia te hazru·d 
to the trial subject, the Investigato r may implemen t the deviation immediately without notification to the sponsor. 
Within [ADDRESS_440635] notify and provide the rationale to the 
Sponsor and as required , the IEC/IRB. 
 
If the deviation potentially impac ts the safety of patient or change s the technic al integrity of the  study,  then  it  
must be repo1 t ed to IEC /IRB. This is a "Maj or Deviatio n". Deviations that contradict the info1mation contained  
in the Infon ned Consent/Assent fonn  s will be considered  Major  Deviatio ns. 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Ine. 
- CR-6521, v 3.[ADDRESS_440636] on patient safety or techni cal integrity  of the study. They  are often 
logistical in nature. 
 
Protocol waivers are proh ibited . 
 
Table 6 lists examp les of deviations  that will constitute major  and mino r protocol  deviations for this study . 
Table 6: Exam ples of major and minor  protocol deviations 
Deviation ca tego1y  Maio r deviation  Minor de viation 
Out-of-windo w visit Visit atten ded > 3 days out of visit 
window defined  in study 
procedure s Visit attended  3 days out of visit 
window defined  lll study 
procedures  
Unanswered PRO que stions If  questionnaire is not comp leted 
(i.e., all questions are unanswered) 
for any visit questionnaire , or more 
than 2 questions are unans wered 
for   the   follo w-up   visit  CLUE  
auestionnaire . Any individua! or multiple PRO 
question s (2 or less) are 
unans wered (i.e., left blank). 
Insufficien t wear of study lenses Subject does not wear study  lenses 
for at least [ADDRESS_440637] will be excluded from the 
Per-Protocol analysis population will be made at the time of coho1t review. 
 
 
11. STUDY TERM INATION 
The occm1·ence  of one or more  Unan ticipated  Serious  Adverse  Device Effec t ([LOCATION_003]DE),  or any SAE  where the 
relationship  to study agen t cannot  be rnled out, may resul t in stoppi[INVESTIGATOR_353853]. 1n the 
event of a [LOCATION_003] DE or SAE,  the Sponsor  may unma sk the treatmen t regimen  for the subject(s) and will discuss 
this with the Investigato r before  any fmiher  subjects are enrolled.  
 
The Sponsor  will detennine  when a study  will be stopped . The Principa l Investigator always  has the discretion to 
initiate stoppi[INVESTIGATOR_353854] 's results are compromised.  
 
JNC reserves the righ t to te1mina te the study at any time for any reason. Addi tionally , the IEC /IRB reserves the 
right to tenninate the study if an unreasonable risk is dete1mined . The study can be tenninate d by [CONTACT_353889] r at the individua ! clinical site due to specific clinical ob servations, if in their opi[INVESTIGATOR_1649], after a discussion 
with JN C, it is detennined that it would be unwise to continue at the clinical site. 
 
JNC (and the IEC/IRB and DMC, if applicable ) will evaluate all adverse  events. If it is determined  that an adve rse 
event presents an unreasonable risk, the inves tigation, or that pa1t of the inves tigation presenting the risk, will be 
te1minate d as soon as possible. 
 
Should the study be te1mi nated (either prematm ·ely or as sched uled), the Investigat or will notify the IEC/IRB and 
Regu lato1yAu thority  as required  by [CONTACT_353890]1yrequirement s. 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.[ADDRESS_440638] Quality Complaint (PQC) refers to any written, electronic, or oral communication that alleges 
deficiencies related to the identity, quality, durability, reliability , safety, effectiveness, or performance of test 
articles after they have been released for clinical trial use.  
 
Potential complaints may come from a variety of sources including but not limited to subjects, clinical research 
associates  (CRA),  clinical  operations  managers  (COM),  medical  monitors,  and site personnel,  etc. The following 
are not considered product quality  complaints:  
• Subject  satisfaction  inquiries  reported  via “Subjective  Questionnaires”  and “Patient  Reported  Outcomes 
(PRO).”  
• Clinical test articles that are stored improperly or damaged after receipt at the investigational  site. 
• Lens replacements that occur due to  drops/fall -outs.  
• Damage deemed by [CONTACT_35513], and not indicat ive 
of a quality deficiency (i.e. tears, rips, etc.), only in situations where there is no deficiency alleged by 
[CONTACT_423].  
 
Within [ADDRESS_440639] be recorded in the 
EDC system, which will trigger an automatic email notification to the appropriate COM/CRA and Clinical QA 
representative. In cases where the EDC syste m in use is not configured to send automatic notifications or when 
an EDC system is not used, the COM/CRA is responsible for notifying Clinical QA upon discovery that a PQC 
has occurred.  
 
Upon receipt of the EDC notification, the COM/CRA will contact [CONTACT_941] s tudy site to collect additional information 
which will include:  
• Date the complaint was received/recorded in the EDC System (Date of Sponsor  Awareness).  
• Who received the  complaint.  
• Study number.  
• Clinical site information (contact [CONTACT_2300], site ID, telephone nu mber).  
• Lot number(s).  
• Unique Subject  Identifier(s).  
• Indication of who first observed complaint (site personnel or  subject).  
• OD/OS indication, along with whether the lens was  inserted.  
• Any related AE number if  applicable.  
• Detailed complaint description (scheduled/unscheduled visit, wear time, symptoms, resolution of 
symptoms, etc.).  
• Eye Care Provider objective (slit lamp) findings if  applicable.  
• Confirmation of product availability for return (and tracking information, if available), or rationale if 
product is not available for  return  
 
Once  a complaint  is received,  it will be assesse d by [CONTACT_19569],  CRA,  or trained  site personnel  to determine  if it is 
an Adverse Event/Serious Adverse Event (AE/SAE). If the complaint results in an AE/SAE, the COM/CRA, or 
trained  site personnel  will follow  section  13 of this protocol.  If the AE/SAE  was potentially  the result  of a product 
quality related deficiency, the se procedures also apply and will be executed in  parallel.  
 
In some cases, a PQC form may be generated in EDC by [CONTACT_35514]. In this event, the PQC forms will be 
marked “Intentionally Left Blank” or “ILB”. Justification for ILB must be documented.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 41 of 163   
  
13. ADVERSE  EVENTS  
 
13.1. Definitions and  Classifications  
Adverse Event (AE) – An AE is “any untoward medical occurrence, unintended disease or injury, or untoward 
clinical signs (including abnormal laboratory findings) in subjects, users or other persons, whether or not related 
to the investigational medical device and whether ant icipated or unanticipated.”  
NOTE: This definition includes events related to the investigational medical device or the comparator, 
and to the procedures involved. For users or other persons, this definition is restricted to events related to 
investigationa l medical devices.1 
 
An AE includes any condition (including a pre -existing condition) that:  
1. Was not present prior to the study, but appeared or reappeared following initiation of the  study.  
2. Was present  prior  to the study  but worsened  during  the study.  This would  include  any condition  resulting 
from concomitant illnesses, reactions to concomitant medications, or progression of disease  states.  
NOTE: Pregnancy must be documented as an adverse event and must be reported to the clinical monitor 
and to the Spons or immediately upon learning of the event.  
 
Serious Adverse Event (SAE) – An SAE is any adverse event that led to any of the following:  
• Death  
• Serious deterioration in the health of the subject that resulted in any of the  following:  
• Life-threatening illness or injury  
• Permanent or persistent impairment of a body structure or a body  function  
• Hospi[INVESTIGATOR_353855] n 
• Medical  or surgical  intervention  to prevent  life-threatening  illness  or injury  or permanent  impairment  to 
a body structure or a body  function.  
• Chronic  disease  
• Foetal distress, foetal death or a congenital physical or mental impairment of birth  defect.  
 
Diagnoses and conditions that are considered Ocular Serious Adverse Events include, but not limited to:  
• Microbial Keratitis  (MK)  
• Iritis (including cells in the anterior  chamber)  
• Permanent decrease in best spectacle corrected visual acuity equivalent to 2 ac uity lines or  greater  
• Central Corneal  Opacity  
• Central Corneal  Neovascularization  
• Uveitis  
• Endophthalmitis  
• Hypopyon  
• Hyphemia  
• Penetration of Bowman’s Membrane  
• Persistent Epi[INVESTIGATOR_93791]  
• Limbal cell Damage leading to  Conjunctivalization  
 
Significant  Adverse  Events  – are defined  as events  that are symptomatic  and warrant  discontinuation  (temporary 
or permanent) of the contact [CONTACT_353891], but not limited t o the 
following:  
• Contact [CONTACT_35516] (CLPU)  
• Significant Infiltrative Events  (SIE)  
• Superior Epi[INVESTIGATOR_32955]  (SEALs)  
• Any Temporary Loss of > 2 Lines of  BSCVA  
• Other grade 3 or higher corneal findings, such as abrasions or  edema  
• Non-contact [CONTACT_71176] - e.g. Epi[INVESTIGATOR_71155]  (EKC)  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 42 of 163   
  
• Asymptomatic Corneal  Scar 
• Any corneal event which necessitates temporary lens discontinuation > 2  weeks  
 
Non-Significant  Adverse  Events  – are defined  as those  events  that are usually  asymptomatic  and usually  do not 
warrant discontinuation of contact [CONTACT_35517] a reduct ion in wear time. However, the Investigator 
may choose to prescribe treatment as a precautionary  measure.  
 
Diagnoses and conditions that are considered Ocular Non -Significant Adverse Events include, but not limited to 
the following:  
• Non-significant Infiltr ative Event  (NSIE)  
• Contact [CONTACT_19573][INVESTIGATOR_19534]  (CLPC)  
• Superficial Punctate Keratitis  (SPK)  
• Conjunctivitis: Bacterial, Viral,  Allergic  
• Blepharitis  
• Meibomianitis  
• Contact  [CONTACT_32984]  
• Localized Allergic Reactions  
• Any corneal  event  not explicitly  defined  as serious  or significant  adverse  event,  which  necessitates  
temporary lens discontinuation < [ADDRESS_440640] (ADE) – An ADE is an “adverse event related to the use of an investigational medical 
device.”  
NOTE 1: This defini tion includes adverse events resulting from insufficient or inadequate instructions 
for use, deployment, implantation, installation, or operation, or any malfunction of the investigational 
medical device.  
NOTE 2: This definition includes any event resultin g from use error or from intentional misuse of the 
investigational medical device.[ADDRESS_440641] (UADE) – A UADE is any serious adverse effect on health or safety or 
any life -threatening problem or death caused by, or associated wit h, the test article, if that effect, problem, or 
death was not previously identified in nature, severity, or degree of incidence in the investigational plan, 
Investigator’s Brochure or protocol, or any other unanticipated serious problem associated with th e test article 
that relates to the rights, safety and welfare of subjects.  
 
13.2. Assessing Adverse Events  
In conjunction with the medical monitor, the Investigator will evaluate adverse events to ensure the events are 
categorized correctly. Elements of categorization will include:  
• Seriousness/Classifications (see definition in section  13.1).  
• Causality or Relat edness – i.e. the relationship between the test article, study treatment or study 
procedures  and the adverse  event  (not related,  unlikely  related,  possibly  related,  or related  - see definition 
in section  13.2.1).  
• Adverse Event Severity – Adverse event severity is used to assess the degree of intensity of the adverse 
event (mild, moderate, or severe - see definition in section  13.2.2).  
• Outcome – not recovered or not resolved, recovering or resolving, recovered or re solved with sequelae, 
recovered or resolved, death related to adverse event, or  unknown.  
• Actions Taken – none, temporarily discontinued, permanently discontinued, or  other.  
 
13.2.1.  Causality Assessment  
Causality Assessment – A determination of the relationship be tween an adverse event and the test article. The 
test article relationship for each adverse event should be determined by [CONTACT_32981]:  
• Not Related - An adverse event that is not related to the use of the test article, study tre atment or study 
procedures.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 43 of 163   
  
• Unlikely  Related  – An adverse  event  for which  an alternative  explanation  is more  likely,  e.g. concomitant 
treatment, concomitant disease(s), or the relationship of time suggests that a causal relationship is not 
likely.  
• Possibly Related – An adverse event that might be due to the use of the test article, or to the study 
treatment or study procedure s. An alternative explanation, e.g. concomitant treatment, concomitant 
disease(s), is inconclusive. The relationship in time is reasonable. Therefore, the causal relationship 
cannot be  excluded.  
• Related – An adverse event that is listed as a possible adver se effect (device) or adverse reaction (drug) 
and cannot be reasonably explained by [CONTACT_4867], e.g. concomitant treatment of 
concomitant disease(s). The relationship in time is very suggestive, e.g. it is confirmed by [INVESTIGATOR_5328] -challenge 
and re -challenge.  
 
13.2.2.  Severity Assessment  
Severity Assessment – A qualitative assessment of the degree of intensity of an adverse event as determined by 
[CONTACT_19577]/her by [CONTACT_423]. The assessment of severity is made irrespective of test 
article, study treatment or study procedure relationship or seriousness of the event and should be evaluated 
according to the following scale:  
• Mild – Event is noticeable to the subject but is easily tolerated and does not interfere with the subject’s 
daily a ctivities.  
• Moderate – Event is bothersome, possible requiring additional therapy, and may interfere with the 
subject’s daily  activities.  
• Severe – Event is intolerable, necessitates additional therapy or alteration of therapy and interferes with 
the subject ’s daily  activities.  
 
13.3. Documentation and Follow -Up of Adverse Events  
The recording and documenting of adverse events (ocular and non -ocular) begin when the subjects are exposed 
to the test article, study treatment or study procedure. Adverse events reported before the use of test article, start 
of study  treatment,  or study  procedures  will be recorded  as medical  history.  However,  if the condition  deteriorates 
at any time during the study, it will be recorded and reported as an AE. Untoward medical events reported after 
the subject’s exit from the study will be recorded as adv erse events at the discretion of the  Investigator.  
 
Upon finding an adverse event, the Principal Investigator [INVESTIGATOR_353856].  
 
Complete  descriptions  of all adverse  events  must  be available  in the subject  record.  All Adverse  Events  including 
local and systemic reactions not meeting the criteria for “serious adverse events” shall be captured on the 
appropriate case report form or electronic data system. All adv erse events occurring while the subject is enrolled 
in the study must be documented appropriately regardless of  relationship.  
 
It is the Investigator’s  responsibility  to maintain  documentation  of each reported  adverse  event.  All adverse  events 
will be foll owed in accordance with applicable licensing requirements. Such documentation will include the 
following:  
• Adverse event (diagnosis not  symptom).  
• Drawings  or photographs  (where  appropriate)  that detail  the finding  (e.g.,  size, location,  and depth,  etc.).  
• Date the clinical site was  notified.  
• Date and time of  onset.  
• Date and time of  resolution.  
• Adverse event classification, severity, and relationship to test articles, as  applicable.  
• Treatment regimen instituted (where appropriate), including concomitant medications prescribed, in 
accordance with applicable licensing requirements.  
• Any referral to another health care provider if  needed.  
• Outcome, ocular damage (if  any).  
• Likely etiology.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 44 of 163   
  
• Best corrected visual acuity at the discovery of the event and upon conclusion of the event, if the AE is 
related to the visual  system.  
 
Upon discovery of an AE that is deemed ‘possibly related’ or ‘related’ to the test article or study pro cedures 
(whether  related  to the visual  system  or not),  an AE review  form  must be completed. Additional 
dated and initialed entries should be made at follow -up evaluations. Separate forms must be completed for each 
eye if the AE is bilateral.  
 
In addition, if an infiltrate(s) is present, he/she will complete the Corneal Infiltra te Assessment eCRF. Where 
necessary, a culture of the corneal lesion will be collected to determine if the infection is microbial in nature. If 
cultures are collected, the date of culture collection and laboratory utilized will be recorded.  
 
Changes  in the severity  of an AE shall  be documented  to allow  an assessment  of the duration  of the event  at each 
level  of intensity  to be performed.  Adverse  events  characterized  as intermittent  require  documentation  of the onset 
and duration of each epi[INVESTIGATOR_1865]. Changes in the assessment of relationship to the test article shall also be clearly 
documented.  
 
Subjects  who present  with an adverse  event  shall  be followed  by [CONTACT_737],  within  licensure,  until all signs 
and symptoms  have  returned  to pre-treatment  status,  stabilized,  or been  satisfactorily  resolved.  If further  treatment 
beyond  licensure  is required,  the patient  will be referred  to the appropriate  health  care provider.  The Investigator 
will use his/her clinical judgment as to whether a subject reporting with an adverse event will continue in the 
study. If a subject is discontinued from the study, it will be the responsibility of the Investigator to record the 
reason  for discontinuation.  The Investigator  will also document  the adverse  event  appropriately  and complete  the 
Adverse Event eCRF. Any subjects with ongoing adverse events related to the test article, study treatment or 
study procedures, as of the final study visit dat e, should be followed to resolution of the adverse event or until 
referral to an appropriate health care provider, as recommended by [CONTACT_737]. Non -ocular adverse events 
that are not related  to the test article,  study  treatment,  or study  procedures  may be recorded  as “ongoing”  without 
further  follow -up. 
 
13.4. Reporting Adverse Events  
The Investigator  will notify  the Sponsor  of an adverse  event  by e-mail,  facsimile,  or telephone  as soon  as possible 
and no later than 24 hours from discovery for any serious /significant adverse events, and 2 days from discovery 
for any non-significant  adverse  event.  In addition,  a written  report  will be submitted  by [CONTACT_45822] 
[INVESTIGATOR_35451]/IRB ac cording to their requirements (section 13.4.2). The report will comment whether the adverse 
event was considered to be related to the test article, study treatment or study  procedures.  
13.4.1.  Reporting Adverse Events to Sponsor 
Serious/Significant Adverse  Events  
The Investigator  will inform  the sponsor  of all serious/significant  adverse  events  occurring  during  the study  period 
as soon as possible by e -mail or telephone, but no later than 24 hours following discovery of the event. The 
Investigator  is obligated  to pursue  and obtain  information  requested  by [CONTACT_353892]. Al l subjects experiencing a serious/significant adverse event must be followed up and all 
outcomes must be  reported.  
 
When medically necessary, the Investigator may break the randomization code to determine the identity of the 
treatment  that the subject  received.  The Sponsor  and study  monitor  should  be notified  prior  to unmasking  the test 
articles.  
 
In the event of a serious/significant adverse event, the Investigator must:  
• Notify the Sponsor  immediately.  
• Obtain  and maintain  in the subject’s  records  all pertinent  medical  information  and medical  judgment  for 
colleagues who assisted in the treatment and follow -up of the  subject.  
• Provide the Sponsor with a complete case history which includes a statement as to whether the event 
was or was not related to the use of the test  article.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 45 of 163   
  
• Notify the IEC/IRB as required by [CONTACT_6179]/IRB reporting procedure according to national  regulations.  
 
Unanticipated (Serious) Adverse Device Effect (UADE)  
In the event of an Unanticipated (Serious) Adverse Device Eff ect (UADE), the Investigator will submit a report 
of the UADE to the Sponsor and IEC/IRB as soon as possible, but no later than [ADDRESS_440642] report the results of the evaluation to FDA, the 
IEC/IRB and participating Investigators within [ADDRESS_440643].  
 
Non-Serious Adverse Events  
All non -serious adverse events, including non -serious adverse device effects, will be reported to the sponsor by 
[CONTACT_35521] 2 days from discovery.  
 
13.4.2.  Reporting Adverse Events to the Responsible IEC/IRB and Health  Authorities  
Adverse event s that meet the IEC/IRB requirements for reporting must be reported within the IEC/IRB’s written 
guidelines. Each clinical site will refer to and follow any guidelines set forth by [CONTACT_19581]/IRB. Each 
clinical site will refer to and follow any gu idelines set forth by [CONTACT_19582].  
 
The Sponsor will report applicable Adverse Events to the local health authorities according to the written 
guidelines, including reporting timelines.  
 
13.5. Event of Special  Interest  
None.  
 
13.6. Reporti ng of  Pregnancy  
Subjects reporting pregnancy (by [CONTACT_6270] -report) during the study will be discontinued after the event is recorded as 
an Adverse Event. Once discontinued, pregnant participants and their fetuses will not be monitored for study 
related  purposes . Pregnant  participants  are not discontinued  from  contact  [CONTACT_353893], but due to general concerns relating to pregnancy and contact [CONTACT_19584]. Specifically, pregnant women 
are discontinued due to fluctuations in ref ractive error and/or visual acuity that occur secondary to systemic 
hormonal changes, and not due to unforeseen health risks to the mother or  fetus.  
 
 
14. STATISTICAL  METHODS  
 
14.1. General  Considerations  
Statistical  Analysis  will be undertaken  by [CONTACT_353894].  A general  description 
of the statistical methods to be implemented in this clinical trial is outlined below. More details will be included 
in the stand -alone Statistical Analysis Plan (SAP). The SAP will be developed and  finalized prior to database 
lock.  
 
All data summaries and statistical analyses will be performed using the SAS software Version 9.4 SAS Institute, 
Cary, NC)7. Throughout the analysis of data, the results for each subject/eye will be used when available fo r 
summarization and statistical analysis. For the analysis of co -primary safety endpoints, unscheduled visits will 
be summarized separately and will not be excluded from the statistical analysis. However, for the analysis of co - 
primary efficacy endpoints and secondary endpoints, unscheduled visits will be summarized separately and 
excluded from the statistical analysis.  
 
Summary  tables  (descriptive  statistics  and/or  frequency  tables)  will be provided  for all baseline  variables,  efficacy 
variables  and safet y variables  as appropriate.  Continuous  variables  will be summarized  with descriptive  statistics  
Clinical Study Protocol 
Page 46 of 163   
 
John son & John son Vision Care, Ine. 
 
(n, mean , standard  deviation(SD) , median , minimum  and maximum ). Frequency  count  and percentage  of subject.s 
or eyes within  each  catego1y will be provided  for categorical  data. 
 
Summ aries  will be presented  by [CONTACT_353895]  (basel ine, fitting  and 1-week  follow -up) and will 
be perfo1med  separately by [CONTACT_353896] (Safety  Popu lation, Per-Protocol  Popula tion or Intent -to-treat, when 
appropri ate). 
 
14.2. Sampl e Size Justification  
This study was designed and powered to test for superiori ty of the test lens after [ADDRESS_440644] 
to the following: distance monocu lar HLHC visual acuity ( logMAR), subjective vis ion scores , toric lens 
orientation, and rotationa l stability. This study was also powered to test superiori ty of the test lenses with respect 
to grade [ADDRESS_440645] for superior ity with respec t to CLUE Comfo1t and Hand ling scores a fter 1-week of lens 
wear. The described  alpha  adjus tment is also factored  into these estimations  of sample size and power.  
 
The sample size for co-prima 1y efficac y endpoi nts was estim ated to achiev e a minimu m statistical power of 90% 
for distance monocular visua l acuity (logMAR) , toric lens orientation, ro tationa l stability, and CLUE Vision 
scores  using  a 2-sided  type I eITor  rate of 5%. Co-prima1y safety  endpoints  (grade  3 or higher  SLFs  and acceptable 
lens fitting) were estima ted to achieve a minimum statistical power of 99% wi th 95% centra l posterior credible 
interval . 
 
A summa1y of his torical studies utilized in the samp le size calculation are s umm arized in Table [ADDRESS_440646] lens by [CONTACT_353897] t. 
Table  7: Historical Stud ies Utilized  for Samp le Size Calculations 
 
 
Study Nu=m=:b:.e.::r:-4-  
-=D;.,e;:..s;:.i:.;..:=---1 
2x3  
---=S.t;u;;;;;d::. 1:P.....:h::a;;;s;:..e;:;     -1 
Feasibility  Numbe r Number  in Safety  Number in  PP 
-_  -=E==nr ol::::el.d.:;    --11--- ..:.-=Po=  =ul a:.t.i;::.o.;:.n::;    ,1.-_  ..i:;.o;:;.i:;.;u:;;::a:;l;t;i:::.o.;:.n::;  ---- 1 
145 144 133 
  2x3 Confoma tion 126 26 119 
PP: Per-Protocol 
 
Table 8: Historical Data by [CONTACT_353898] t - Test Lens  
 
 
Endpoint Tvue   
Endpoint  Data 
Tvue   
Value  
*Primary Safety  Grade 3 + SLFs (Adverse Even t) 
Rate  0% 
Acceptab le Lens Fitting  100%  
 
**Prima1y 
Efficacy  Distance Monocu lar Visual Ac uity (logMAR)   
Mean 
(SD) -0.115 (0.0769)  
Abso lute Toric  Rotation  10° 97.5% 
Lens  Stability  with Blinks  5° 100%  
CLUE Vision Scores  67.4 (19.67) 
 
**Secondary  CLUE Handling Scores  Mean 
(SD) 65.4 (21.50)  
CLUE Comfo rt Scores  67.9 (21.50)  
SD=Standard Deviation  
*Summ aries for the primai y safety endpoints were provided for the safety population; all ava ilable data was 
included  
**Summ aries for primary efficacy and seconda1y endpoints were provided for the per-protocol popu lation at the 
1-week follow -up evalua tion. 
 
 
 
Clinical Study Protocol 
Page 47 of 163   
 CR-6521, v 3.0 -  
 
 
JJV C CONFIDE NTIAL  
Clinical Study Protocol 
Page 48 of 163   
 [COMPANY_012] Vision Care, Inc.  
 
Co-Primary Safety Endpoint Sample Size Calculations:  
 
Grade 3 or Higher Slit Lamp Findings (SLFs)  
Grade 3 or Higher SLFs related to study lens wear will be converted to a binary response as 𝑌𝑌 = [ADDRESS_440647] 
eye has a clinically significant SLF, and 𝑌𝑌 = 0 otherwise, for analysis purposes. From the historical data there 
was none or an extremely low rate (< 1%) for clinically significant SLFs (Grade 3 or higher) for the test lens. 
Assuming a correlation of 0.[ADDRESS_440648], a total of 5000 replicating 
trials were simulated with a reference rate of 2% (worse -case scenario). Given the rare event binary outcome of 
slit lamp findings, each replicated sample was analyzed using a Bayesian beta -binomial model with correlated 
binary data (Diniz et al; 2010).8 For each simulated trial, the upper bound of the 95% central posterior credible 
interval constructed for the percentage of grade [ADDRESS_440649] lens was compared to a margin of 
5%. With the proposed sample siz e, at least 99% of the estimated 95% credible intervals had the upper bound 
below 5%.  
 
Acceptable Lens Fitting  
Acceptable  lens fitting  will be converted  to a binary  response  as 𝑌𝑌 = [ADDRESS_440650]  eye has acceptable  lens fitting, 
and 𝑌𝑌 = 0 otherwise , for analysis purposes. As indicated in the historical data of these lenses there was an 
extremely high rate (> 99%) acceptable lens fitting for the test lens. Assuming a correlation of 0.[ADDRESS_440651], a total of 5000 replicating trials were simulated with a reference rate of 
99% (worse -case scenario). Given the rare event binary outcome of Y=0 (unacceptable lens fitting), each 
replicated sample was analyzed using a Bayesian beta -binomial model with correlated bina ry data (Diniz et al; 
2010).8 For each simulated trial, the upper bound of the 95% central posterior credible interval constructed for 
the percentage of acceptable lens fittings for the test lens was compared to a margin of 80%. With the proposed 
sample si ze, at least 99% of the estimated 95% credible intervals had the lower bound above  80%.  
 
Co-Primary Efficacy Endpoint Sample Size Calculations:  
 
Distance Monocular Visual Acuity (logMAR) and CLUE Vision Scores  
Sample size calculations for visual acuity and vision scores were carried out separately using one -sided, one - 
sample  mean  t-test, with a type I error  rate of 5% for each hypothesis.  The hypothesis  regarding  visual  acuity  was 
powered to 99%, while the hypo thesis for CLUE Vision scores was powered to 91%. Sample size calculations 
were performed using the One-Sample T -Tests for Superiority by a Margin procedure in Power Analysis & 
Sample  Size (PASS2021)  software  Version  21.0.6  (NCSS  LLC,  Kaysville  UT).[ADDRESS_440652]  an 80% threshold  and have  an event  rate greater  than 97%.  A reference  rate of 
97.5%  was used for toric lens orientation,  while  a worst -case scenario  of 98% was used for rotational  stability.  
 
Toric  lens orientation  and rotational  stability  will be converted  to a binary  response  as 𝑌𝑌 = [ADDRESS_440653]  eye has 
absolute toric lens orientation ≤ 10° (rotational stability: Y=[ADDRESS_440654] eye has lens stability with blinks ≤ 5°) 
and 𝑌𝑌 = 0 otherwise,  for analysis  purposes.  As indicated  historical  data of these  products  there  was an extremely 
high rate (> 97%) for both toric lens orientation and rotational stability for the test lens. Assuming a correlation 
of 0.[ADDRESS_440655], a total of 5000 repli cating trials were simulated with 
a reference rate of 97.5% for toric rotation and 98% for rotation stability (worse -case scenario). Given the rare 
event binary outcome of Y=0, each replicated sample was analyzed using a Bayesian beta -binomial model with 
correlated  binary  data (Diniz  et al; 2010).8 For each simulated  trial, the upper  bound  of the 95% central  posterior 
credible interval constructed for the percentage of acceptable lens fittings for the test lens was compared to a 
margin  of 80%.  With  the proposed  sample  size, at least 99% of the estimated  95% credible  intervals  had the lower 
bound above 80%.  
 
Secondary Endpoint Sample Size Calculations:  
 
 
 
 
 
 
 
CR-6521,  v 3.0 JJVC CONFIDENTIAL  
Clinical Study Protocol 
Page 49 of 163   
 [COMPANY_012] Vision Care, Ine. 
 
CLUE Handling and Comfo1 t Scores  
Sample size calculations for handling and comfo1 t scores we re caITie d sepa rate ly ou t using one -sided, one -sample 
mean t-test, with a type I eITor rate of 2.5% for each hypothesis . To  preserve  the  overall  study  power ,  each 
endpoint was powered to 99%. Samp le size calcu lations were perfo1med  using  the  One-Sample  T -Tests  for 
SuperiOl'i ty b y a Margin procedure in Power Analysis & Samp le  Size (PASS2021)  software  Version  2 1.0.6 
(NCSS LLC, Kays ville UT).9 
 
Table 9 below, displays  samp le size estima tes by [CONTACT_77433].  As indica ted below , co-primary  safety  endpoin ts were 
powered ~99% individual ly yieldin g a combined powe r of ~98%. With respect to co-prima1y efficacy , each 
hypothesis , except  for CLUE  Vision (powered  to 91%)  was powered  to ~99% , which provided a combine  power 
of ~88% . Therefo re, the overall comb ined study  power  for co-primary  safety  and co-primaiy  efficacy  hypo theses 
is ~86%  and is considere d reasona ble to suppo 1t  any conclusion s from  these analyse s. Furthe1 more, seconda1y 
endpoints  were  powe red to achieve at least 99%  statis tical power.  This  was considered  to have a minimal  impact 
on overall study  power  because of the multibranch  gate keepi[INVESTIGATOR_353857]. 
 
Table 9: Samo le Size Estima tes fo r Co-Primarv Safetv. Efficacv and Seco ndarv End)oints  
Endpoint 
Tvoe  
Endpoint  
Test Tvoe Sample 
Size  
Power (% ) 
Prima1y 
Safety  Grade 3 or Hillher SLFs (5%) Statisticallv less then (5%)  100 99 
Accep table Lens Fitting (%) Statistically gre ater then  
(80% ) 100 99 
 
 
Prima1y 
Efficacy  Distance (4m) Monocu lar Visua l 
Acuitv (lollMAR)  Super iority (0.00 ) 9 99 
Absolute Toric Rotation  < 100 Statistically gre ater then  
( 80   % ) 40 99 
Lens  Stabi lity with Blinks  5° Statistically grea ter then 
(80%) 100 99 
CLUE Visio ns Scores  Suoeriori tv (62)  144 91 
Seconda1y  CLUE Hand ling Scores  Suoeriori tv (61) 135 97 
CLUE Comfo1 t Scores  Suoeriori tv (58)  [ADDRESS_440656] 165 subjects. Data collec ted 
from  this study  may be utilized  to pe1fonn  a meta -analysis  at a later date, therefore , the targe t comp letion  for this 
study  was increased  to 165 subjects to accommoda te this possibi lity. 
 
14.3. Analysis Populations 
Safety Population: 
All subjects who are adminis tered any test article  excluding  subjects who drop  out prior  to administering  any test 
article . At least one observa tion should be recorded.  
 
Per-Protocol Population: 
All subjec ts who successfully  comp lete all visits and do not substa ntially deviate  from  the protocol as detennined 
by [CONTACT_353899]1t  review  collllllittee  prior to database hard lock. Justification for the exclusion  of subjects with 
protocol deviations  from  the per-protocol  population  set will be documented  in a memo  to file. 
 
Intent-to-Treat (I TT) Population: 
All randomized subjects regardless of actua l treatment and su bsequent withdrawal from the study or deviation 
from the protocol. A t least one observa tion s hould be recorded . 
 
14.4. Level of Statistical Significance 
All co -prima1y safety , co-primary efficacy , and secondaty hypotheses will be tested using a multibranch gate 
keepi[INVESTIGATOR_353858] . Study hypotheses will be evaluated sequentially as follows:  
 
Clinical Study Protocol 
Page 50 of 163   
 CR-6521, v 3.0 -  
 
 
JJVC CONFIDE NTIAL 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 51 of 163   
 � 𝑍𝑍 =  
First, co -primary safety hypotheses will be evaluated using 95% central posterior credible intervals for the 
probability  of grade  [ADDRESS_440657] co- 
primary efficacy hypotheses. Ea ch co -primary efficacy hypothesis will be tested with a type I error rate of 5%. 
All co -primary safety and co -primary efficacy hypotheses must be met to test any secondary hypotheses. 
Secondary hypotheses will be tested utilizing a Bonferroni adjustment10 with an overall two -sided family -wise 
type I error rate of 5% (2.5%  individually).  
 
14.5. Primary Analysis  
Methodology regarding the plan for testing and/or handling statistical associations between co -primary safety 
and/or efficacy endpoints will be documented in the SAP.  
 
Co-Primary Safety Analyses:  
All primary safety analysis will be conducted on the safety population.  
 
Grade 3 or Higher SLF  
Grade 3 of Higher SLFs will be analyzed using a Bayesian beta -binomial model with correlated binary data.8 
 
The Model:  
Let 𝑌𝑌1   and 𝑌𝑌2   denote the binary outcomes of lens fit acceptance (Yes/No) in left and right eyes, respectively, 
across dispensing and follow-up visits when wear ing the test lens. Considering the correlation, 𝜌𝜌, between  𝑌𝑌1  and 
𝑌𝑌2, the distribution of the sum 𝑌𝑌  =  𝑌𝑌1   +  𝑌𝑌2  is obtained by [CONTACT_340377]. One of them follow a 
binomial distribution 𝐵𝐵𝐵𝐵𝐵𝐵(2, 𝑝𝑝) with mixing probability (1 −  𝜌𝜌) and the other one follows a modified Bernoulli 
distribution, 𝑀𝑀𝐵 𝐵𝑀𝑀𝑀𝑀𝐵𝐵(𝑝𝑝), taking value 0 and 2 rather than conventional 0 and 1, with mixing probability 𝜌𝜌: 
 
𝑃𝑃(𝑌𝑌  =  𝑦𝑦| 𝑝𝑝, 𝜌𝜌)  =  (1 −  𝜌𝜌)𝐵𝐵𝐵𝐵𝐵𝐵(2, 𝑝𝑝)𝐼𝐼𝐴𝐴1   +   𝜌𝜌𝑀𝑀𝐵 𝐵𝑀𝑀𝑀𝑀𝐵𝐵(𝑝𝑝)𝐼𝐼𝐴𝐴2  , 
 
where 𝐼𝐼𝐴𝐴1    =  {0, 1, 2}, 𝐼𝐼𝐴𝐴2  =  {0, 2} and 𝑝𝑝 is the probability of success (i.e., acceptable lens fitting). 
 
To overcome the complexity of the mixture likelihood a latent variable 𝑍𝑍𝑖𝑖 , i = 1, 2 is introduced in the model to 
indicate in which component of the model the observation 𝑦𝑦𝑖𝑖 , i=1, 2, belongs to, that is,  
1, if the observation belong  to the MBern(p),  
𝑖𝑖 � 0, if the  observation  belong  to the  Bin(2,  p) 
The joint distribution of the augmented data (𝑌𝑌𝑖𝑖 , 𝑍𝑍𝑖𝑖 ), 𝐵𝐵 = 1, 2 , is given by  
P(Y = y , Z = z | p, ρ) = ρzipyizi/2(1 − p )(2−y i)zi/2(1 − ρ )1−z i 2 � p 
i i yi yi(1−z i)(1 − p)(2−y i)(1−z i) 
The probability p links to the regression variables through a logit transformation as follow:  
 
logit (p) =   β 0  +  β 1lens  
 
It is assumed that β0, β1 and 𝜌𝜌 to be independent with a non -informative prior N(0, 1000) for β0 and β1, and 
beta(0.5, 0.5) for 𝜌𝜌. The Metropolis sampler algorithm as implemented in the SAS/STAT  MCMC Procedure7 will 
be used to estimate the posterior distributions of the parameters (β0, β1, 𝜌𝜌). Inferences will be made based on a 
posterior credible interval for the relevant  parameters.  
 
Bayesian Estimation and Statistical Evaluation of Hypothesis:  
Superiority  of the test lens relative  to the pre-defined  threshold  with respect  to grade  3 or higher  will be evaluated 
using Bayesian  statistics.  
 
Primary Safety Hypothesis 1:  
The null and alternative hypotheses for evaluating superiority of the test lens relative to 5% are as follows:  
 
 
𝐻𝐻0: 𝑝𝑝T  ≥ 5% 
𝐻𝐻𝐴𝐴: 𝑝𝑝T  < 5%, 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.[ADDRESS_440658] lens. Based on Bayesian 
posterior  probability  distribution  of the proportion  𝑝𝑝𝑇𝑇 , superiority  is interpreted  as 95% probability  of test being 
statistically lower than the threshold of 5% (i.e., 𝑝𝑝T  < 0.05). If the upper bound of the 95% central posterior 
credible interval is below 0.05, it can be concluded that there is 95% probability that the test lens is superior to 
5% (statistically less than) based on the observed  sample.  
 
In the case of zero clinically significant SLF, a Bayesian hierarchical model accounting for zero -event problem 
will be considered.8 
 
Acceptable Lens Fitting  
Lens fit acceptance will be analyzed using a Bayesian beta -binomial model with correlated binary data.8 
 
Bayesian Estimation and Statistical Evaluation of Hypothesis:  
Superiority of the test lens relative to the pre -defined threshold with respect to accept able lens fitting will be 
evaluated using Bayesian statistics.  
 
Primary Safety Hypothesis 2:  
The null and alternative hypotheses for evaluating superiority of the test lens relative to 80% are as follows:  
 
𝐻𝐻0: 𝑝𝑝T  ≤ 80%  
𝐻𝐻𝐴𝐴: 𝑝𝑝T  > 80%, 
where 𝑝𝑝T  is the probability of event (i.e., probability of acceptable lens fitting while wear ing the test lens). Based 
on Bayesian  posterior  probability  distribution  of the proportion  𝑝𝑝𝑇𝑇 , superiority  is interpreted  as 95% probability 
of the test lens being statistically larger than the pre-defined threshold of 80% (i.e., 𝑝𝑝T  > 80) with respect to 
acceptable lens fitting rate. If the lower bound of the 95% central posterior credible interval is above 80%, it can 
be concluded  that there  is 95% probability  that the test lens is superior  to the 80% threshold  (statistically  greater) 
based on the observed sample.  
 
In the case of all eyes have  an acceptable  lens fit (i.e., zero unacceptable  lens fits), a Bayesian  hierarchical  model 
accounting for zero -event problem will be considered.8 Details of this model will be provided in the stand -alone 
SAP.  
 
Co-Primary Efficacy Analyses  
 
Visual Acuity (VA)  
Distance, monocular, high -luminance, high -contrast (HLHC), VA after [ADDRESS_440659] characteristics such as, gender, age and/or cylinder power may be included in the model if 
appropriate. Site ID and subject nested within site will be included in the model as random effects (G -side). The 
residual error between measurements within the same subject across study period will be modeled using an 
unstructured (UN) covariance structure. If the model fails to converge with a UN covariance, then a compound 
systemic  (CS)  covariance  structure  will be used.  The Kenward  and Roger  Method  will be used for the denominator 
degrees  of freedom.11 Visual  Acuity  scores  will be estimated  using  95% confidence  intervals  (CI) constructed  for 
the least -square means  (LSM).  
 
 
Primary Efficacy Hypothesis 1:  
The null and alternative  hypothesis  for distance  monocular  HLHC  VA to test for superiority  of test relative  to the 
threshold 0.0 logMAR are as  follows:  
 
𝐻𝐻 𝑜𝑜 : 𝜇𝜇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇  ≥ 0 logMAR  
𝐻𝐻𝐴𝐴: 𝜇𝜇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇  < 0 logMAR  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.[ADDRESS_440660]  to distance 
monocular HLHC VA. Superiority will be declared if the upper limit of the 95% CI is below  0.0. 
 
 
Toric Lens Orientation and Rotational Stability at Least 15 - Minutes Following Lens Settling  
Absolute toric lens orientation (degrees) will be dichoto mized as Y=1 if the absolute lens orientation (degrees) ≤ 
10° and Y=0, otherwise. Rotational stability will be quantified by [CONTACT_353900] (degrees). Lens 
stability will be dichotomized as Z=1 if the lens stability with blinks (degrees) ≤ 5° a nd Z=0, otherwise.  
 
Y and Z will be analyzed separately using a generalized linear mixed model with a binary distribution and the 
logit as the link function. Sequence of lens wear, lens type and period will be included in the model as fixed 
effects. Subjec t characteristics such as, gender, age and/or cylinder power may be included in the model if 
appropriate. Site ID and subject nested within site will be included in the model as random effects (G -side). The 
residual error between measurements within the sa me subject across study period will be modeled using an 
unstructured (UN) covariance structure. If the model fails to converge with a UN covariance, then a compound 
systemic  (CS)  covariance  structure  will be used.  The Kenward  and Roger  Method  will be used for the denominator 
degrees of  freedom.11 
 
 
Primary Efficacy Hypothesis 2:  
The null and alternative hypothesis to test for superiority of absolute lens orientation ≤ 10° for the test lens 
relative to the threshold 80% are as follows:  
 
𝐻𝐻𝑜𝑜 : 𝑝𝑝𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇    ≤ 80% 
𝐻𝐻𝐴𝐴: 𝑝𝑝𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇  > 80%  
 
Where  𝑝𝑝𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇  , represents  the population  percentage  for the percentage  of eyes wearing  the test lens with absolute 
lens orientation ≤ 10°. Superiority will be declared if the lower limit of the 95% CI is above  80. 
 
Depending on the observed response rates for the percentage of subjects’ eyes with absolute lens orientation ≤ 
10° and the percentage of subjects’ eyes with lens stability with blinks ≤ 5°, a Bayesian hierarchical model 
accounting for zero event problem may be considered (i.e., 0% of eyes with toric rotation >10° [or lens stability  
>5°]) . Details of this model will be provided in the stand -alone SAP . 
 
Primary Efficacy Hypothesis 3:  
The null and alternative  hypothesis  to test for superiority  of lens stability  with blinks  ≤ 5° for the test lens relative 
to the threshold 80% are as  follows:  
 
𝐻𝐻𝑜𝑜 : 𝑝𝑝𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇    ≤ 80% 
𝐻𝐻𝐴𝐴: 𝑝𝑝𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇  > 80%  
Where 𝑝𝑝𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇  , represents the population percentage for the percentage of eyes wearing the test lens with lens  
stability with blinks ≤ 5°. Superiority will be declared if the lower limit of the 95% CI is above 80.  
 
CLUE Vision Scores  
CLUE  vision  scores  after [ADDRESS_440661] characteristics such as, gender, age and/or cylinder power may be included in the model if appropriate. 
Site ID will be included in the model as a random effect (G -side). The residual error between measurements 
within the same subject will be modeled using an unstructured (UN) covariance structure. If the model fails to 
converge  with a UN covariance,  then a compound  systemic  (CS)  covariance  structure  will be used.  The Kenward 
and Roger  Method  will be used for the denominator  degrees  of freedom.11 CLUE  Vision  Scores  estimates  for each 
study  lens will be estimated  using  95% confidence  intervals  (CI) constructed  for the least-square  means  (LSM).  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 54 of 163   
  
Primary Efficacy Hypothesis 4:  
The null and alternative hypothesis to test for superiority of CLUE vision score for the test lens relative to the 
threshold 62 are as follows:  
 
𝐻𝐻𝑜𝑜 : 𝜇𝜇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇  ≤ 62 
𝐻𝐻𝐴𝐴: 𝜇𝜇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇  > [ADDRESS_440662]  to CLUE  vision 
scores. Superiority will be declared if the lower limit of the 95% CI is above  62. 
 
14.6. Secondary Analysis  
CLUE Handling and Comfort Scores  
CLUE Handling and Comfort scores after [ADDRESS_440663]  characteristics  such as, gender,  age and/or  cylinder  power  made  be included 
in the model if appropriate. Site  ID will be included in the model as a random effect (G -side). The residual error 
between  measurements  within  the same  subject  will be modeled  using  an unstructured  (UN)  covariance  structure. 
If the model  fails to converge  with a UN covariance,  then a compound  systemic  (CS)  covariance  structure  will be 
used. The Kenward and Roger Method will be used for the denominator degrees of freedom.11 CLUE Handling 
and Comfort scores for each study lens will be estimated using 97.5% confidence intervals (CI) const ructed for 
the least -square means  (LSM).  
 
Secondary Hypothesis 1:  
The null and alternative  hypothesis  to test for superiority  of CLUE  Handling  score  for the test lens relative  to the 
threshold 61 are as follows:  
 
𝐻𝐻𝑜𝑜 : 𝜇𝜇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇  ≤ 61 
𝐻𝐻𝐴𝐴: 𝜇𝜇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇  > [ADDRESS_440664]  to CLUE 
Handling scores. Superiority will be declared if the lower limit of the 97.5% CI is above  61. 
 
Secondary Hypothesis 2:  
The null and alternative hypothesis to test for superiority of CLUE Comfort score for the test lens relative to the 
threshold 58 are  as follows:  
 
𝐻𝐻𝑜𝑜 : 𝜇𝜇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇  ≤ 58 
𝐻𝐻𝐴𝐴: 𝜇𝜇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇  > [ADDRESS_440665]  to CLUE 
comfort scores. Superiority will be declared if the lower limit of the 97.5% CI is above  58. 
 
 
14.7. Exploratory Analysis  
 
Ability to see comfortably while driving during the day or Reduction in the feeling of tired eyes from using a  
computer or other digit al device  
Subjective responses for exploratory endpoints will be the outcome ( aval) defined as category one if a subject’s 
response is ‘Excellent’, ‘Very Good’, ‘Fair’, or ‘Poor’.  
 
 
My vision was clear enough to allow me to drive at night  
Subjective responses for exploratory endpoints will be the outcome ( aval) defined as category one i f a subject’s 
response is ‘Strongly Agree’ or ‘Agree’, the outcome is defined as category two if a subject’s response is ‘Not 
Applicable’, ‘Strongly Disagree’, ‘Disagree’, or ‘Neither Agree nor Disagree’.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 55 of 163   
  
Statistical Model:  
The outcome for e ach item will be analyzed separately using a generalized linear mixed model with a binary 
distribution and the logit as the link function. In each model, sequence of lens wear, period, lens type will be 
included  as fixed  effects.  Site will be included  as a random  effect.  Residual  errors  between  measurements  within 
the same  subject  will be modeled  using  an unstructured  covariance  (UN)  structure.  Comparisons  between  the test 
and control will be carried out using 2 -sided 95% confidence intervals ( CIs) constructed for the odds ratio (test 
over control). Non -inferiority will be concluded if a lower limit of a 95% CI is above  0.67.  
 
 
Hypothesis Testing  
The null and alternative hypothesis to test for non -inferiority of the test lens compared to the con trol lens will be 
conducted separately for each item as follows:  
 
Ho: OR ≤ 0.67 
Ha: OR > 0.[ADDRESS_440666] clinical trials 
don’t  provide  the evidence  that subject  dropout  is systematic  or not-at-random.  To evaluate  the impact  of missing 
data,  sensitivity  analysis  will be conducted  using  multiple  imputation  methods  if the proportion  of subject  dropout 
is greater than the 15%. The SAS/ STAT procedures PROC MI and PROC MIANALYZE will be utilized with a 
parametric regression method used to make at least [ADDRESS_440667]  KEEPI[INVESTIGATOR_1645]/ARCHIVING  
 
15.1. Electronic Case Report Form/Data  Collection  
The data for this study  will be captured  on electronic  case report  forms  (eCRFs)  using  the BioClinica  EDC  system. 
An authorized data originator will enter study data into the eCRFs using the EDC system. Data collected on 
equipment that is not captured in EDC will be formatted to the specification of the JJVC database manager and 
sent t o JJVC for analysis.  
 
No external data sources will be included in this study.  
 
The clinical data will be recorded on dedicated eCRFs specifically designed to match the study procedures for 
each visit.  Only  specifically  delegated  staff can enter  data on a CRF.  Once  completed,  the eCRFs  will be reviewed 
for accuracy and completeness and signed by [CONTACT_737]. The sponsor or sponsor’s representatives will be 
authorized to gain access to the subject recordation for the purposes of monitoring and auditing the study.  
 
Edit checks, electronic queries, and audit trails are built into the system to ensure accurate and complete data 
collection. Data will be transmitted from the clinical site to a secure central database as forms are completed or  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 56 of 163   
  
updated, ensuring information accuracy, security, and confidentiality. After the final database lock, the 
Investigator will be provided with Individual Patient Profiles (IPP) including the full audit trail on electronic 
media in PDF format for all of the st udy data. The IPP must be retained in the study files as a certified copy of 
the source data for the study.  
 
The content and structure of the eCRFs are compliant with ISO14155:2020.[ADDRESS_440668] should be available for the following:  
• subject  identification  
• eligibility  
• study identification  
• study discussion  
• provision of and date of informed consent  
• visit dates  
• results of safety and efficacy parameters as required by [CONTACT_93865]  
• a record of all adverse  events  
• follow -up of adverse  events  
• medical history and concomitant  medication  
• test article receipt/dispensing/return records  
• date of study  completion  
• reason for e arly discontinuation of test article or withdrawal from the study, if  applicable  
 
The subject record is the eCRF or an external record. The author of an entry in the subject record must be 
identifiable. The first point of entry is considered to be the sour ce record.  
 
Adverse event notes must be reviewed and initialed by [CONTACT_737].  
 
15.3. Trial Registration on  ClinicalTrials.gov  
This study will be registered on ClinicalTrials.gov by [CONTACT_1034].  
 
 
16. DATA  MANAGEMENT  
 
16.1. Access to Source  Data/Document  
The Investigator/Institution will permit trial -related monitoring, audits, IEC/IRB review and regulatory 
inspection(s) by [CONTACT_353901]/documents. Should the clinical site be contact[CONTACT_353902]/IRB or regulatory authority, JJVC must be contact[CONTACT_19592] [ADDRESS_440669]  and therefore  may disclose 
it as required  to other  clinical  investigators  and to regulatory  agencies.  In order  to allow  the use of the information 
derived from this clinical study, the Investigator understands that he/she has an obligation to provide complete 
test results and all data developed during this study to the  Sponsor.  
 
16.3. Data Quality  Assurance  
Steps will be taken to ensure the acc uracy and reliability of data, including the selection of qualified investigators 
and appropriate clinical sites and review of protocol procedures with the Principal Investigator. The Principal  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.[ADDRESS_440670] access to study -related source data/documents and reports for the purpose of monitoring and 
auditing by [CONTACT_353903].  
 
16.4. Data Monitoring Committee  (DMC)  
Not applicable.  
 
 
17. CLINICAL  MONITORING  
The study monitors will maintain close contact [CONTACT_35530] [INVESTIGATOR_3355]’s designated 
clinical site personnel. The monitor’s responsibilities will include:  
• Ensuring that the investigation is being conducted according to the proto col, any subsequent versions, 
and regulatory requirements are  maintained.  
• Ensuring the rights and wellbeing of subjects are  protected.  
• Ensuring adequate resources, including facilities, laboratories, equipment, and qualified clinical site 
personnel.  
• Ensuring that protocol deviations are documented with corrective action plans, as  applicable.  
• Ensuring that the clinical site has sufficient test article and  supplies.  
• Clarifying questions regarding the  study.  
• Resolving study issues or problems that may arise.  
• Reviewing of study records and source documentation verification in accordance with the monitoring 
plan.  
 
 
18. ETHICAL AND REGULATORY  ASPECT S 
 
18.1. Study -Specific Design  Considerations  
Potential  subjects  will be fully  informed  of the risks  and requirements  of the study,  and, during  the study,  subjects 
will be given any new information that may affect their decision to continue participation. Subjects will be told 
that their consent to participate in the study is voluntary and may be withdrawn at any time with no reason given 
and without penalty  or loss of benefits to which they would otherwise be entitled. Subjects will only be enrolled 
if they are fully able to understand the risks, benefits, and potential adverse events of the study and provide their 
consent  voluntarily.  
 
18.2. Investigator  Responsi bility  
The Principal Investigator [INVESTIGATOR_353859], the investigational plan, according to ISO [ZIP_CODE]:2020,[ADDRESS_440671] maintain clinical study files in accordance with applicable regulatory 
requirements.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.[ADDRESS_440672]  (IEC/IRB)  
Before  the start of the study,  the Investigator  (or Sponsor  when  applicable)  will provide  the IEC/IRB  with current 
and complete copi[INVESTIGATOR_23747] (where  applicable):  
• Final  protocol.  
• Sponsor -approved  informed  consent  form  (and any other  written  materials  to be provided  to the subjects)  
• Investigator’s Brochure (or equivalent  information).  
• Sponsor -approved subject recruitment materials.  
• Information on compensation for study -related injuries or payment to subjects for participation in the 
study.  
• Investigator’s curriculum vitae, clinical licenses, or equivalent information (unless not required, as 
documented by  [CONTACT_8134]/IRB).  
• Information regarding funding, name [CONTACT_19618], institutional affiliations, other potential conflicts 
of interest, and incentives for  subjects.  
• Any other documents that the IEC/IRB requests to fulfill its  obligation.  
 
This study will be undertaken only after IEC/IRB has given full approval of the final protocol, the informed 
consent form, applicable recruiting materials, and subject compensation p rograms, and the Sponsor has received 
a copy of this approval. This approval letter must be dated and must clearly identify the documents being 
approved.  
 
During  the study,  the Investigator  (or Sponsor  when  applicable)  will send the following  documents  to the IEC/IRB 
for their review and approval, where  appropriate:  
• Protocol  revisions  
• Revision(s) to informed consent form and any other written materials to be provided to  subjects  
• If applicable, new or revised subject recruitment materials approved by [CONTACT_16049] 
• Revisions  to compensation  for study -related  injuries  or payment  to subjects  for participation  in the study  
• Investigator’s Brochure  revisions  
• Summaries of the status of the study (at least annually or at intervals stipulated in guidelines of the 
IEC/IRB)  
• Reports  of adverse  events  that are serious,  unanticipated,  and associated  with the test articles,  according 
to the IRB’s  requirements  
• New information that may adversely affect the safety of the subjects or the conduct of the  study  
• Major protocol deviations as required by [CONTACT_146017]/IRB  
• Report of deaths of subjects under the Investigator's  care 
• Notification if a new Investigator is responsib le for the study at the clinical  site 
• Any other requirements of the  IEC/IRB  
 
For protocol revisions that increase subject risk, the revisions and applicable informed consent form revisions 
must be submitted promptly to the IEC/IRB for review and approval b efore implementation of the change(s).  
 
At least once  a year,  the IEC/IRB  will review  and reapprove  this clinical  study.  This request  should  be documented 
in writing.  
 
At the end of the study, the Investigator (or Sponsor where required) will notify the IEC/IRB about the study 
completion. Documentation of this notification must be retained at the clinical site and a copy provided to the 
CRO or Sponsor as applicable.  
 
18.4. Informed  Consent  
Each  subject  or their representative,  must  give written  consent  according  to local  requirements  after the nature  of 
the study has been fully explained. The consent form must be signed before performance of any study -related 
activity.  The consent  form  that is used must  be approved  by [CONTACT_353904]/IRB.  The 
informed consent is in accordance with principles that originated in the Declaration of Helsinki,2 and ISO 
[ZIP_CODE]:[ZIP_CODE] guidelines, applicable regulatory requir ements, and Sponsor Policy.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.[ADDRESS_440673]'s dated signature. After having obtained the consent, a copy of the informed consent form must be given 
to the subject.  
 
18.5. Privacy of Personal  Data  
The collection, processing and disclosure of personal data and medical information related to the Study Subject, 
and personal data related to Principal Investigator [INVESTIGATOR_71158] (e.g., name, clinic address and 
phone number, curricul um vitae) is subject to compliance with the Health Information Portability and 
Accountability Act (HIPAA)[ADDRESS_440674] these data, to m aintain the confidentiality of the person’s 
related health and medical information, to properly inform the concerned persons about the collection and 
processing of their personal data, to grant them reasonable access to their personal data and to prevent a ccess by 
[CONTACT_35532].  
 
All information  obtained  during  the course  of the investigation  will be regarded  as confidential.  All personal  data 
gathered in this trial will be treated in strictest confidence by [CONTACT_4718], monitors, Sponsor’s personnel and 
IEC/IRB. No data will be disclosed to any third party without the express permission of the subject concerned, 
with the exception of Spo nsor personnel (monitor, auditor), IEC/IRB and regulatory organizations in the context 
of their investigation related activities that, as part of the investigation will have access to the CRFs and subject 
records.  
 
The collection and processing of personal  data from subjects enrolled in this study will be limited to those data 
that are necessary to investigate the efficacy, safety, quality, and utility of the investigational product(s) used in 
this study.  
 
These data must be collected and processed with ade quate precautions to ensure confidentiality and compliance 
with applicable data privacy protection laws and regulations.  
The Sponsor ensures that the personal data will be:  
• processed fairly and  lawfully.  
• collected  for specified,  explicit,  and legitimate  purposes  and not further  processed  in a way incompatible 
with these purposes.  
• adequate, relevant, and not excessive in relation to said  purposes.  
• accurate and, where necessary, kept  current.  
 
Explicit consent for the processing of personal data will be obtained from the participating subject before 
collection  of data.  Such  consent  should  also address  the transfer  of the data to other  entities  and to other  countries.  
 
The subject has the right to request through the Investigator access to his personal data and the right to request 
rectification of any data that are not correct or complete. Reasonable steps should be taken to respond to such a 
request, taking into consid eration the nature of the request, the conditions of the study, and the applicable laws 
and regulations.  
 
Appropriate technical and organizational measures to protect the personal data against unauthorized disclosures 
or access, accidental or unlawful dest ruction, or accidental loss or alteration must be put in place. Sponsor 
personnel whose responsibilities require access to personal data agree to keep the identity of study subjects 
confidential.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.[ADDRESS_440675]  RETENTION  
In compliance with the ISO [ZIP_CODE]:2020 guidelines,1 the Investigator/Institution will maintain all CRFs and all 
subject records that support the data collected from each subject, as well as all study documents as specified in 
ISO [ZIP_CODE]:2020,1 and all study documents as specified by [CONTACT_8146](s). The 
Investigator/Institution will take measures to prevent accidental or premature destruction of these documents.  
 
Essential  documents  must  be retained  until at least two (2) years  after the last approval  of a marketing  application 
in an ICH region  and until there  are no pending  or contemplated  marketing  applications  in an ICH region  or until 
at least two (2) years  have  elapsed  since  the formal  discontinuation  of clinical  development  of the investigational 
product. These documents will be retained for a longer period if required by [CONTACT_35533]. It is the responsibility of the Sponsor to inform the 
Investigator/Institut ion as to when these documents no longer need to be  retained.  
 
If the responsible  Investigator  retires,  relocates,  or for other  reasons  withdraws  from  the responsibility  of keepi[INVESTIGATOR_169746], custody must be transferred to a person who will accept the responsibility. The Sponsor must 
be notified  in writing  of the name  [CONTACT_353945].  Under  no circumstance  shall  the Investigator 
relocate or dispose of  any study documents before having obtained written approval from the  Sponsor.  
 
If it becomes necessary for the Sponsor or the appropriate regulatory authority to review any documentation 
relating to this study, the Investigator must permit access to such reports.  
If the Investigator has a question regarding retention of study records, he/she should contact [CONTACT_19599].  
 
 
20. FINANCIAL  CONSIDERATIONS  
Remuneration  for study  services  and expenses  will be set forth  in detail  in the Clinical  Research  Agreement.  The 
Research  Agreement  will be signed  by [CONTACT_45822]  [INVESTIGATOR_1238] a JJVC  management  representative  prior  to 
study initiation.  
 
JJVC reserves the right to withhold remuneration for costs associated with protocol violations such as:  
• Continuing an ineligible subject in the study.  
• Scheduling a study visit outside the subject’s acceptable visit  range.  
 
JJVC  reserves  the right  to withho ld final remuneration  until all study  related  activities  have  been  completed,  such 
as: 
• Query resolution.  
• Case Report Form signature.  
• Completion of any follow -up action  items.  
 
21. PUBLICATION  
There is no plan to publish this outcome of this investigation.  
 
 
22. REFERENCES  
1. ISO [ZIP_CODE]:2020:  Clinical  investigation  of medical  devices  for human  subjects  — Good  clinical  practice, 
Available  at: 
https:// www.iso.org/standard/[ZIP_CODE].html  
2. Declaration  of Helsinki  – Ethical  principles  for Medical  Research  Involving  Human  Subjects,  Available 
at: https://www.wma net/policies -post/wma -declaration -of-helsinki -ethical -principles -for-medical - 
research -involving -human -subjects/  
3. United      States      (US)      Code      of      Federal      Regulations      (CFR).  Available at: 
https:// www.gpo.gov/fdsys/browse/collectionCfr.action?collectionCode=CFR  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 61 of 163   
  
4. Straker B.Investigator’s Brochure CR-6521 Toric lens  design in senofilcon A with HEV -blocking 
chromophore  ). December,  2022.  
5. Wirth  RJ EM, Henderson  M, et al. Development  of the Contact  [CONTACT_353905]:  CLUE  Scales.  
Optom Vis Sci. 2016(93(8)):801 -808. 
6. Straker  B.Customer  Requirements  Document   (CRD)  ( ) Project TRIUMPH for 
Astigmatism . November 23,  2022.  
7. SAS Institute Inc: SAS® 9.4 Statements: Reference, Third Edition. Cary, NC SAS Institute Inc;  2014.  
8. CAR Diniz, MH Tutia, Leite L. Bayesian analysis  of a correlated binomial model. Brazilian Journal of 
Probability and Statistics.  2010;24(1).  
9. PASS. Power Analysis and Sample Size Software. Kaysville, Utah, [LOCATION_003]: NCSS, LLC;  2021.  
10. C B. Calculation of the insurance groups of heads. Studies in Honour of Prof essor Salvatore Ortu 
Carboni.  1935:[ADDRESS_440676] MG, Roger JH. Small Sample Inference for Fixed Effects from Restricted Maximum 
Likelihood. Biometrics.  1997;53(3):983.  
12. Health  Information  Portability  and Accountability  Act (HIPAA),  Available  at: 
https:// www.hhs.gov/hipaa/for -professionals/privacy/index.html  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 62 of 163   
  
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES)  
Clinical Study Protocol  
[COMPANY_012] Vision Care, Inc. Protocol 6521  Confidential  1 
PRO SPECIFICATIO  
Page 63 of 163  2 Final 2022 -12-15 CR-6521, v 3.0  JJVC CONFIDENTIAL   
  
 
Clinical Study Protocol  
[COMPANY_012] Vision Care, Inc. Protocol 6521  Confidential  2 
PRO SPECIFICATIO  
Page 64 of 163  2 Final 2022 -12-15 CR-6521, v 3.0  JJVC CONFIDENTIAL   
  
 
Clinical Study Protocol  
[COMPANY_012] Vision Care, Inc. Protocol 6521  Confidential  3 
PRO SPECIFICATIO  
Page 65 of 163  2 Final 2022 -12-15 CR-6521, v 3.0  JJVC CONFIDENTIAL   
  
 
Clinical Study Protocol  
[COMPANY_012] Vision Care, Inc. Protocol 6521  Confidential  4 
PRO SPECIFICATIO  
Page 66 of 163  2 Final 2022 -12-15 CR-6521, v 3.0  JJVC CONFIDENTIAL   
  
 
Clinical Study Protocol  
[COMPANY_012] Vision Care, Inc. Protocol 6521  Confidential  5 
PRO SPECIFICATIO  
Page 67 of 163  2 Final 2022 -12-15 CR-6521, v 3.0  JJVC CONFIDENTIAL   
  
 
Clinical Study Protocol  
[COMPANY_012] Vision Care, Inc. Protocol 6521  Confidential  6 
PRO SPECIFICATIO  
Page 68 of 163  2 Final 2022 -12-15 CR-6521, v 3.0  JJVC CONFIDENTIAL   
  
 
Clinical Study Protocol  
[COMPANY_012] Vision Care, Inc. Protocol 6521  Confidential  7 
PRO SPECIFICATIO  
Page 69 of 163  2 Final 2022 -12-15 CR-6521, v 3.0  JJVC CONFIDENTIAL   
  
 
Clinical Study Protocol  
[COMPANY_012] Vision Care, Inc. Protocol 6521  Confidential  8 
PRO SPECIFICATIO  
Page 70 of 163  2 Final 2022 -12-15 CR-6521, v 3.0  JJVC CONFIDENTIAL   
  
 
Clinical Study Protocol  
[COMPANY_012] Vision Care, Inc. Protocol 6521  Confidential  9 
PRO SPECIFICATIO  
Page 71 of 163  2 Final 2022 -12-15 CR-6521, v 3.0  JJVC CONFIDENTIAL   
  
 
Clinical Study Protocol  
[COMPANY_012] Vision Care, Inc. Protocol 6521  Confidential  10 
PRO SPECIFICATIO  
Page 72 of 163  2 Final 2022 -12-15 CR-6521, v 3.0  JJVC CONFIDENTIAL   
  
 
Clinical Study Protocol  
[COMPANY_012] Vision Care, Inc. Protocol 6521  Confidential  11 
PRO SPECIFICATIO  
Page 73 of 163  2 Final 2022 -12-15 CR-6521, v 3.0  JJVC CONFIDENTIAL   
  
 
Clinical Study Protocol  
[COMPANY_012] Vision Care, Inc. Protocol 6521  Confidential  12 
PRO SPECIFICATIO  
Page 74 of 163  2 Final 2022 -12-15 CR-6521, v 3.0  JJVC CONFIDENTIAL   
  
 
Clinical Study Protocol  
[COMPANY_012] Vision Care, Inc. Protocol 6521  Confidential  13 
PRO SPECIFICATIO  
Page 75 of 163  2 Final 2022 -12-15 CR-6521, v 3.0  JJVC CONFIDENTIAL   
  
 
Clinical Study Protocol  
[COMPANY_012] Vision Care, Inc. Protocol 6521  Confidential  14 
PRO SPECIFICATIO  
Page 76 of 163  2 Final 2022 -12-15 CR-6521, v 3.0  JJVC CONFIDENTIAL   
  
 
Clinical Study Protocol  
[COMPANY_012] Vision Care, Inc. Protocol 6521  Confidential  15 
PRO SPECIFICATIO  
Page 77 of 163  2 Final 2022 -12-15 CR-6521, v 3.0  JJVC CONFIDENTIAL   
  
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
APPENDIX B: PATIENT INSTRUCTION GUIDE  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 78 of 163   
  
A patient instruction guide (PIG) will be provided separately  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT)  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 79 of 163   
  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Ine. 
Page 80 of 163   
 ACUVUE'8   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Q_q ysH; dralux e™ 
 
ACUVU E OASYS• Brand Contac t Lense s 1-Day 
withHydraluxe ™ Technology  
ACUVUE OASYS•Brand Contact [CONTACT_32993] 1-Day 
wlthHydraluxe "' Technology tor ASTIGMATISM  
senofilcon A Sofi (hydrophilic) Contact [CONTACT_353906]  
f""D""iw. 7 CAUTIO N: U.S.Federa !law restricts this d8\lice to 
sale by [CONTACT_353907].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
IMPORTANT : Please read carefully and keep thls 
infonnation tor future use. 
This Package  Insert  and Frtting  Guide  is intended  tor the 
EyeCareProfesslona ,lbut shoukl  be made  avallable  to 
patients  upon  request  
The Eye Care Professional  should  provide  the patient 
wlthtlle appropriate  lnstructions  thatpertaln  to the 
patient's  prescribed  lenses.  Copi[INVESTIGATOR_353860].acuvue.com.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Ine. 
Page 81 of 163   
 CR-6521,  v 3.0 -  
 
 
JJVC CONFIDENTIAL  
Clinical Study Protocol 
[COMPANY_012] Vision Care , Ine. 
- CR-6521, v 3.0 JJVC CONFIDEN TIAL  
Page 82 of 163  
  
 
SYMBOLS KEY  
 
The following symbols may appear on the label or carton:  
 
SYMBOL   
ffi] Consult lnstructions for Use 
.I Manufactured by [CONTACT_50450] 
d Date of Manufacture  
 Use By [CONTACT_1782] (expi[INVESTIGATOR_320])  
I LOTI  Batch Code  
1   STERILEI    a1 Sterile Using Steam or Dry Heat  
® Single -Use 
DIA Diameter  
BC Base Curve  
D Diopter (lens power)  
CYL Cylinder  
AXIS  Axis 
CE 
0086  Quality System Certification Symbol  
@ 
UV Blocklng  UV-Blocking  
e) Fee Pa id for Waste Management  
I IJcOnfy I CAUTION: U.S. Federa! law restricts this device  
to sale by [CONTACT_35537] a licensed practitioner  
e Lens Orientation Correct  
X X Lens Orientation lncorrect (Lens lnside Out) 
Clinical Study Protocol 
[COMPANY_012] Vision Care , Ine. 
- CR-6521, v 3.0 JJVC CONFIDEN TIAL  
Page 83 of 163  
  
 
DESCRIPTION  
ACUVUE OASYS® Brand Contact [CONTACT_32993] 1 -Day and ACUVUE OASYS® 
Brand Contact [CONTACT_32993] 1 -Day for ASTIGMATISM are soft (hydrophilic) 
contact  [CONTACT_353908].They are availableas 
spherical or toric lenses respectively.  
These  lenses  are made  of a silicone  hydroge l material  containing  an interna! 
wetting  agent , visibility  tint, and UV absorbing  monomer  and are tinted  blue 
using  Reactive  Blue Dye #4 to make  the lenses  more visible for handling.  
A benzotriazo le UV absorbing  monomer  is used  to block UV radiation . The 
trans mittancecharacteristics  for these  lenses  are less than 1% in the UVB 
rangeo f 280 nm to 315 nm and less than 10% in the UVA range  of 316 nm 
to 380 nm for the entire power  range.  
Lens Properties:  
The phys ical/opticalproperties of the lens are : 
• Specific  Gravity (calculated):  0.98 - 1.12 
• Refractive  lndex:  
• Light  Transmission:  
• Surface  Character : 
• Water  Content: 
• Oxygen  Permeability:  
 
VALUE 
122 x 10 ·11 (cm2/sec)  
(mi O/ mi x mm Hg) at 35°C  
103 x 10 ·11 (cm2/sec)  
(mi O/ mi x mm Hg) at 35°C  
Lens Parameters:  
• Oiameter  Range:  
• Center  Thickness:  
• Base Curve  Range : 
• Spherica l Power  Range:  
• Cylinder  Power  Range : 
• Axis Range:  1.42  
85%  minimum 
Hydrophilic 
38%  
 
 
METHOD  
Fatt (boundary corrected, non ­ 
edge corrected)  
Fatt (boundary corrected, edge 
corrected)  
 
 
12.0 mm to 15.0 mm 
varies with power  
7.85 mm to 10.00 mm  
-20.000 to [PHONE_7322]  
-0.250 to -10.000  
2.5° to 180 ° 
Clinical Study Protocol 
[COMPANY_012] Vision Care , Ine. 
- CR-6521, v 3.0 JJVC CONFIDEN TIAL  
Page 84 of 163  
  
 
AVAILABLE LENS PARAMETERS  
 
ACUVUE OASYS® Brand 1 -0ay with Hydraluxe TM Technology are 
hemispherical shells of the following dimensions:  
Diameter:  14.3 mm 
Center  Thickness:  0.085  mm to 0.221  mm (varies  with power)  
Base  Curve: 
Powers:  8.5 mm, 9.0 mm  
-0.500 to -6.000 (in 0.250 increments)  
-6 .50 0  to  -12.000 (in 0.500  increments)  
[PHONE_7323]  to [PHONE_7324]  (in 0.250  increments)  
[PHONE_7325]  to [PHONE_7326]  (in 0.50D  increments)  
 
 
 
ACUVUE OASYS® Brand 1 -0ay with Hydraluxe TM Technology tor 
ASTIGMATISM are hemitoric shells of the following dimensions:  
Diameter:  14.3 mm 
Center  Thickness:  0.075 mm to 0.172 mm (varies with  power)  
Base  Curve:  8.5 mm 
Powers:  +0.00D to -6.00D (in 0.25D increments) 
Cylinders: -0.75D, -1.25D, -1.75D,  -2.25D*  
Axis: 10° to 180° in 10° increments  
*-2.250 cylinder is avai lble in 10°, 20°, 70°, 80°, 90°, 100°, 110°,  
160°, 170°, 180° axes on ly. 
 
 
+0.25D to +4.00D (in 0.25D increments)  
-6.50D  to -9.00D  (in 0.50D  increments) 
Cylinders: -0.75D, -1.25D,  -1.75D  
Axis: 10°, 20°, 70°, 80°, 90°, 100°, 110°, 160°,  
170°, 180° 
Clinical Study Proto col 
John son & John son Vision Care, Ine. 
- CR-6521, v 3.0 JJVC CONFIDE NTIAL  
Page 85 of 163   
 
z  
 
TRANSMITTANCE CURVES  
ACUVUE OASYS® 1 -Day with Hydraluxe TM Technology (senof licon A) 
Visibility  Tinted  with UV Blocker  vs. 24 yr. o ld human  cornea  and 25 yr. old 
human crystalline  lens. 
 
 
oz 
ci5 
CI) 
 
CI) 
 
a:  
 
100 
90 
80 
70 
60 
50 ACUVUE OASYS®  
1-Day with 
Hydraluxe TM 
Technology  
(senofilcon A)* 
24 YR. OLD  HUMAN  
t- 40 
30 
20 
10 : , 
; I CORNEA1 
25 YR. OLD HUMAN 
CRYSTALLINE  LENS2 
0 200· 300 -\oo 500 600 700 800 
WAVELEN GHT 
(NANOMETERS)  
 
 
 
* The data was obtained  from measurements  taken  through  the central  3-[ADDRESS_440677]  marketed  lens(-9.00D  lens, 0.075  mm center  thickness).  
1 Le rman, S., Radiant Energy and the Eye, MacM illan,NewYork, 1980 , p. 58, figure 2-21 
 
2Waxler, M., Hitchins,  V.M ., Op tical Radiation and Visual Health, CRC  Press , Boca  Raton, [LOCATION_012] , 
1986, p. 19, figure  5 
 
WARNING : UV absorbing contact [CONTACT_353909], such as UV absorbing goggles 
or sunglasses because they do not completely cover the eye and 
surrounding  area  . The patient  should  continue  to use UV absorbing 
eyewear as  directed . 
 
ACTIONS  
ln its hydrated  state,  the contact  [CONTACT_13293],when  placed  on the cornea , acts as 
a refracting  medium  to focus  light rays onto the retina . 
The transmittance  characteristics  for these  lenses are less than 1% in the 
UVB range  of 280 nm to 315 nm and less than 10% in the UVA range  of 
316 nm to 380 nm for the entire  power  range.  
I 
I 
Clinical Study Proto col 
John son & John son Vision Care, Ine. 
- CR-6521, v 3.0 JJVC CONFIDE NTIAL  
Page 86 of 163   
  
 
NOTE: Long -term e xposure to UV radiation is one of the risk 
factors assoc iated with cataracts. Exposure is based on a number 
of factors such as environmental conditions (altitude , geography , 
cloud cover ) and personal factors (extent and nature of outdoor 
activit ies). UV-Blockingcontact [CONTACT_353910] U V radiat ion. However, clinical stud ies have not 
been done to demonstrate that wearing UV-Blocking contact 
[CONTACT_35541][INVESTIGATOR_353861].The Eye Care Professional should be consulted for more 
information.  
 
INDICATIONS (USES)  
ACUVUE OASYS® Brand Contact [CONTACT_32993] 1 -Day with Hydra l uxe TM 
Technology are indicated for daily disposable wear for the optical 
correction of refractive ametropia (myopia and hyperopia) in phakic or 
aphakic  persons  with non-diseased  eyes  who may have  1.00D  or less of 
astigmatism.  
 
ACUVUE  OASYS®  Brand  Contact  [CONTACT_32993]  1-Day with Hydraluxe rM Tech­ 
nolog y for ASTIGMA TISMare indicate d for daily disposabl e wear for the 
optical correct ion of refractiveametrop ia (myopia  and hyperopia)  in phakic 
or aphakic  persons  with non-diseased  eyes  who may have  0.50D  to 3.00D 
of astigm atism. 
 
These lense s contain  a UV Blocker to help protec t again st transmissio n of 
harmful UV radiation  to the cornea  and into the eye. 
 
CONTRAINDICATIONS (REASONS NOT TO USE)  
 
DO NOT  USE  these  contact  [CONTACT_353911]:  
• Acute  or subacu te inflammationor  infection  of the anterior chamber 
of the eye. 
• Any eye disease,injury  or abnormality  that affects  the cornea, 
conjunctiva, or  eyelids.  
• Severe insufficiency of lacrima l secretion(dry  eye).  
Clinical Study Proto col 
John son & John son Vision Care, Ine. 
- CR-6521, v 3.0 JJVC CONFIDE NTIAL  
Page 87 of 163   
  
 
• Cornea l hypoesthesia (reduced corneal  sensitivity). 
• Any systemic disease t hat may affect the eye or be exagge rated by 
[CONTACT_253442] . 
• Allergic reactions  of ocular  surfaces  or adnexa  that may be induced 
or exagge rated by [CONTACT_353912]. 
• Ocular irritation  due to allergic reactions  which may be caused  by 
[CONTACT_353913] (i.e., rewetting drops) that contain 
chemicals  or preservatives  (such  as mercury , Thimerosal , etc.) to 
which some  peop le may develop  an allerg ic response.  
• Any active corneal  infection (bacterial, fungal, protozoa l, or vira!). 
• lf eyes  become  red or irritated . 
 
WARNINGS  
Patients  should  be advised  of the following  warnings  pertaining  to 
contact [CONTACT_93827] : 
EYE PROBLEM$ , INCLUDING  CORNEAL  ULCERS,  CAN  DEVELOP 
RAPI[INVESTIGATOR_353862];  IF THE PATIENT  EXPE­ 
RIENCES:  
• Eye Discomfort,  
• Excessive  Tearing,  
• Vision  Changes,  
• Loss of  Vision,  
• Eye Redness,  
• Or Other  Eye Problems,  
THE PATIENT SHOULD BE INSTRUCTED TO IMMEDIATELY RE­ 
MOVE  THE LENSES  AND  PROMPTLY  CONTACT  [CONTACT_353914].  
• When p rescribed for daily wear , patients should be instructed not 
to wear lenses while sleepi[INVESTIGATOR_007]. Clinica l studies have s hown  that 
the risk of serious  adve rse reactions  is increased  when  lenses  are 
worn overnight , and that the risk of ulcerative kera titis is grea ter for  
Clinical Study Proto col 
John son & John son Vision Care, Ine. 
- CR-6521, v 3.[ADDRESS_440678] lens users than for daily wear users.3 
• Studies have shown that contact [CONTACT_126129] a higher incidence of adverse reactions than nonsmokers . 
• Problems with contact [CONTACT_126130]. Patients shou ld be caut ioned that proper 
use and care of contact [CONTACT_353915] l 
for the sate use of these  products.  
• The overall  risk of ulcerative  kerat itis may be reduced  by [CONTACT_353916].  
3 New England Journal of Medic ine, September 21, 1989; 321 (12), pp. [ADDRESS_440679] ions for Use and Warnings : 
• Water Activity 
lnstructions for  Use 
Do not expose contact [CONTACT_35551] . 
WARNING : 
Water can harbor microorganisms that can lead to severe infection, 
vision loss or blindness . lf lenses have been submersed in water 
when participating in water sports or swimming in pools, hot tubs, 
lakes, or oceans, the patient should be instructed to discard them 
and replace them with a new pair. The Eye Care Professiona l should 
be consu lted for recommendations regarding wearing lenses dur ing 
any activity invo lving water.  
PRECAUTIONS  
 
Special Precaut ions for Eye Care Professionals : 
• Due to the small number of patients enrolled in clinical investiga­ 
tion of lenses, all refractive powers, design conf igurations, or lens 
parameters  available  in the  lens material  are not evaluated  in signif­ 
icant numbers. Consequently, when selecting an appropriate lens 
design and parameters, the Eye Care Professional should consider 
all characteristics of t he lens that can affect lens performance and 
ocular health, including oxygen permeabil ity, wettabi lity, centra l and 
periphera l thickness, and optic zone  diameter.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 89 of 163   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 90 of 163   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Clinical Study Protocol  
Page 91 of 163   
 [COMPANY_012] Vi sion Care , Ine. 
 
Other Top ics to Discuss with Patients : 
• Always contact [CONTACT_353917]­ 
cine in the  eyes.  
• Certain medications, such as antihistamines, decongestants, 
diuretics, musc le relaxants, tranquilizers, and those tor motion 
sickness  may cause  dryness  ot the eye, increased  lens awareness, 
or blurred vision. Shou ld such conditions exist, proper remedial 
measures shou ld be prescribed. Depending on the severity, this 
could include  the use ot lubricating  drops that are indicated tor use 
with soft contact [CONTACT_353918] d iscontinuance of contact  
[CONTACT_353919] n is being used.  
• Oral contraceptive users could deve lop visua l changes or changes 
in lens tolerance when using contact [CONTACT_13276]. Patients shou ld be 
cautioned  accordingly.  
• As with any contact [CONTACT_13293], follow -up visits are necessary to assure 
the continuing health of the patient's eyes. The patient should be 
instructed as to a recommended tollow -up schedu le. 
Who Should Know That the Patient is Wear ing Contact [CONTACT_32993]?  
• Patients shou ld intorm all doctors (Health Care Protessionals) about 
being a contact [CONTACT_35560].  
• Patients shou ld always inform their emp loyer of being a contact  
[CONTACT_35560]. Some jobs may require use of eye protection equip­ 
ment or may require that the patient not wear contact  [CONTACT_13276].  
 
ADVERSE REACTIONS  
 
The patient  should  be informed  that the following  problems  may 
occur when wearing contact  [CONTACT_13276] : 
• The eye may burn,  sting,  and/or  itch. 
• There may be less comtort than when the lens was first p laced on 
the eye. 
• There  may be a teeling  ot something  in the eye (foreign body, 
scratched  area). 
• There may be the potentia l tor some  temporary  impairment  due to 
 
Clinical Study Protocol  
Page 92 of 163   
 CR-6521, v 3.0 -  
 
 
 
 
JJVC CONFIDE NTIAL  
Clinical Study Protocol  
Page 93 of 163   
 [COMPANY_012] Vision Care, Inc.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CR-6521,  v 3.0 JJVC CONFIDENTIAL  

Clinical Study Protocol 
[COMPANY_012] Vision Care , Ine. 
Page 94 of 163  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GENERAL FITTING GUIDELINES  
 
A. Patient Selection  
Patlents selec ted to wear these lenses should be chosen based on: 
• Motivatio n to wear lenses  
• Ability to follow instructionsregard ing lenswear  care 
• Gene ral health  
• Ability to adequatety  hande  andcare  tor the tenses  
• Ability to unde rstandthe risk andbenefi ts of tenswear  
Patlents v.i1o do not meet theabove criteria shou ld not be pro\/lded wlth 
oontact tenses.  
B. Pre-fitting  Examination  
lnitial evalua lton of the patlent shoold begln witha thorough case history 
to deter minen the reare any oontrain dication sto contact [CONTACT_353920]. During 
the case  lis tory, thepatient's llislJal  needs  and expectations  shOuld  be 
determ ined as well asanassessment  of their overa ll ocular , physical, and 
mental health.  
Preceding thein ijiaJselection of trialoontact lenses, a comprehensive 
ocular evalualion should be pertormed that includes , but isnot li ed to, 
themeasurement  of distance and near visual  acuit y, distanc eand near 
refractille  prescri ption CTncluding determinin gthepreferre d read  ngdistance 
torpresby[CONTACT_35562] ), kerato metry,and biomicroscopi [INVESTIGATOR_353863]. 
Basedon thls eva luatlon,ii lt isdetermined thal thepatient is eigible to 
wear these lenses , the Eye Care Professional should proceed to the tens 
fitting instl\Jctions asout lined below.  
C . lnitial Power D eterrnination  
Aspec tacteretraction should be per1ormed to estab lishthe palient's  
basel ine relractlve  status andto  g1.1de in th e select lon of theappropriate 
lenspower.  Remember  to compensate  tor vertex distance  ntherefraction  
is greate r than:t4.00D . 
 
D. Base Curve Selection (Trial LensFrtting)  
The following tlial lenses should be selected tor patien ts regard less o! kera ­ 
tometryreadings.  However, comea lcurvatll'8  measurements  shoudl  be 
pertormed to establish thepatien t's basel ine ocular status. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical Study Protocol 
[COMPANY_012] Vision Care , Ine. 
Page 95 of 163  
 CR-6521,  v 3.0 -  
 
 
 
JJVC CONFIDENTIAL  
Clinical Study Protocol 
[COMPANY_012] Vi sion Care , Ine. 
- CR-6521, v 3.0 JJVC CONFIDE NTIAL  
Page 96 of 163   
  
 
• ACUVU E OASY S® 1- Day: 8.5 mm/1 4.3 mm 
• ACUVU E OASY S® 1-Day for ASTIGMATIS M: 8.5 mm/14.3 mm 
 
The trial lens should  be placed  on each  of the patient's  eyes  and evaluated 
after the patient  has adjusted  to the lenses . 
 
1. Criteria  of a Prope lry Fit Lens  
A proper ly fit lens will center  and completely  cover  the cornea  (i.e., no 
limba! exposure),  have  sufficient movement  to provide tear exchange 
under the contact [CONTACT_353921], and be comfortable. The lens 
should move freely when manipulated digita lly with the lower lid, and 
then return  to its properly  centered  position  when  released . 
 
2. Criteria  of a Flat Fitting  Lens  
A flat fitting  lens may exhibit  one or more  of the following  characteris­ 
tics: decentratio ,nincomplete  cornea l coverage  (i.e., limba! exposure ,) 
exces sive moveme nt with the blink, and/o r edge stand off. lf the lens is 
judged  to be flat fitting,  it should not be dispensed  to the patient.  
3. Criteria  of a Steep  Fitting  Lens  
A steep fitting lens may exhibit one or more of the following charac­ 
teristics: insufficient  movement  with the blink,  conjunctival  indentat ion, 
and resistance  when  pushing  the lens up digitally  with the lower  lid. 
lf the lens is judged to be steep fitting , it should not be dispensed to 
the patient.  
 
lf the initialtr ial base  curve  is judged  to be flat or steep  fitting, the alternate 
base curve , if availab le, should be trial fit and evaluated after the patient 
has adjusted to the lens. The lens should move freely when manipulated 
digitally  with the lower lid, and then return  to a properly  centered  position 
when  released . lf resistance  is encountered  when  push ing the lens up, the 
lens is fitting tightly and should  not be dispensed  to the patient. 
 
E. Final Lens Powe r (Spherica l) 
A spherical  over-refraction  should  be performed  to determ ine the final lens 
powe r after the lensfit is judge d acceptable . The sphericalover-refraction 
should be combined with the trial lens power to determine the final lens 
prescription. The patient should experience good visual acuity with the 
correct  lens powe r unlessthere is excessiv e residual astigmatis m. 
Clinical Study Protocol 
[COMPANY_012] Vi sion Care , Ine. 
- CR-6521, v 3.0 JJVC CONFIDE NTIAL  
Page 97 of 163   
  
 
Example 1  
Oiagnostic lens:  -2.000 
Spherical over -refraction : -0.250  
Final lens power : -2.250  
 
Example 2  
Oiagnostic lens:  -2.000 
Spherical over -refraction:  [PHONE_7327]  
Final lens power:  -1.750 
 
lf vision  is accep  table, perform  a slit lamp examination  to assess  adequate 
fit (centration and movemen t). lf the fit is acceptable, d ispense the lenses 
and instruct the patient to return in one week for reassessment (see 
dispensing  and follow up information  in PATIENT  M ANAGEMEN T). 
AII patients should be supplied with a copy of the PATIENT 
INSTRUCTION GUIDE for these lenses . Copi[INVESTIGATOR_35456] .acuvue.com.  
 
TORIC FITTING GUIDELINES  
 
Although  most  aspects  of the fitting  procedure  are identica l for all types 
of soft contact [CONTACT_13276] , including toric lenses , there are some addit ional 
steps  and/or  rules to follow to assure  the proper  fit of toric lenses . 
The only new steps  you must  follow  in prescrib ing ACUVUE  OASYS ® 
1-Day for ASTIGMAT ISM are that you must  determine  the stability, 
repeatability, and drift angle of the lens axis so that you can prescribe the 
correct lens axis for the patient.  
A. How to Determine Lens Cylinder and Axis Or ientation  
1. Locate the Orientat ion Marks  
To help determine the proper orientation of the tor ic lens, you'II 
find two primary marks approximate ly 1 mm from the lens edge 
representing  the vertical  posit ion on oppos  ite ends  of the lens at 
6 and 12 o'clock  (Fig.  1). Because  of the lens' ballasting  system , 
either  mark  can represent  the vertical  position  - there  is no "top " 
and "bottom  " as in a prism -ballasted  lens.  You don't need  to view 
both marks to assess orientation; simply look for the 6 o'clock 
mark  as you would with a prism -ballasted  lens.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 98 of 163   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 99 of 163   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Clinical Study Protocol 
[COMPANY_012] Vision Care,  Ine. 
- CR-6521, v 3.[ADDRESS_440680] (spectacle) refraction : 
0 .0 . -3.000  / -1.000 X 90° 20/20  
O.S. -4.75 0  I - 2.00 0  X  90° 20/[ADDRESS_440681] ic lenses of  -3.000 /  -0.750 x 90° for the  right 
eye and -4.500 / -1.750 x 90° for the left eye, the nearest lenses 
available to the spherical power , cylinder power, and axis needed . 
For the left eye, since the manifest refraction called for -4.750, 
compensating for vertex distance the sphere is reduced by 0.[ADDRESS_440682] the lens on 
each eye and allow a minimum of 3 minutes for it to equilibrate , 
based on the patient 's initial response to the lens. lf the lens has 
not yet stabilized, recheck until  stable.  
 
Right Eye  
The orientation  mark  on the right lens rotates  left trom  the 6 
o'clock  position  by 10° and remains  stable in this position. 
Compensation  for this rotation  should  be done  as follows : 
Compensate  the 10° axis drift by [CONTACT_353922].  
Here is the Rx Prescribed:  
0 .0. -3.000 / -0.750 X 100°  
 
Left Eye  
The orientation  mark  on the left lens rotates  right trom  the 6 
o'clock  position  by 10° and remains  stable in this position . 
Compensate  for the 10° axis drift by [CONTACT_353923].  
Here is the Rx  Prescribed:  
O.S. -4.500 I - 1 .75 0 x 80° 
lf vision is acceptable, perform a slit lamp examination to assess 
adequate fit (centration and movement). lf fit is acceptable, 
dispense the lenses instructing the patient to return in one week 
for reassessment (see dispensing and follow -up information in 
PATIENT M ANAGEMENT) . 
 
Ali patients should be supplied with a copy of the PATIENT 
INSTRUCTION GUIDE for these lenses. Copi[INVESTIGATOR_35456].acuvue.com.  
Clinical Study Protocol 
[COMPANY_012] Vision Care,  Ine. 
- CR-6521, v 3.[ADDRESS_440683] adequate ly 
corrected distance and near visual acu ity in each eye. The 
amblyopic patient or t he patient wit h significant astigmatism 
(greater than 1.00D) in one eye may not be a good candidate for 
monovision correction with these lenses.  
Occupational and environmental visual demands should be 
considered. lf the pat ient requires crit ical v ision (v isual acuity and 
stereopsis), it should be determined by [CONTACT_353924] f unction adequately wit h monovision cor rection. Monovision 
contact [CONTACT_35568] : 
• visually demanding situations such as operating potential ly 
dangerous machinery or performing other potentially hazardous 
activities;  and 
• driving automobi les (e.g., driving at night) . Patients  who cannot 
meet state driver 's licensing requirements with monovision 
correction should be advised to not drive with this correction, 
OR may require  that addit ional over-correction  be presc ribed.  
2. Patient Education  
AII p at ients do not functio n equally wel l with monovision correc­ 
tion. Patients may not perform as well for certain tasks w ith this 
correction as they have with spectacles (multifocal, bifocal, trifocal, 
readers, progressives) . Each patient should understand that 
monovision, as well as other pres by[CONTACT_35569], can c reate 
a vision compromise that may reduce visual acuity and depth 
perception for distance and nea r tasks. Therefore, cau tion should 
be exercised when the patient is wearing the correction for the first 
time until they are familiar  with the vision provided in visuallychal­ 
lenging environments (e .g., reading a menu in a dim restaurant, 
driving at night in rainy/foggy conditions, etc.). During the fitting 
process, it is necessary for the patient to rea lize the disadvantages 
as well a s the advantages of c lear near vision and stra ight ahead 
and upward gaze that monovision contact [CONTACT_35570] . 
Clinical Study Protocol 
[COMPANY_012] Vision Care,  Ine. 
- CR-6521, v 3.0 JJVC CONFIDEN TIAL  
Page 102 of 163  
  
 
B. Eye Selection  
1. Ocular Preference Determination  Methods  
Generally, the non -dom inant eye is corrected for near v ision. The 
following two methods for eye domina nce can be used . 
Method 1 : Determine which eye is the "sighting eye." Have the 
patient po int to an object at the far end of the room. 
Cover  one eye. lf the patient is stil! pointing  direct ly at the 
object,  the eye being  used  is the dominant (sight ing) eye. 
Method 2: Determine which eye will accept the added power with 
the least reduction in  vision. Place a hand -held trial lens 
equal to the spectacle near ADD in front o f one eye 
and t hen the other while the distance refractive error 
correction is in place for both eyes. Determine whethe r 
the patien t functions best with the near ADD lens over 
the right or left  eye. 
 
2. Other Eye Selection  Methods  
Other methods i nclude the "Refractive Error Me thod " and the 
"Visual Demands Method ." 
Refractive Error Method  
For anisometropic  correct ion, it is generally  best to fit the more 
hyperop ic (less  myop  ic) eye for distance  and the more  myopic 
(less hyperop ic) eye fo r near. 
 
Visual Demands Method  
Consider  the patient's  occupation  during the eye select ion process 
to determine  the critical  vision requirements . lf a patient's  gaze  for 
near tasks is usually in one direct ion, correct the eye on that side 
for near. 
Example: A secretary who p laces copy to the left side o f the desk 
will function best with the near lens o n the left eye . 
 
C. Special Fitting  Characteristics  
 
1. Unilateral Vision  Correction  
There  are circumstances  where  only one contact  [CONTACT_35571]. 
As an example , an emmetropic  patient would only require  a near 
lens, whereas  a bilateral  myope  would require  corrective  lenses on 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 103 of 
163  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 104 of 
163  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Clinical Study Protocol  
Page 105 of 163  
 [COMPANY_012] Vision Care, Ine. 
 
Monovision fitt ing success can be improved by [CONTACT_35576]:  
• Reverse the distance and near eyes if a patient is having trouble 
adapting.  
• Refine the lens powers if there is trouble with adaptation . 
Accurate lens power is critical tor presby[CONTACT_93931] . 
• Emphasize  the benefits  of clear  near vision  and straight ahead 
and upward  gaze  with monovis ion. 
The decision to fit a patient with monovis ion correction is most 
appropriately  left to the Eye Care  Professiona l in conjunct ion with the 
patient after carefu lly cons idering the patient 's needs.  
AII patients should be supplied with a copy of the PATIENT 
INSTRUCTION GUIDE for these lenses. Copi[INVESTIGATOR_35456].acuvue.com.  
 
PATIENT MANAGEMENT  
Dispensing Visit  
Each sterile lens is supp lied ina foi l-sealed p lastic package conta ining 
buffered saline solution w ith methyl ether cellulose. To remove the lens 
trom the container, peel back the foil seal, place a finger on the lens, and 
slide the lens up the side of the bowl of the lens package until it is free of 
the container . 
• Evaluate  the physical  fit and visual  acuity  of the lens on each  eye. 
• Teach  the patient  how to apply  and remove  his or her lenses . 
• Explain  daily disposable  lens wear  and schedule  a follow -up 
exam ination . 
• Provide the patient with a copy of the PATIENT 
INSTRUCTION  GUIDE  for these  lenses.  Copi[INVESTIGATOR_353864] .acuvue.com.  
REVIEW  THESE  INSTRUCTIONS  WITH  THE PATIENT  SO THAT  HE 
OR SHE  CLEARLY  UNDERSTANDS  THE PRESCRIBED  WEARING 
AND REPLACEMENT  SCHEDULES.  
Follow -Up Examinations  
Follow -up care (necessary to ensure cont inued successful contact [CONTACT_94638]) should include routine periodic progress exam inations, management 
of specific problems, if any, and a review with the patient of the wear 
schedule, daily disposable modality, and proper lens hand ling procedures.  
 
Clinical Study Protocol  
Page 106 of 163  
 CR-6521, v 3.0 -  
 
 
 
JJVC CONFIDEN TIAL  
Clinical Study Protocol  
Page 107 of 163  
 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CR-6521,  v 3.0 JJVC CONFIDENTIAL  

Clinical Study Protocol 
[COMPANY_012] Vi sion Care,  Ine. 
- CR-652 1, v 3.0 JJVC CONFIDEN TIAL  
Page 108 of 16 3  
  
 
the criteria  for successful  fit are not satisfied  during  any follow -up 
examinations, repeat the patient's trial fitting procedure and refit 
the patient.  
 
WEARING SCHEDULE  
The wearing  schedule  should  be determined  by [CONTACT_253449]. 
Regular  checkups,  as determined  by [CONTACT_353925],are  also 
extremely  important.  
Patientstend to overwear the lenses initially. The Eye Care Professional 
should  emphasize  the importance of adhering  to the initial  maximum  wear­ 
ing schedule. Maximum wearing time should be determined by [CONTACT_353926]'s physio logicaleye condition, 
because  individua!  response  to contact  [CONTACT_353927].  
 
The maximum suggested wearing time for these lenses is: 
Day Hours  
1 6-8 
2 8-10 
3 10-12 
4 12-14 
5 and atter all waking  hours 
 
 
REPLACEMENT SCHEDULE  
These  lenses  are indicated  for daily disposable  wear  and should be 
discarded upon  remova l. 
 
LENS CARE DIRECTIONS  
When lenses are prescribed for daily disposable wear, the Eye Care 
Professional  should  previde the patient  with appropriate  and adequate 
warnings  and instructions  for daily dispo  sable lens wear  at the time they 
are dispensed.  
Clinical Study Protocol 
[COMPANY_012] Vi sion Care,  Ine. 
- CR-[ADDRESS_440684]  spare  lenses  or 
spectacles  available . 
Basic lnstructions  
• Always  wash,  rinse,  and dry hands  before  handling  contact  [CONTACT_13276].  
• Do not use saliva  or anything  other  than the recommended  solutions 
for lubrica ting or rewetting  lenses . Do not put lenses  in the mouth . 
• Eye Care  Professionals  may recommend  a lubricating/rewetting 
solution  which  can be used  to wet (lubricate)  lenseswhile  they are 
being  worn  to make  them  more  comfortable . 
Care for a Sticking (Non -Moving) Lens  
lf the lenssticks  (stops  moving),the patient  should  be instructed  to apply 
a few drops  of the recommended  lubricating  or rewetting  solution  direct ly 
to the eye and wait until the lens begins  to move  freely on the eye before  
removing  it. lf non-movement  of the lens continuesafter  a few minutes,  the 
patient  should  immediately  consult  the Eye Care  Professional.  
 
EMERGENCIES  
 
The patient  should  be informed  that if chemicals  of any kind (household 
products, gardening solutions, laboratory chemicals, etc.) are splashed 
into the eyes,  the patient  should:  FLUSH  EYES  IMMEDIATELYWITH  TAP 
WATER  AND IMMEDIATELY  CONTACT  [CONTACT_353928]  A HOSPI[INVESTIGATOR_93807].  
 
HOW SUPPLIED  
 
Each  UV-blocking  sterile  lens is supplied  ina foil-sealed  plastic  package 
containing  buffered  saline  solution  with methy l ether  cellulose.  The plastic 
package is marked w iththe following:  
• ACUVUE  OASYS®  1 -Day: base  curve,  power , diameter,  lot number,  
and expi[INVESTIGATOR_78288] 
• ACUVUE  OASYS®  1-Day for ASTIGMATISM:  base  curve,  power, 
diameter,  cylinder,axis, lot number,  and expi[INVESTIGATOR_353865] & Johnson Vi sion Care,  Ine. 
- CR-[ADDRESS_440685] ionsobserved in 
patients  wearing  these  lenses  or experienced  with these  lensesshould  be 
reported  to: 
 
 
[COMPANY_012] Vision Care, Ine. 
[ADDRESS_440686]  
Jacksonv ille, FL [ZIP_CODE]  
[LOCATION_003] 
Tel: 1 - 800 -843 -2020  
www.acuvue.com  
Clinical Study Protocol  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 111 of 163   
 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 112 of 163   
  
APPENDIX D:  
• LENS FITTING  CHARACTERISTICS  
• SUBJECT REPORTED OCULAR  SYMPTOMS  
• DETERMINATION OF DISTANCE SPHEROCYLINDRICAL  REFRACTIONS  
• BIOMICROSCOPY  SCALE  
• DISTANCE AND NEAR VISUAL ACUITY  EVALUATION  
• TORIC FIT  EVALUATION  
• ETDRS DISTANCE VISUAL ACUITY MEASURMENT  PROCEDURE  
• PATIENT REPORTED OUTCOMES  
• LENS INSERTION AND  REMOVAL  
• VISUAL ACUITY CHART LUMINANCE AND ROOM ILLUMINATION TESTING   
 
 
 
 
 
 
 
 
 
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 113 of 163   
  
LENS FITTING CHARACTERISTICS  
Clinical Stud y Protocol  
John son & John son Vision Care, Ine. 
 Title: Lens Fitting  Chara cteristics   
Document T     
Revision Number: 6 
- CR-6521, v 3.0 JJV C CONFIDENTIAL  
Page 114 of 163  
  
 
 
 
 
 
 
 
 
 
 

Clinical  Stud y Protocol  
- CR-6521, v 3.0 JJV C CONFIDENTIAL  
Page 115 of 163  
 
Document T  
Revision Number: 6 John son & John son Vision Care, Ine. 
 Title: Lens Fittin g Chara cteristic s  
 
 
 
 

Clinical  Stud y Protocol  
- CR-6521, v 3.0 JJV C CONFIDENTIAL  
Page 116 of 163  
 
Document T     
Revision Number: 6 John son & John son Vision Care, Ine. 
 Title: Lens Fitting  Chara cteristics   
 
 
 
 
 
 
 
 
 
 
 
 
■ 

Clinical Study Protocol  
Page 117 of 163  
 [COMPANY_012] Vision Care, Inc.  
Title:  Lens Fitting  Characteristics  
Document Type:      
Document Number:   Revision Number:  6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CR-6521,  v 3.0 JJVC CONFIDENTIAL  
Clinical Study Protocol  
Page 118 of 163  
 
Document T 
Revision Numb er: 6 John son & John son Vi sion Care, Ine. 
 Title: Lens  Fitting  Characteristics  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical Study Protocol  
Page 119 of 163  
 CR-6521, v 3.0 -  
 
 
JJVC C ONFIDE NTIAL  
Page 120 of 163  
 Clinical Study Protocol 
[COMPANY_012] Vision Care,  Inc. 
 
SUBJECT REPORTED OCULAR  SYMPTOMS/PROBLEMS  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CR-6521,  v 3.0 JJVC CONFIDENTIAL  
Page 121 of 163  
 
Clinical Stud y Protocol  
John son & John son Vision Care , Ine. 
Title ---------------------  Subject Reported Ocular  Symptoms /Problems  
Document T   
 
 
Revision Number: 4  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Page 122 of 163  
 CR-6521, v 3.0 -  
 
 
 
JJV C CONFIDE NTIAL  
Page 123 of 163   
 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
DETERMINATION OF DISTANCE SPHEROCYLINDRICAL REFRACTIVE ERROR  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CR-6521,  v 3.0 JJVC CONFIDENTIAL  
Clinical Study Protocol  
Page 124 of 163  
 
Title ------------------------  Determination  of Distance  Spherocylindrical  Refractive  Enor  Document T  
Revision Number: 5 
John son & John son Vision Care, Ine. 
 
 
 
 
 
 
 
 
I 
 
 
 
 
·-I 
I 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Clinical Study Protocol  
Page 125 of 163  
 C  R -652   1 , v 3.0 -  
 
 
 
JJV C CONFIDEN TIAL  
Clinical Study Protocol  
Page 126 of 163  
 Title:  Determination of Distance Spherocylindrical Refractive  Error  
Document  Type:      
Document  Number:   Revision Number:  5 [COMPANY_012] Vision Care, Inc.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CR-6521,  v 3.0 JJVC CONFIDENTIAL  
Clinical  Stud y Protocol  
- CR-6521, v 3.0 JJV C CONFIDE NTIAL  
Page 127 of 163  
 
Title ----------------------  Determination  of Distance  Spheroc ylindrical  Refractive  Enor  Document T  John son & John son Vision Care , Ine. 
 
 
5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Clinical  Stud y Protocol  
- CR-6521, v 3.0 JJV C CONFIDE NTIAL  
Page 128 of 163  
 
Title ----------------------  Determination  of Distance  Spheroc ylindrical  Refractive  Enor  Document T  John son & John son Vision Care , Ine. 
 
 
5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Clinical  Stud y Protocol  
- CR-6521, v 3.0 JJV C CONFIDE NTIAL  
Page 129 of 163  
 
Title ----------------------  Determination  of Distance  Spheroc ylindrical  Refractive  Enor  Document T  John son & John son Vision Care , Ine. 
 
 
5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I 
 
I 
I 

Page 119 of 163   
 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
BIOMICROSCOPY SCALE  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CR-6521,  v 3.0 JJVC CONFIDENTIAL  
Clinical Stud y Protocol  
John son & John son Vi sion Care , Ine. 
 Title:  
Document T 
Revision Number: 10 
CR-6521, v 3.0 JJV C CONFIDENTIAL  
Page 120 of 163  
 -  
 
 
 
 
 
 
 
Page 1 of5  

Clinical Stud y Protocol  
John son & John son Vi sion Care , Ine. 
 Title:  
Document T 
Revision Number: 10 
CR-6521, v 3.0 JJV C CONFIDENTIAL  
Page 121 of 163  
 -  
 
 
 
 
 
 
Page 2 of5 

Clinical Stud y Protocol  
John son & John son Vi sion Care , Ine. 
 Title:  
Document T 
Revision Number: 10 
CR-6521, v 3.0 JJV C CONFIDENTIAL  
Page 122 of 163  
 -  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 3 of5 

Clinical Stud y Protocol  
John son & John son Vi sion Care , Ine. 
 Title:  
Document T 
Revision Number: 10 
CR-6521, v 3.0 JJV C CONFIDENTIAL  
Page 123 of 163  
 -  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 4 of5  

Clinical Study Protocol 
Johnson  & Johnson  Vision  Care,  Ine. 
CR-6521, v 3.0 JJV C CONFIDENTIAL  
Page 124 of 163  
 -  
 
 
 
 
 
 
 
 
■  
I  
I  
 
 
 
 
 
 
 
 
 
Page 5 ofS 
 Title:   
DocumentT  

Page 125 of 163   
 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
DISTANCE AND NEAR SNELLEN VISUAL ACUITY EVALUATION  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CR-6521,  v 3.0 JJVC CONFIDENTIAL  
Clinical Study Protocol  
Page 126 of 163  
 
John son & John son Vision Care, Ine. 
Title -----------------------  Distance  and Near  Snellen  Visual  Acuity  Evaluation  
Document T  
Revision Number: 5 
 
 
 
I 
I 
I 
·I ­ 
 
 
 
I  
I 
I 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Clinical Study Protocol  
Page 127 of 163  
 CR-6521,  v 3.0 -  
 
 
JJV C CONFIDEN TIAL  
Clinical Study Protocol  
Page 128 of 163  
 [COMPANY_012] Vision Care, Inc.  
Title:  Distance and Near Snellen Visual Acuity  Evaluation  
Document Type:      
Document Number:   Revision Number:  5 
 
 
 
 
 
 
 
CR-6521,  v 3.0 JJVC CONFIDENTIAL  
Clinical  Stud y Protocol  
- CR-6521, v 3.0 JJV C CONFIDENTIAL  
Page 129 of 163  
 
Title -----------------------  Distance  and Near  Snellen  Visual  Acuity  Evaluation  Document T  
John son & John son Vision Care, Ine. 
 
 
 
 
 
 
 
 
 
 
I  
I 
 
 
I 
I 
I 
I  
I 
I 
 

Clinical  Stud y Protocol  
- CR-6521, v 3.0 JJV C CONFIDENTIAL  
Page 130 of 163  
 
John son & John son Vision Care, Ine. 
Title -----------------------  Distance  and Near  Snellen  Visual  Acuity  Evaluation  
Document T  
Revision Number: 5 
Page 131 of 163   
 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
TORIC FIT EVALUATION  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CR-6521,  v 3.0 JJVC CONFIDENTIAL  
Clinical Study Protocol  
Page 132 of 163  
  Title:  John son & John son Vision Care , Ine. 
Toric  Fit Evaluati on  
 
 
 
I 
I 
 
 
 
DocumentT     
Revision Number: 7 

Clinical Study Protocol  
Page 133 of 163  
 CR    -6 5 2 1 ,  v  3 . 0 -  
 
 
JJV C CONFIDE NTIAL  
Clinical Study Protocol  
Page 134 of 163  
 [COMPANY_012] Vision Care, Inc.  
Title:  Toric Fit  Evaluation  
Document Type:      
Document Number:   Revision Number:  7 
 
 
 
 
 
 
 
 
 
CR-6521,  v 3.0 JJVC CONFIDENTIAL  
Clinical Stud y Protocol  
- CR-6521, v 3.0 JJVC C ONFID ENTIAL  
Page 135 of 163  
  Title:  John son & John son Vi sion Care, Ine. 
Toric Fit Evaluation  
 
 
 
 
 
 
Document T 

Clinical Stud y Protocol  
- CR-6521, v 3.0 JJVC C ONFID ENTIAL  
Page 136 of 163  
  Title:  John son & John son Vi sion Care, Ine. 
Toric Fit Evaluat ion  
 
 
 
Document T    
Revision Numb er: 7 

Page 137 of 163  
 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
PATIENT REPORTED OUTCOMES  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CR-6521,  v 3.0 JJVC CONFIDENTIAL  
Page 138 of 163  
 
 -  
 
Title: Clinical Stud y Protocol  
John son & John son Vi sion Care, Ine. 
Patient Reported Outcomes  
Document Type:    
Document Number:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ------------- - Rveision Number:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pag1ofl  -3---  
 
 CR-521,v3.0 JJVC CONFIDENTIAL  

Page 139 of 163   
 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
LENS INSERTION AND REMOVAL  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CR-6521,  v 3.0 JJVC CONFIDENTIAL  
Clinical  Stud y Protocol  
Page 140 of 163  
 
 Title:  
 
 
■- 
■ - 
■ 
 
 
 
 
■- John son & John son Vision Care , Ine. 
Lens  Insertion  and Removal   
 
 
 
 
 
 
 
 
■ 
■ 
I 
I 
 
 
DocumentT     
Revision Number: 3 

Clinical  Stud y Protocol  
Page 141 of 163  
 CR-6521, v 3.0 -  
 
 
JJV C CONFIDE NTIAL  
Clinical Study Protocol  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 142 of 163   
 [COMPANY_012] Vision Care, Inc.  
Title:  Lens Insertion and  Removal  
Document Type:      
Document Number:   Revision Number:  3 
 
 
 
 
 
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 143 of 163   
 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
VISUAL ACUITY CHART LUMINANCE AND ROOM ILLUMINATION TESTING  
Clinical  Stud y Protocol  
Page 144 of 163  
 
Title -----------------------  Visual  Acuity  Chart  Luminance  and Room  Illumination  Testing Document T  
Revision Number: 4 
John son & John son Vision Care, Ine. 
 
 
 
 
 
 
·­I 
I 
I 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical  Stud y Protocol  
Page 145 of 163  
 CR-6521,  v 3.0 -  
 
 
JJV C CONFIDENTIAL  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
Visual Acuity Chart Luminance and Room Illumination Testing  Title:  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 146 of 163   
  Document Type:  
Document Number:     
Revision Number:  4 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
Visual Acuity Chart Luminance and Room Illumination Testing  Title:  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 147 of 163   
 Document Type:      
Document Number:   Revision Number:  4 
 
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
Visual Acuity Chart Luminance and Room Illumination Testing  Title:  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 148 of 163   
 Document Type:      
Document Number:   Revision Number:  4 
 
 
 
 
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
Visual Acuity Chart Luminance and Room Illumination Testing  Title:  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 149 of 163   
 Document Type:      
Document Number:   Revision Number:  4 
 
 
 
 
 
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
Visual Acuity Chart Luminance and Room Illumination Testing  Title:  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 150 of 163   
 Document Type:      
Document Number:   Revision Number:  4 
 
 
 
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
Visual Acuity Chart Luminance and Room Illumination Testing  Title:  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 151 of 163   
 Document Type:      
Document Number:   Revision Number:  4 
 
 
 
 
 
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
Visual Acuity Chart Luminance and Room Illumination Testing  Title:  
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 152 of 163   
 Document Type:      
Document Number:   Revision Number:  4 
 
 
 
 
 
 
CR-6521, v 3.0  JJVC CONFIDENTIAL  
Page 153 of 163   
 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
APPENDIX E: IRIS COLOR SCALE  
Page 154 of 163  
 Clinical Study Protocol 
[COMPANY_012] Vision Care , Ine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Page 155 of 163  
 CR-6521, v 3.0 -  
 
 
JJV C CONFIDE NTIAL  
Page 156 of 163   
 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
APPENDIX  F: GUIDELINES FOR COVID -19 RISK MITIGATION  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CR-6521,  v 3.0 JJVC CONFIDENTIAL  
Clinical Stud y Protocol 
John son & John son Vi sion Care , Ine. 
   Title: Guid elines for COVID -19Ri sk Miti ation  
   Docu ment T,  e:  
   Docum ent Numb er:     
  Revision Numb er: 5  
Pa ge 157 of 163  
 -  
 
1.0 PURPO SE 
 
The pmpose  of this documen t is to provide guidelines  for the re-opening  or initia tion of clinical  study  sites 
participa ting in [COMPANY_012] Vision Care , fuc. (JJVCI ) clinical studies during the COVID -19 
pandemic . 
 
2.0 SCOPE 
 
This document pro vides guide lines for John son & John son Vision Care (JJVCI ) to address the po tential risks 
from COVID -19 to study subjects, investigators , study site staff, and monitors at study sites. The guidance 
provided in this document is in effec t from the date of appro val through the date of retirement of this Work 
Instruction . At a minimum , this Work fustrnction will be reviewed and upda ted on a quarterly basis, as 
appropriate.  
 
NOTE: Re -opening of site s outside of the US will be evaluated on a countr y by [CONTACT_64206] y basis subject 
to local health authot ·ity guidance.  
 
3.0 DEFI NITIO NS 
 
American  Acad emy of Optom etry (AAO ): The American  Academy  of Optometiy  is an organization  of 
optometri sts based in Orlando , [LOCATION_012]. It s goal is to maintain and enhance excellence in optometi -ic 
practice, by [CONTACT_353929]. The AAO holds an annua l 
meeting , publishe s a monthly  scientific  jown  al, gives  creden tials to optometi -ists through  the fellowship 
process  and publi shes position statemen ts. 
 
American  Optometri c Association  (AOA ): The Ame1 -ican Op tometi -ic Ass ocia tion , founded  in 1898 , is 
the leading authority on quality care and an advoca te for our na tion's health , representing more than 44,000 
Doctors of Optometiy (O.D.), optometi -ic profe ss iona ls, and op tometiy student s. Doctor of Optometiy take 
a leading role in patient care with  respect to eye and vision care,  as well as genera l  health and well-being. 
As primary health care providers, Doctor of Op tometiy ha ve extensive, ongoing ti·aining to examine , 
diagnose , treat and manage ocula r disorders, disea ses and injw -ies and systemic diseases that manifest in the 
eye. The American Optometi -ic Association is a federation of state, student , and anned forces optometric 
associations. Through these affiliations , the AOA serves members con sisting of optometi -ists, stu dents of 
op tometiy  , paraop  tome ti·ic assistants  and technician s. The AOA  and its affiliates  work  to provide the public 
with quality vision and eye care. 
Centers fot· Disease Control  and Prevention  (CDC): The Centers  for Disea se Conti·ol  and Prevention  is a 
national public heal th institute in the [LOCATION_002]. It isa [LOCATION_002] federa! agency, under the 
Departmen t of Heal th and Human  Services , and is headqua1tered  in Atlanta , Georgia.  
COVID -19: CwTent outbreak of re spi[INVESTIGATOR_141876]1ydi sease cau sed by a novel corona virns. The virns has be.en 
named "S ARS -CoV -2" and the disease it causes has been named " Corona virns Disease 2019 " (COVID - 
19). 
Clinical  Study: Volunta1y  research  stu dies conducted  in people  and designed  to answer specific  questions 
abou t the safety or effecti veness of drng s, vaccin es, other therapie s, or new ways of using existing 
ti·eatinen ts. May  also be called  clinical  trials , studies , research , ti·ials, or protocol s. 
Clinical  Study Site: Location  where a clinica l study is conducted , such as a doctor 's office , university, or 
labora to1y. Clinical studies are conducted by [CONTACT_353930] (s) responsible for the 
conduc t of the clinical study at a study site. If a study is conducted by a team of indi viduals , the 
fuvestigator  is the responsible  leader  of the team  and may be called  the P1-incipal  fu vestigat  or. 
C linical Op era tion s Manag er (COM): The John son & Johnson Vision Care (JJVCI ) individua! 
respon sible for the overall management of a clinical ti-ial. 
 
 
Page 1 of 11 
 
CR-6 521, v 3 .0 JJV C CO NFIDE NTIAL  
Clinical Stud y Protocol 
John son & John son Vi sion Care , Ine. 
   Title: Guid elines for COVID -19Ri sk Miti ation  
   Docu ment T,  e:  
   Docum ent Numb er:     
  Revision Numb er: 5  
Page 2 of 11 
CR-6521, v 3.0 JJVC C ONFIDE NTIAL  
Page 158 of 163  
  
Monitor : An indi vidual de signated to oversee the progre ss of a clinical study and en sure tha t it is 
conduc ted, recorded , and repo1ted in accordance with the pro tocol, Standard Operating Procedure s (SOP s), 
Good  Clinical  Practice  (GCP) , and applicable  regulatory  requiremen ts. 
 
Medica!  Safety Officer (MS O): Physician  who has primary  accoun tability  in their  product  portfolio  for 
product  health  and safety , and who serves as an independen t medic al voice for patient  safety.  
 
Safety Mana gement Team (SMT): A cro ss-functional , collaborati ve team responsible for review, 
assessment and e valuationof medica! safety data arising from any source throughou t the product life cycle . 
 
4.[ADDRESS_440687] of the clinical study. This guidance does not supersede 
any local or go vemment requirement s or the clinical judgement of the in vestigator to protec t the health , safety 
and well-being of participan ts and site staff. If, at any time, a paiticipan t's safety is considered to be at ri sk, 
study in tervention will be discontinued , and study follo w-up will be conducted as outlined in the protocol.  
 
During  the COVID -19 pande1nic , the additional risks listed  below need  to be considered  for study  paiticipant s 
and study  personnel:  
 
4 . I I Addi tional Risks Related to the COVID -19 Pandernic:  
• The po ssible transrnission of the Corona virus infection and consequent complication s, beyond the 
risk of ad verse events due to the in vestigational de vice and/or  procedure s. 
• The risk may be higher  in an optometric  clinical  study  becau se of the close contac t the subject  will 
have with health  cai·e  profes  sional  s during  the procedure s and assessments  (since the investigator 
must make the measurement s close to the subject ' s face) and, in addition the need for multiple 
follo w-up visits/exam s which may expose the subjec t to o ther patient s and/or heal thcai·e 
profe ssional s who 1night  be transmi  tting the virus, even if they do not  have symptoms. 
• Potential disruption s to the study may be neces saiy due to current or future pandernic -related  
emergenc y restriction s, which may lead to delays in scheduled  follo w-up visits. 
• Subject s experiencing  an adverse event related  to contact  [CONTACT_353931] -[ADDRESS_440688] contracted COVID -19 during  paiticipa tion ina study , he/she will be 
discontinued  from  the study  and follo wed until  COVID -19 Adverse Event (AE) resolu tion. 
 
To help minirnize the abo ve potential risk s, JJVCI recollllllend re viewing/compl ying with local , state, 
and go vemmental guidance for COVID -19 ri sks. 
 
JJVCI will pro vide the follo wing study specific document s with language pe1taining to COVID -19 ri sks: 
 
4.1. I Info1med  Consent: 
 
Will include info1mation conceming the study-associated ri sks related to the COVID -19 pandemic 
in bold fon t and/or boxed on the first page of the Informed Consent document:  
 
 
 
Clinical Stud y Protocol 
John son & John son Vi sion Care , Ine. 
   Title: Guid elines for COVID -19Ri sk Miti ation  
   Docu ment T,  e:  
   Docum ent Numb er:     
  Revision Numb er: 5  
Page 2 of 11 
CR-6521, v 3.0 JJVC C ONFIDE NTIAL  
Page 159 of 163  
 - 
Clinical Stud y Protocol 
John son & John son Vi sion Care , Ine. 
   Title: Guid elines for COVID -19Ri sk Miti ation  
   Docu ment T,  e:  
   Docum  ent N umb  er:     
  R e vis ion N umb  er: 5  
Page 3 of 11 
CR-6521, v 3.0 JJVC C ONFIDE NTIAL  
Page 160 of 163  
  
STUDY AS SOCIATED RISKS RELATED TO COVID -19 (CORONAVIR US) PANDEMIC  
 
It is import ant to note that this study will be conducted , at least in pa1t , during  the COVID -[ADDRESS_440689] for you. This  is pa1t iculady importan t for this 
study due, in part, to the closeness of the doctor  during  the study examination s. 
 
The poten tial effec ts of the disease are not fully known, at this time, and may include long-te1m seriou s health 
consequence s. In severe cases, this may result in hospi[INVESTIGATOR_353866]/or dea th. Based  on cun-ent knowledge  from  the 
Centers for Disease Control and Prevention (CDC), those at high-risk for severe illness from COVID -19 include 
older adult s and people  with unded ying medica!  condi tions. 
 
During  this study, all appropria te measures will be taken  to minimize  risks including  the use of personal prote ctive 
equipmen t such as masks and gloves, as well as proper  sanitization. This is in confo1mance  to guidance from  the 
CDC , local health depa1tmen ts, and the state and county in which the study doctor 's office is located. However, 
these measure s may not completel y elimina te the risks associated with contracting COVID -19. 
 
If you are found  to have contracted  COVID -19 or feel ill with flu-like symptoms during  participation in the study, 
you will not be pe1mitted  to continue  in-office study follo w-up visits, but you will recei ve instmctions and your 
condition  will be moni tored by [CONTACT_353932]/or  study staff. 
 
4.1.[ADDRESS_440690] (Attachment -B): 
 
Will include COVID -19 risk contro l methods that are required b y a site to conduc t JNCI clinical 
studie s. The risk control s are consistent with CDC , AOA , AAO Guidance. The Princ ipal 
Investigator will review/sign the study specifi c checkli st prior to the Site Initiation Mee ting. 
 
 
4.1.3 Protocol Compliance Investigator (s) Signature  [CONTACT_3490]: 
 
Will include  a statement  indicating that the Principal  Investigator (PI) agree s to conduct  the study 
in complian ce with all local, state, and govemmental  guidance 's for COVI D-[ADDRESS_440691] read the sugge sted gu idance pro vided b y JNCI pertaining to the COVID -19 ri sk mitig ation, 
(COVID -19 Work In struction in the Append ix of this protocol ). I agree to condu ct this study in 
compliance with local , state, govemmental guidance for COVID -19 risks. 
 
4.1.4 Study Site Initiation Training  Slides: 
 
Will include sugge stions to help mi tigate potent ial transmission of COVID -19. Sugge stions may 
include  maintaining  social distancing  in the clinical  site by [CONTACT_353933] s, 
wearing proper PPEs, frequent d isinfection, and installing shield s on the slit lamp and o ther 
applicable  equipmen t. 
 
S.O G UIDAN CE FOR REMOTE SUBJECT VISITS 
 
Potential  dismptions to the study may be nece ssary due to cmTent or future  pandemic -related  emergenc y 
restrictions. Possible disruption  of the study  as a result of COVI D-[ADDRESS_440692] s may be delayed in being seen for study follo w up visit(s), for example  due to COVID -[ADDRESS_440693]' s concem s or fe ars abou t COVI D-19 risk. When appropri ate, the remo te 
assessment  will be conducted  to the extent possible. Discussions with the subjec t during  remote  assessment s 
may include : 
 
 
Clinical Stud y Protocol 
John son & John son Vi sion Care , Ine. 
   Title: Guid elines for COVID -19Ri sk Miti ation  
   Docu ment T,  e:  
   Docum  ent N umb  er:     
  R e vis ion N umb  er: 5  
Page 3 of 11 
CR-6521, v 3.0 JJVC C ONFIDE NTIAL  
Page 161 of 163  
 - 
Clinic al Study Proto col 
John son & John son Vision Care, Ine. 
   Title: Guidelines for COVID -19 Risk Miti ation  
   Document T,  e:  
   Document Number:     
  Revision Numb er: [ADDRESS_440694] a1ticle when applicab le and fea sible. 
Change of Medica l History 
(Adverse Events) and 
Concomitan t Medications / 
Therapie s Review Record  any adverse  events or medical  history changes  from  the 
previous  study  visit with the subject/parents . 
Review the subject ' s concomitan t medications /therapie s and record 
any changes  from  the previous study  visit. 
Wearing Time and 
Comp liance  Record the average wearing time (including number ofhow -s per day 
dw-ing weekdays and weekends, and number of days per week) . 
Confinn compliance with the prescribed wear schedule.  
• Record and discuss the lens wear compliance based on the 
subjec t's self-repor t. For example , the subjects  will be asked  the 
time of the day the subject typi[INVESTIGATOR_353867] , the number  of days  per week 
lenses were  wom , and the number  of consecuti ve days the subject 
didn ' t wear  the study  lenses, etc. 
 
The discu ssion with the subject  will be documen ted in EDC  under  Tele -Visit and a minor  protocol  deviation 
will be noted . If dw-ing the telephone  consultation,  a subjec t states he/she wishes  to discontinue  participa ting 
in the study , instrnct the subjec t to stop wearing the study lenses and schedule the subject to retum to the 
clinic for a Final Evaluation at the at earlie st possible time. Subjec ts should retum all unused lenses to the 
clinic at the last visit. 
 
Changes in study visit schedules , missed visits, or participant discontinuation s may lead to missing data, 
includin g   data  related   to   protoco l-specified   procedure s.  Case  repo1t   fonns    shoul d   captur e  specific 
info1mation regarding the basis of missing data, including the relation ship to the COVID -19 pandemic.  
 
6.0 STUDY CONDUC T DURING PANDEM IC 
 
It is recognized  that the Coronavirns  Disea se 2019  (COVID -19) pandemic  may have an impact  on the conduct 
of this clinical  study due to, for example , self-isolation/quarantineby  [CONTACT_353934] -site personnel ; 
travel restrictions/limi ted access to public places , including Optometty Clinics ; and change s in clinic 
procedures required to address the COVID -19 challenge.  
 
Eve1y effort should be made to adhere to protocol-specified assessments for study participants , including 
follow -up. Howe ver, if scheduled visits cannot be conducted in person at the study site it is sugg ested that 
assessments be perfo1med to the extent possib le remotely /vittually or delayed until such time that on-site 
visits can be resumed in order to continue par ticipant monitoring in accordance with the protocol where 
possib le. At each contac t, pait icipants will be interviewed to collect safety data. Key efficacy endpoint 
assessments should be perfo1med if required and as  feasible. 
 
Modifications  to protocol -required  assessments  may bepennitted  via COVID -19 Appendix  after  consultation 
with the paiticipant , investigator , and the sponsor. Missed assessments /visits will be captured in the clinical 
tt·ial management system for protocol deviations. Intenup tions of test a1t icle wear or discontinuations of 
study inter ventions and withdrawa l from the study should be documented with the prefix "COVID -19- 
related" in the case repo 1t  f01m  (CRF). 
 
Clinic al Study Proto col 
John son & John son Vision Care, Ine. 
   Title: Guidelines for COVID -19 Risk Miti ation  
   Document T,  e:  
   Document Number:     
  Revision Numb er: 5  
Pag e 4 of 11 
CR-652 1, v 3.0 JJVC  CONFIDEN TIAL  
Page 163 of 163  
 - 
Clinical Stud y Protocol 
John son & John son Vi sion Care , Ine. 
   Title: Guid elines for COVID -19Ri sk Miti ation  
   Docu ment T,  e:  
   Docum  ent N umb  er:     
  R e vis ion N umb  er: [ADDRESS_440695]  the sponsor's respon sible 
medic al monitor  to discuss initia l plans for study  inter vention  and follo w-up. The medical  monitor  will 
notify the Safety  Management  Team  of any subjec t(s) that have reported  "COVID -19", "Asymptomatic 
COVID -19", or "SuspectedCOVID -19" adverse events within  [ADDRESS_440696]  as a result of the COVID -19 pandemic  will be summarized  in the 
clinical study  repo1t . 
 
COVID -19 screening procedure s that may be mandated by [CONTACT_353935]1ted as an amendmen t to the protocol e ven if đone during clinical study visits. 
 
6.1 Monitorin  g Vi sit s 
 
When  on-site moni toring  by [CONTACT_19613], the spon sor' s site monitor  will contact [CONTACT_353936]. 1n such cases, on-site monitoring  visits will resume when feasible , with 
increa sed frequency  to addres s the source  data verification  backlog . 
 
Even with staffing  limita tions during  this COVID -[ADDRESS_440697]  proce ss. When  conditions  pennit , all 
parties  involved in this clinical  trial should communicate  relevant infonnation  in a timely  manner  so that 
all relevant pa1tie s remain sufficiently infon  ned. 
 
6.1.1 Study Site Initiation: 
 
During the period that this Work Instruction i s in effec t, Site Initiation Meeting s and training of 
study si te staff will be conducted remotely . The JJVCI study team will conduct training via Skype, 
Zoom , Microsoft Teain s orsimilar softwai·ea s well as utilize online traini  
tud site training will be documen ted utilizin . Site  Initiation  Report --- ­ 
per Study  Site Initiation  
- On-site visits may be considered when, for example , hands -on training  or evaluation  of site facilitie s 
is required. While on site, the Clinical Research Associate (CRA) will follo w all local, state, and 
governnientalpolicie s for COVID-19 Risk  Mitigation , including  social  distancing , wearing  of PPE, 
etc. as applicable  for the locationof  the study  site. 
 
6.1.2 Interim Monitoring Visits (if applicable):  
 
During the period that this Work Instrnction is in effec t, Interim Monitoring On -site visits will be 
kept to a minimum and include on ly those tasks that the CRA cannot pe1fonn remotely (e.g., source 
document verifica tion, test a1ticle reconciliation , etc.). 
 
To ensure da.ta  integrity during  the conduct  of ali JJVC  studie s, clinica l study teams will follo w the 
study specific Clinical Monitoring Plan  
While  on site, the CRA  will follo w all local, state, and governnienta l policie s for COVID -19 Risk 
Mitigation , including social distancing , weai·ingof PPE, etc. as applicable for the location of the 
study  site. 
 
 
 
 

Clinical Stud y Protocol 
John son & John son Vi sion Care , Ine. 
   Title: Guid elines for COVID -19Ri sk Miti ation  
   Docu ment T,  e:  
   Docum  ent N umb  er:     
  R e vis ion N umb  er: 5  
Page 5 of 11 
CR-6521, v 3.0 JJV C CONFIDE NTIAL  
Page 165 of 163  
 - 
Clinical Stud y Protocol 
John son & John son Vi sion Care , Ine. 
Page 6 of 11 
CR-6521, v 3.0 JJVC CONFIDE NTIAL  
Page 166 of 163  
  
 
 
6.1.3 Study Site Closure:  
 
Duringthe period that this Work Instrnction is in effect , the dura.tion ofthe Study Site C losure Visit 
will be limited to ta.sk s tha t the CRA cannot perfonn remote ly (e.g., source document verifica.tion , 
test article final reconcilia.tion and retum , etc.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Title: 
   Document T,  e: Guid elines for COVID -19 Risk Miti ation   
Clinical Stud y Protocol 
John son & John son Vi sion Care , Ine. 
Page 6 of 11 
CR-6521, v 3.0 JJVC CONFIDE NTIAL  
Page 167 of 163  
 - 
Clinical Stud y Protocol  
John son & John son Vi sion Care , Ine. 
   Title: Guid elines for COVID -19Ri sk Miti ation  
   Docu ment T,  e:  
   Docum  e nt N umb e r :     
  R e vi s ion N umb e r : 5  
Page 7 of 11 
CR -6 521, v 3.0 JJVC C O NFID ENTIAL  
Page 158 of 163  
  
A t ta c hm e nt A: S tud y S ite Co rr es pond e n ce 
 
XXXX XX , 2020  
 
 
 
Re: COVID -19 Mitigation Plan , <<CR-xxxx/ protocol title>> 
 
 
Dear <<Principal Investigat or>> and Study Team , 
 
Coronavirns (COVID -19) has impacted several communities and business activities over the past several months. 
While we work toward the successful conduct of clinical studies , our commitment continues to be the safety of 
patients, healthcare profe ssionals, and to our communi ties. 
 
Therefore , we would like to share the following revisions/additions related to the above referenced Johnso n & 
Johnson Vision  Care  company  sponsored clinical trial(s) you are ctmently  working on or considering pa1tic ipation 
within. 
 
Proto col: 
 
• Guideline s for COVID-19 Risk Mitigation provided in the Appendix  section. 
 
Proto col Signature [CONTACT_3490]: 
 
• Will include a statement  indicating  the Principa l Investigat or agrees  to conduc t the study  in compliance  
with all local , state, and govemmental  guidelines  for COVID -19 risk mitigati on. 
 
Informed Consent: 
 
• Will include infonna tion conceming  the study-associated risks related to the COVID -19 pandemic  in bold 
font and/or boxed  on the first page  of tlie Info1me d consent documen t. 
 
COVID -[ADDRESS_440698] for Clinical Studie s: 
 
• Will include COVID -19 risk control measure s that are required to ensure the safety and health of subjects , 
site staff and moni tors during tlie pandemic.  
 
We want to encour age the need for open line s of communication about potential challenges you may foresee as the 
result of the cun-ent C OVID - 19 situa tion . Therefore , we encourage you to reg ularly connec t with your respective 
Johnson & John son clinica l study team (Clinical Researc h Associa te (CRA), Lead CRA or Study Managers).  
 
Thank you for your continued engagement , collaboration , and dedicatio n to your study subjects during this 
challenging time. 
 
 
Please file this letter in your site file study con-es pondenc e. 
 
 
 
 
 
 
 
Clinical Stud y Protocol  
John son & John son Vi sion Care , Ine. 
   Title: Guid elines for COVID -19Ri sk Miti ation  
   Docu ment T,  e:  
   Docum  e nt N umb e r :     
  R e vi s ion N umb e r : 5  
Page 7 of 11 
CR -6 521, v 3.0 JJVC C O NFID ENTIAL  
Page 158 of 163  
 - 
Clinic al Study Proto col 
John son & John son Vision Care, Ine. 
   Title: Guidelines for COVID -19 Risk Miti ation  
   Document T,  e:  
   Do cum ent N umb  er:     
  R evis ion N umb  er: 5  
Page 8 of 11  
CR-6521, v 3.0 JJVC  CONFIDEN TIAL  
Page  159 of 163  
  
 
Att ac hment B: COVID -[ADDRESS_440699] 
 
 
 
Study Number 
SiteNumber  
Principal Investigato r (PI) Name 
 
 
[CONTACT_353946] -[ADDRESS_440700]  John son & John son Vison  Care  clinical 
studie s. Please review the follo wing requirement s and Initial each  requiremen t. 
 
PI [INVESTIGATOR_353868]2 Measures  
 Si<ma2e within site describin 2 Risk Contro l metho ds 
 Social Distancin2 oractices thro,w : hout site (waitin2 rooms lobbv. exam room s. etc.) 
 Non-contact [CONTACT_353937] s of staff and oa tients 
 Trainin2 on oatient flow and oh vsical dist ancin2 in waitin2 room  
 Establish lon2er time frame betwe.en oatien t annoin tmen ts to reduce oersons in the site 
 Staff  should  receive job-specific training  on PPE and demon strate compe tency with selection and 
proper use of PPE and wear at all tirnes during interac tions with subjec ts (e.g., putting on and 
remo ving without  self-contamination ) 
 
 
PI [INVESTIGATOR_353869], site staff should regulai ·ly monitor themselves for fe ver and symptoms  
of COVID -19 including temp erature check s 
 Any staff member  (including  non-study clinic  staff and Investigato rs) showing signs ofbeing  sick 
or testing positive for COVID -[ADDRESS_440701] and the Spon sor shall be informed  
NOTE: Inform JJV C in [ADDRESS_440702] 20 second s or use an alcohol-based hand sanitizer 
when thev airive before and after each oatient before eating and after using the ba throom . 
 Cleaning  and disinfection  procedure s for exam  room s and instnunents or equipment  between 
oatient s with 2loves. 
 Cleaning and disinfection procedure s for commonl y touched surface s (door s, chairs, compu ters, 
phone s, etc.) with gloves. 
 
 
PI [INVESTIGATOR_93814] a Patient or Study Visit: 
 Patients should  be asked prior  to entering  the site about  fever and respi[INVESTIGATOR_93815] a fainil y member  have had contact [CONTACT_353938] -[ADDRESS_440703] p atients that compani ons should rema in outside of the facility and no t accompan y the 
patient into the facility  unless they are a parent/guardianof  the patient or if they are a trne 
cai·e gvi er and need to assist the oatient 
 Reque st the patient to call or text the office upon an ival so entrance to and mo vement through  
facility can be coordina ted by [CONTACT_353939] & John son Vision Care, Ine. 
   Title: Guidelines for COVID -19 Risk Miti ation  
   Document T,  e:  
   Do cum ent N umb  er:     
  R evis ion N umb  er: 5  
Page 8 of 11  
CR-6521, v 3.0 JJVC  CONFIDEN TIAL  
Page  159 of 163  
 - 
Clinic al Study Proto col 
John son & John son Vision Care, Ine. 
   Title: Guidelines for COVID -19 Risk Miti ation  
   Document T,  e:  
   Do cum ent N umb  er:     
  R evis ion N umb  er: [ADDRESS_440704] Entering the site: 
 T em pera ture checks utilizing a non-conta ct thennometer for all p atients and companion s entering 
the site. 
 All oatients and comoanion s must wear cloth or d isoosable ma sk at all times in the site 
 Main tain social distancing . Waiting room s or lobbies should be as empty as possible. Ad vise 
seated patient s to remain at least 6 feet from one another. 
 Communal obiects in (e.g. toys, reading materials, etc.) should be removed or cleaned regulad y. 
 
 
 
I ce1tify that I have read and agree  to implement  all the listed  COVID -19 Risk Control Measures required  for the 
conduc t of John son & John son Vision Care  studie s. 
 
 
 
 
 
 
 
Principal Investigator [INVESTIGATOR_353870] & John son Vision Care, Ine. 
   Title: Guidelines for COVID -19 Risk Miti ation  
   Document T,  e:  
   Do cum ent N umb  er:     
  R evis ion N umb  er: 5  
Page 9 of  11 
CR-6521, v 3.0 JJVC  CONFIDEN TIAL  
Page  160 of 1 63  
 - 
Clinical Stud y Protocol 
John son & John son Vi sion Care , Ine. 
   Title: Guid elines for COVID -19Ri sk Miti ation  
   Docu ment T,  e:  
   Docum  ent N umb  er:     
  R e vis ion N umb  er: 5  
Page 161 of 163  
 -  
RESOURCE LINKS 
 
US Resource Link s 
 
• OSHA  Training  
https: //www.osha.gov /SLTC/covid -19/controlp revention.htm l 
 
Personal Protec tive Equipmen t (PPE) Training  
CDC: https: //www.cdc .gov/coronavims /2019 -ncov/hcp /using -ppe.htm l 
 
• l&R Training  
ACUVUE ® Len sAssis t: https:  // www.acuvue .com/lensassis t 
 
• Clinic Preparedne ss Guides  
CDC: https: //www.cdc .gov/coronavi ms/2019 -ncov/hcp /clinic -preparedness html  
AOA: https: //aoa.uberflip.com/i/124043 7-aoa-w idance -for-re-opening -practices -covid ·19/1?m4= 
American Optometric Association : https: //v.rww.aoa.org /optome try -practice -reactivation -preparednes s­ 
guide 
 
• ln-Office  Disinfec tion of Multi -Patient  Use Diagno stic Contac t Lense s 
https: //www.gpli .info/wp-content/uploads /2020 /03/2020 -01-15-in-office -disinfec ting-of-diagnostic ­ 
lenses.pdf  
 
OUS Resource Link s 
 
• Update s on local regulations in Hong Kong  
https: //www.coronavims.gov  hk/eng/index .html  
 
• Resumption of optical services in England: Letter from Matt Neligan and Poonam Shruma  
https: //www.england  nhs.uk/coronavims /wp-content/uploads/ sites/52/2020 /04/C0601 -reopening -of-optical ­ 
services -letter-17- june-2020.pdf  
 
• NHS Optical  Letter  
https: //www.england nhs.uk/coronavims /wp-content/uploads/si tes/52/2020 /04/C0127 -optical -letter -l -april- 
2020.pdf  
 
• The College of Optometri sts primary eye care COVID -19 guidance: Red phase 
https://www.college -optometrists .org/the -college /media -hub/news -listing/coronavims -covid -19-guidance ­ 
for-optometrists .html  
 
• The College  of Optometris ts COVID -19: College upda tes 
https: //www.college -optometrists .org/the -college /media -hub/news -listing/coronavims -2019 -advice -for­ 
optometrists .html#CollegeGuidelines  
 
• Infection Control Guideline s. (n.d.). Retrie ved from Canadian Association Of Optometri sts: 
https: //opto. ca/sites/defau lt/files/resource s/document s/infection _control_guidelines _2016.pdf  
 
• Infection prevention and control for COVID -19: Interim guidance for outpa tient and ambulato1y cru·e 
s etting s . (2020 , May 23 May) . Retrie ved from Govemment of Canada: https: //www .canada .ca/en/public ­ 
health/services /diseases/2019 -novel-corona vims-infection/guidance -documents /interim -guidance­ outpatien t-
ambulato1 y-care-setting s html  
 
 
 
 
 
Page 10 of ll 
 
CR-6521, v 3.0 JJVC  CONFIDE NTIAL  
Clinical Stud y Protocol 
John son & John son Vi sion Care , Ine. 
   Title: Guid elines for COVID -19Risk Miti ation  
   Docu ment T,  e:  
   Docum  ent N umb  er:     
  R e vis ion N umb  er: 5  
Page162 of163  
 -  
• Info1mation for Members On Corona vims (COVID -19). (n.d.). Retrie ved from Canadian Association Of 
Optometri sts: 
https: //opto. ca/sites/defau lt/files/resource s/document s/info1mation _for_members _on_corona vims.pdf 
 
• Coronavims  (COVID -19) resource s for health professionals , including  aged  care providers, pathology  
providers and health care managers. (2020 , Septembe r 24). Retrie ved from Australian Govemment  
Departmen t of Heal th: 
https: //www health.gov.au/resources /collection s/coronavims-covid-19-resource s-for-health -professionals­  
including -aged -care-providers-pathology -providers-and-health-care-managers  
 
• Environmenta l Cleaning and Disinfection Principle s for COVID -19. (n.d.). Retrie ved from Australian  
Govemment Depa11men t of Health:  
https: //www .health.gov.au/sites /defau lt/files/document s/2020 /03/environmenta l-cleaning -and-disinfection ­ 
principle s-for-covid -19.pdf 
 
• Infection control guidelines and advice. (n.d.). Retrieved from Optometiy Austi·alia : 
https: //www .optometiy .org.au/practice -profe ssional-support /corona vims-covid-19-what -optometri sts-need­  to-
know/covid-19-clinical -advice/infec tion-conti·o l-guidelines -and-advice / 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 11 ofll  
 
CR-6521, v3.0 JJVCCONFIDENTIAL  
Page 163 of 163   
 Clinical Study Protocol 
[COMPANY_012] Vision Care,  Inc. 
 
PROTOCOL COMPLIANCE INVESTIGATOR(S) SIGNATURE  [CONTACT_93962]: CR -[ADDRESS_440705] Lenses in Senofilcon A with a Blue - 
Blocking Chromophore  
 
Version and Date: 3.[ADDRESS_440706] this study according to ISO [ZIP_CODE]:2020,1 the Declaration of Helsinki,2 [LOCATION_002] (US) 
Code of Federal Regulations (CFR),3 and the pertinent individual country laws/regulations and to comply with 
its obligations, subject to ethical and safety considerations. I, as the Principal Investigator, am responsible for 
ensuring  that all clinical  site personnel,  including  Sub-Investigators,  adhere  to all regulations  and GCP  guidelines 
regarding clinical trials during and after study  completion.  
 
I will a ssure that no deviation from or changes to the protocol will take place without prior agreement from the 
Sponsor and documented approval from the Institutional Review Board (IRB), except where necessary to 
eliminate an immediate hazard(s) to the trial part icipants.  
 
All clinical site personnel involved in the conduct of this study have completed Human Subjects Protection 
Training.  
 
I agree to ensure that all clinical site personnel involved in the conduct of this study are informed about their 
obligations in meeting the above commitments.  
 
I shall not disclose the information contained in this protocol or any results obtained from th is study without 
written authorization.  
 
I have read the suggested guidance provided by [CONTACT_19610] -19 risk mitigation, (COVID -19 
Work  Instruction  in the Appendix  F of this protocol).  I agree  to conduct  this study  in compliance  with local,  state, 
governmental guidance for COVID -19 risks.  
 
 
Principal  
Investigator:   
    
   
 [INVESTIGATOR_353871] (Printed)   
 
Institution/Site:    
Institution/Site  Name  
 
 
[CONTACT_16277]/Site Address  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CR-6521,  v 3.0 JJVC CONFIDENTIAL  